

Presbyterian Health Plan and Presbyterian Insurance Company Individual and Family Metal Plans/Employer Group Metal Plans Formulary, Therapeutic Class Listing

This list is in order by therapeutic class. To find a specific drug, use the search feature available in Adobe Acrobat Reader (keyboard shortcut: Ctrl+F).

What Is A Formulary?

A drug Formulary, or preferred drug list, is a continually updated list of medications and related products supported by current evidence-based medicine, judgment of physicians, pharmacists and other experts in the diagnosis and treatment of disease and preservation of health.

The primary purpose of the Formulary is to encourage the use of safe, effective and most affordable medications. Presbyterian Health Plan administers a “closed Formulary,” which means that non-Formulary drugs are not routinely reimbursed by the plan. Medical exceptions policies provide access to non-Formulary medication when medical necessity is established.

The medications listed on the Formulary are subject to change per the management activities of Presbyterian Health Plan Pharmacy and Therapeutics Committee pursuant to N.M.S.A. 1978, §59A-23-7.13.

How Is the Formulary Managed?

Presbyterian Health Plan Pharmacy Services applies utilization management tools to Formulary drugs such as prior authorization, step therapy and quantity limits.

“Prior authorization” is a clinical evaluation process to determine if the requested healthcare service is medically necessary, a covered benefit, and if it is being delivered in the most appropriate healthcare setting. Our Medical Director or other clinical professional will review the requested healthcare service and, if it meets our requirements for coverage and medical necessity, it is authorized (approved) before those services are provided.

The prior authorization process and requirements are regularly reviewed and updated based on various factors including evidence-based practice guidelines, medical trends, practitioner/provider participation, state and federal regulations, and our policies and procedures.

“Step therapy” promotes the appropriate use of equally effective but lower-cost Formulary drugs first. With this program, prior use of one or more “prerequisite” drugs is required before a step-therapy medication will be covered. Prerequisite drugs are Food and Drug Administration (FDA)-approved and treat the same condition as the corresponding step-therapy drugs.

Formulary drugs may also limit coverage of quantities for certain drugs. These limits help your provider and pharmacist check that the medications are used appropriately and promote patient safety.

Presbyterian Health Plan uses medical guidelines and FDA-approved recommendations from drug makers to set these coverage limits. Quantity limits include the following:

- **Maximum Daily Dose** limits quantities to a maximum number of dosage units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a single day. Limits are based on daily dosages shown to be safe and effective, and that are approved by FDA.
- **Quantity Limits Over Time** limits quantities to number of units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a defined period of time.

For the most up-to-date Formulary drug information, visit your searchable formulary found at <https://client.formularynavigator.com/Search.aspx?siteCode=0324498195>.

You may obtain more information by calling our local Pharmacy Services team, Monday through Friday, 7 a.m. to 6 p.m. at:








Presbyterian Insurance Company Commercial: (505) 923 -6980 or 1-800-923-6980




Presbyterian Health Plan Commercial HMO: (505) 923-5678 or 1-800-356-2219

You can also send pharmacy inquires to info@phs.org.







Some medications may be excluded as determined by benefit.











Definition of Status

| Icon | Status | Definition |
|---|-----------------|--|
|  | Tier 1 | Tier 1 Preferred Generic. |
|  | Tier 2 | Tier 2 Preferred Generic. |
|  | Tier 3 | Tier 3 Preferred Brand. |
|  | Tier 4 | Tier 4 Non-Preferred Drug. |
|  | Tier 5 | Tier 5 Self-Administered Specialty Pharmaceutical. |
|  | \$0 | Zero Dollar Copay |
|  | Medical Benefit | A medical drug is any drug administered by a healthcare professional and is typically given in the member's home, provider's office, freestanding (ambulatory) infusion suite, or outpatient facility. Medical drugs may require a prior authorization, and some must be obtained through the Specialty Pharmacy network. For a complete list of medical drugs to determine which require prior authorization, please see the Presbyterian Health Plan Pharmacy Services website at www.phs.org . |

| Icon | Status | Definition |
|---|-------------------|--|
|  | Medical Exception | A process to request an exception to Formulary/Preferred Drug List (PDL) drug limitations and restrictions such as coverage of a non-Formulary drug, quantity limits and step-therapy requirements. The request can be made by a prescriber, a member or their appointed representative. The prescriber must provide information to support the medical exception request by fax, phone or mail. |
|  | Benefit Exclusion | Benefit Exclusion not a covered benefit. |
|  | Non-Formulary | Non-Formulary drugs require a medical exception to the Formulary due to allergy, adverse reactions, or no response to all Formulary drugs. Medical exception policies provide access to non-Formulary medications when medical necessity is established. |

Definition of Restrictions

| Icon | Restriction | Definition |
|---|---------------------------------------|---|
|  | Age Restriction | A coverage limit based on minimum or maximum age of the member in order to ensure safety and effectiveness of treatments and drug dosages. |
|  | Behavioral Health | <p>Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero cost share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.</p> |
|  | Sexually Transmitted Infections | <p>Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.</p> |
|  | Diagnosis Code | Diagnosis Code. |
|  | Generic Indicator | A generic drug is approved by the FDA as having the same active ingredient and may be substituted for the brand name drug. Generally, generic drugs cost less than brand name drugs. |
|  | Insulin for Diabetes Cost Sharing Cap | <p>The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total of \$25.00* per 30-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.</p> |

| Icon | Restriction | Definition |
|---|----------------------------|---|
|  | Limited Access | Limited Access. |
|  | Non-Extended Day Supply | This drug is limited to a one-month supply. |
|  | Note | Note |
|  | Prior Authorization | Prior Authorization is a clinical evaluation process to determine if the requested health care service is medically necessary, a covered benefit, and if it is being delivered in the most appropriate health care setting. Our Medical Director or other clinical professional will review the requested health care service and, if it meets our requirements for coverage and medical necessity, it is authorized (approved) before those services are provided. |
|  | Quantity Limit | <p>Formulary drugs may also limit coverage of quantities for certain drugs. These limits help your doctor and pharmacist check that the medications are used appropriately and promote patient safety. Presbyterian Health Plan uses medical guidelines and FDA-approved recommendations from drug makers to set these coverage limits. Quantity limits include the following:</p> <ul style="list-style-type: none"> • Maximum Daily Dose limits quantities to a maximum number of dosage units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a single day. Limits are based on daily dosages shown to be safe and effective, and that are approved by the FDA. |
|  | Quantity Limit (Over Time) | Quantity Limits Over Time limits quantities to number of units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a defined period of time. |
|  | Schedule II Max Day | Schedule II maximum of 30-day supply. |
|  | Specialty Pharmacy | Most specialty pharmaceuticals require prior authorization and must be obtained through the Specialty Pharmacy network. Specialty pharmaceuticals are often high cost, typically greater than \$600 for up to a 30-day supply. Specialty pharmaceuticals are not available through the retail or mail order option and are limited to a 30-day supply. Certain specialty pharmaceuticals are limited to an initial fill up to a 15-day supply to ensure patients can tolerate the new medication. |
|  | Split Fill - New Starts | Certain specialty pharmaceuticals are limited to an initial fill up to a 15-day supply to ensure patients can tolerate the new medication. |
|  | Step Therapy | Step therapy promotes the appropriate use of equally effective but lower-cost Formulary drugs first. With this program, prior use of one or more “prerequisite” drugs is required before a step therapy medication will be covered. Prerequisite drugs are FDA- |

| Icon | Restriction | Definition |
|------|-------------|---|
| | | approved and treat the same condition as the corresponding step-therapy drug. |

Can the Formulary change during the year?

The Formulary can change throughout the year. Some reasons why it can change include:

- New drugs are approved
- Existing drugs are removed from the market
- Prescription drugs are removed from the market
- Prescription drugs may become available over the counter (without a prescription)
- Brand-name drugs lose patent protection and generic versions become available
- Changes based on new clinical guidelines

If we remove drugs from our Formulary, add quantity limits, prior authorization, and/or step therapy restrictions on a drug; or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 60 days before the change becomes effective.

What if my drug is not Covered?

You or your doctor can ask us to make an exception (**prior authorization**) to our coverage rules. We will work with your prescriber to get additional information to support your request. There are several types of exceptions that you can ask us to make.

- You can ask us to cover your drug even if it is not on our Formulary.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, we limit the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover more.

Our review of a prior authorization request will determine if the proposed care involves a covered service, is medically necessary and whether an alternative type of prescription medication should be pursued instead of, or before, the requested prescription medication. Our decisions concerning medical necessity and Formulary alternatives will be guided by current clinical guidelines and will be made by an appropriate medical professional. Prior authorization does not guarantee payment. We are not required to pay for an authorized service if your coverage ends before you receive the service.

Prior Authorization Request Processing Times

Standard Pharmacy Prior Authorization Requests

When all necessary information is provided with the Drug Prior Authorization request, standard requests are processed as expeditiously as the member's health requires, within **72 hours** after the request is received.

Expedited Pharmacy Prior Authorization Requests:

When a member or their provider believes that waiting for a decision under the standard time frame could place the member's life, health or ability to regain maximum function in jeopardy, a prior

authorization can be expedited. These requests are processed within **24 hours** after the request is received.

If additional information is required in order to decide on a prior authorization, Presbyterian Pharmacy Services team will contact your prescriber by phone and, if necessary, by fax.

Once a decision has been made, you will receive a notification with either an approval or adverse determination.

Learn more about Presbyterian's Nondiscrimination Notice and Interpreter Services at <https://www.phs.org/Pages/nondiscrimination.aspx>.

Disclaimers

Please be sure a prescription drug benefit is part of your specific coverage before consulting this list. If you do not know which list is correct, you may obtain more information by calling our local Pharmacy Services team, Monday through Friday, 7 a.m. to 6 p.m. at:

Presbyterian Insurance Company Commercial: (505) 923 -6980 or 1-800-923-6980

Presbyterian Health Plan Commercial HMO: (505) 923-5678 or 1-800-356-2219

You can also send your pharmacy inquiries to **info@phs.org**.

Coverage for some drugs may be limited to specific dosage forms and/or strengths. Your benefit design determines what is covered for you and what your copayment will be. Please refer to your benefit materials for your specific coverage information.

This list is not all-inclusive, nor does it imply a guarantee of coverage. In addition, coverage for some drugs listed may be limited to specific dosage forms and/or strengths. Substitution of a generic product for a brand-name drug is mandatory when a generic equivalent is available. If a member requests the brand-name drug in this situation, a pharmacy exception (prior authorization) may be required, and the member must pay the difference in cost between the generic and branded versions. Non-Formulary medications are not considered for coverage unless trial and failure of Formulary alternatives are documented.

Please see your Subscriber and Guide to Your Managed Care Plan (GSA) for further details.

CURRENT AS OF 6/1/2024

| Drug Name | Tier | Notes |
|---|------|---|
| *ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS* | | |
| *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** | | |
| <i>guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** | | |
| <i>atomoxetine hcl oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| *AMPHETAMINE MIXTURES*** | | |
| <i>amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 2 | PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years and Max 18 Years) |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>amphetamine-dextroamphetamine oral capsule extended release 24 hour 20 mg, 25 mg, 30 mg</i> | 2 | PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 3 Years) |
| <i>amphetamine-dextroamphetamine oral tablet 30 mg</i> | 2 | PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 3 Years and Max 18 Years) |
| * AMPHETAMINES*** | | |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg, 15 mg</i> | 2 | PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 6 Years and Max 18 Years) |

| Drug Name | Tier | Notes |
|---|-------------|--|
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 5 mg</i> | 2 | PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>dextroamphetamine sulfate oral tablet 10 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 3 Years) |
| <i>lisdexamfetamine dimesylate oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg</i> | 4 | QL (30 EA per 30 days); AL (Min 6 Years) |
| <i>methamphetamine hcl oral tablet 5 mg</i> | 4 | PA; PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (150 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| * ANALEPTICS*** | | |
| CAFCIT INTRAVENOUS SOLUTION 60 MG/3ML | MB | |
| <i>caffeine citrate intravenous solution 60 mg/3ml</i> | 2 | |
| <i>caffeine citrate oral solution 20 mg/ml</i> | 2 | |
| * ANOREXIANTS NON-AMPHETAMINE*** | | |
| <i>benzphetamine hcl oral tablet 25 mg, 50 mg</i> | 4 | PA; QL (90 EA per 30 days) |
| <i>diethylpropion hcl er oral tablet extended release 24 hour 75 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| <i>diethylpropion hcl oral tablet 25 mg</i> | 4 | PA; QL (90 EA per 30 days) |
| <i>phendimetrazine tartrate er oral capsule extended release 24 hour 105 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| <i>phendimetrazine tartrate oral tablet 35 mg</i> | 4 | PA; QL (180 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>phentermine hcl oral capsule 15 mg, 30 mg, 37.5 mg</i> | 4 | |
| *ANTI-OBESITY AGENT COMBINATIONS** | | |
| CONTRAVE ORAL TABLET EXTENDED RELEASE 12 HOUR 8-90 MG | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days) |
| *DOPAMINE AND NOREPINEPHRINE REUPTAKE INHIBITORS (DNRIS)*** | | |
| SUNOSI ORAL TABLET 150 MG, 75 MG | 5 | PA; QL (30 EA per 30 days); AL (Min 18 Years) |
| *HISTAMINE H3-RECEPTOR ANTAGONIST/INVERSE AGONISTS*** | | |
| WAKIX ORAL TABLET 17.8 MG | 5 | PA; LA; QL (60 EA per 30 days); AL (Min 18 Years) |
| WAKIX ORAL TABLET 4.45 MG | 5 | PA; LA; QL (14 EA per 7 days); AL (Min 18 Years) |
| *STIMULANTS - MISC.*** | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | PA; QL (30 EA per 30 days) |
| <i>dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 15 mg</i> | 4 | PA; PA required for age 19 years and older.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years) |
| <i>dexmethylphenidate hcl er oral capsule extended release 24 hour 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years) |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>dexmethylphenidate hcl oral tablet 10 mg, 2.5 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years) |
| <i>dexmethylphenidate hcl oral tablet 5 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years and Max 22 Years) |
| METADATE ER ORAL TABLET EXTENDED RELEASE 20 MG | 2 | PA required for age 19 years and older; QL (90 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl er (cd) oral capsule extended release 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</i> | 2 | QL (30 EA per 30 days); AL (Min 6 Years) |
| <i>methylphenidate hcl er (osm) oral tablet extended release 18 mg, 27 mg, 54 mg</i> | 2 | PA required for age 19 years and older.; QL (30 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl er (osm) oral tablet extended release 36 mg</i> | 2 | PA required for age 19 years and older.; QL (60 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl er oral tablet extended release 10 mg</i> | 2 | PA required for age 19 years and older.; QL (60 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl er oral tablet extended release 20 mg</i> | 2 | PA required for age 19 years and older.; QL (90 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 54 mg</i> | 2 | PA required for age 19 years and older.; QL (30 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl er oral tablet extended release 24 hour 36 mg</i> | 2 | PA required for age 19 years and older.; QL (60 EA per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl oral solution 10 mg/5ml</i> | 2 | PA; PA required for age 19 years and older.; QL (450 ML per 30 days); AL (Min 6 Years and Max 12 Years) |
| <i>methylphenidate hcl oral solution 5 mg/5ml</i> | 2 | PA; PA required for age 19 years and older.; QL (180 ML per 30 days); AL (Min 6 Years and Max 12 Years) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | PA required for age 19 years and older.; QL (90 EA per 30 days); AL (Min 3 Years and Max 18 Years) |
| <i>methylphenidate hcl oral tablet chewable 10 mg, 2.5 mg, 5 mg</i> | 4 | QL (90 EA per 30 days); AL (Min 3 Years) |
| <i>modafinil oral tablet 100 mg, 200 mg</i> | 2 | QL (30 EA per 30 days) |
| *AMINOGLYCOSIDES* | | |
| *AMINOGLYCOSIDES*** | | |
| <i>amikacin sulfate injection solution 50 mg/ml</i> | MB | |
| <i>gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%</i> | MB | |
| <i>neomycin sulfate oral tablet 500 mg</i> | 2 | |
| <i>paromomycin sulfate oral capsule 250 mg</i> | 4 | |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | 5 | SP |
| <i>tobramycin sulfate injection solution 1.2 gm/30ml, 10 mg/ml, 80 mg/2ml</i> | MB | |
| *ANALGESICS - ANTI-INFLAMMATORY* | | |
| *ANTIRHEUMATIC - JANUS KINASE (JAK) INHIBITORS*** | | |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG, 30 MG | 4 | PA; QL (30 EA per 30 days); SP |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 45 MG | 4 | PA; QL (90 EA per 365 days); SP |
| XELJANZ ORAL SOLUTION 1 MG/ML | 4 | PA; QL (300 ML per 30 days); AL (Min 2 Years and Max 12 Years); SP |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 4 | PA; QL (60 EA per 30 days); SP |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 11 MG | 4 | PA; QL (30 EA per 30 days); SP |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 22 MG | 4 | PA; QL (112 EA per 6 days); SP |
| *ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES*** | | |
| AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML | 4 | PA; Coverage applies to approved products only. Covered NDCs: 55513-0482-01 and 555130482-02; QL (1.6 ML per 28 days); SP |
| AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.8ML | 4 | PA; Coverage applies to approved products only. Covered NDCs: 72511-0400-01 and 72511-0400-02.; QL (3.2 EA per 28 days); SP |
| AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 80 MG/0.8ML | 4 | PA; Coverage applies to approved products only. Covered NDCs: 55513-0481-01 and 55513-0481-02; QL (1.6 ML per 28 days); SP |

| Drug Name | Tier | Notes |
|--|------|--|
| AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML | 4 | PA; Coverage applies to approved products only. Covered NDCs: 55513-0479-01 and 55513-0479-02; QL (1.6 ML per 28 days); SP |
| AMJEVITA-PED 10KG TO <15KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.2ML | 4 | PA; QL (0.4 ML per 28 days); SP |
| AMJEVITA-PED 15KG TO <30KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.4ML | 4 | PA; QL (0.8 EA per 28 days); SP |
| HUMIRA (2 PEN) SUBCUTANEOUS PEN- INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML | 4 | PA; QL (2 EA per 28 days); SP |
| HUMIRA (2 PEN) SUBCUTANEOUS PEN- INJECTOR KIT 80 MG/0.8ML | 4 | PA; QL (1 EA per 28 days); SP |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML | 4 | PA; QL (2 EA per 28 days); SP |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML | 4 | PA; QL (2 EA per 28 days); SP |
| HUMIRA-PED<40KG CROHNS STARTER SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML & 40MG/0.4ML | 4 | PA; QL (1 EA per 30 days); SP |
| HUMIRA-PED>=40KG CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML | 4 | PA; QL (1 EA per 30 days); SP |
| HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML | 4 | PA; QL (2 EA per 28 days); SP |
| HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML | 4 | PA; QL (2 EA per 28 days); SP |
| *CYCLOOXYGENASE 2 (COX-2) INHIBITORS*** | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 2 | QL (60 EA per 30 days) |
| *GOLD COMPOUNDS*** | | |
| RIDAURA ORAL CAPSULE 3 MG | 3 | |
| *INTERLEUKIN-6 RECEPTOR INHIBITORS*** | | |
| ACTEMRA ACTPEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 162 MG/0.9ML | 4 | PA; QL (3.6 ML per 28 days); SP |
| ACTEMRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 162 MG/0.9ML | 4 | PA; QL (3.6 ML per 28 days); SP |
| KEVZARA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 150 MG/1.14ML, 200 MG/1.14ML | 4 | PA; QL (2.28 ML per 28 days); SP |
| KEVZARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/1.14ML, 200 MG/1.14ML | 4 | PA; QL (2.28 ML per 28 days); SP |

| Drug Name | Tier | Notes |
|--|------|--------------------------------|
| *NONSTEROIDAL ANTI-INFLAMMATORY AGENT COMBINATIONS*** | | |
| <i>diclofenac-misoprostol oral tablet delayed release 50-0.2 mg, 75-0.2 mg</i> | 4 | |
| *NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)*** | | |
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | 2 | |
| <i>diclofenac sodium oral tablet delayed release 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>etodolac er oral tablet extended release 24 hour 400 mg, 500 mg, 600 mg</i> | 2 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 2 | |
| <i>fenoprofen calcium oral tablet 600 mg</i> | 3 | |
| <i>flurbiprofen oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 2 | |
| <i>indomethacin er oral capsule extended release 75 mg</i> | 2 | |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 2 | |
| <i>ketoprofen oral capsule 50 mg, 75 mg</i> | 2 | |
| <i>ketorolac tromethamine intramuscular solution 30 mg/ml</i> | MB | |
| <i>ketorolac tromethamine oral tablet 10 mg</i> | 2 | QL (20 EA per 30 days) |
| <i>meclofenamate sodium oral capsule 100 mg, 50 mg</i> | 3 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 2 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>naproxen dr oral tablet delayed release 375 mg, 500 mg</i> | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 2 | |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | 2 | |
| <i>oxaprozin oral tablet 600 mg</i> | 2 | |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | |
| <i>tolmetin sodium oral capsule 400 mg</i> | 3 | |
| <i>tolmetin sodium oral tablet 600 mg</i> | 3 | |
| *PHOSPHODIESTERASE 4 (PDE4) INHIBITORS*** | | |
| OTEZLA ORAL TABLET 30 MG | 4 | PA; QL (60 EA per 30 days); SP |

| Drug Name | Tier | Notes |
|---|------|--|
| OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG | 4 | PA; QL (60 EA per 30 days); SP |
| *PYRIMIDINE SYNTHESIS INHIBITORS*** | | |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 2 | |
| *SELECTIVE COSTIMULATION MODULATORS*** | | |
| ORENCIA CLICKJECT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 125 MG/ML | 4 | PA; QL (4 ML per 28 days); SP |
| ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML | 4 | PA; QL (4 ML per 28 days); SP |
| ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/0.4ML | 4 | PA; QL (1.6 ML per 28 days); SP |
| ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 87.5 MG/0.7ML | 4 | PA; QL (2.8 ML per 28 days); SP |
| *SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR AGENTS*** | | |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML | 4 | PA; QL (4 ML per 28 days); SP |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML | 4 | PA; QL (2 ML per 28 days); SP |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML | 4 | PA; QL (2 ML per 28 days); SP |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/ML | 4 | PA; QL (4 ML per 28 days); SP |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML | 4 | PA; QL (4 ML per 28 days); SP |
| *ANALGESICS - NONNARCOTIC* | | |
| *ANALGESICS-SEDATIVES*** | | |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | 2 | QL (6 EA per 1 day) |
| <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i> | 2 | QL (6 EA per 1 day) |
| *SALICYLATES*** | | |
| <i>aspirin ec oral tablet delayed release 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Min 45 Years) |
| <i>aspirin ec oral tablet delayed release 81 mg</i> | \$0 | AL (Min 45 Years) |
| <i>aspirin low dose oral tablet 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>aspirin low dose oral tablet delayed release 81 mg</i> | \$0 | AL (Min 45 Years) |
| <i>aspirin oral tablet 325 mg, 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>aspirin oral tablet delayed release 325 mg, 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |

| Drug Name | Tier | Notes |
|---|-------------|--|
| <i>aspirtab oral tablet delayed release 324 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Min 45 Years) |
| BAYER ASPIRIN ORAL TABLET 325 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| BAYER ASPIRIN ORAL TABLET DELAYED RELEASE 325 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| BAYER ASPIRIN REGIMEN ORAL TABLET DELAYED RELEASE 325 MG | \$0 | \$0 Copay per PPACA guidelines; AL (Min 45 Years) |
| <i>childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>cvs aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>cvs aspirin oral tablet delayed release 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>cvs childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>diflunisal oral tablet 500 mg</i> | 2 | |
| <i>ec-81 aspirin oral tablet delayed release 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>eq aspirin low dose oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>eq aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>eq aspirin oral tablet delayed release 325 mg, 500 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>eq childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>eql aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>eql childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>gnp aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>gnp aspirin oral tablet delayed release 325 mg, 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>hm aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>hm aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| MEDI-FIRST ASPIRIN ORAL TABLET 325 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| MEDIQUE ASPIRIN ORAL TABLET 325 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>mm aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |

| Drug Name | Tier | Notes |
|---|-------------|--|
| NORWICH ASPIRIN ORAL TABLET 325 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>px aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>px aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>px enteric aspirin oral tablet delayed release 325 mg, 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>qc aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>qc aspirin oral tablet delayed release 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>qc childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>ra aspirin oral tablet 325 mg, 500 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>ra childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>salsalate oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>sb aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>sb aspirin oral tablet delayed release 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>sb childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>sm aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>sm childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| ST JOSEPH ADULT ORAL TABLET CHEWABLE 75 MG | 2 | AL (Min 45 Years and Max 79 Years) |
| ST JOSEPH ASPIRIN ORAL TABLET CHEWABLE 81 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| ST JOSEPH ASPIRIN ORAL TABLET DELAYED RELEASE 81 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>tgt aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>tgt aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>tgt aspirin oral tablet delayed release 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>tgt childrens aspirin oral tablet chewable 81 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| <i>th aspirin oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>th enteric aspirin oral tablet delayed release 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 45 Years) |
| *ANALGESICS - OPIOID* | | |
| *CODEINE COMBINATIONS*** | | |
| <i>acetaminophen-codeine #2 oral tablet 300-15 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (13 EA per 1 day); AL (Min 12 Years) |
| <i>acetaminophen-codeine #3 oral tablet 300-30 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (13 EA per 1 day); AL (Min 12 Years) |
| <i>acetaminophen-codeine #4 oral tablet 300-60 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (13 EA per 1 day); AL (Min 12 Years) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (166 ML per 1 day); AL (Min 12 Years) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (13 EA per 1 day); AL (Min 12 Years) |
| <i>butalbital-apap-caff-cod oral capsule 50-325-40-30 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (6 EA per 1 day); AL (Min 12 Years) |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for patients 12 to 18 years of age.; QL (6 EA per 1 day); AL (Min 12 Years) |
| *HYDROCODONE COMBINATIONS*** | | |
| <i>hydrocodone-acetaminophen oral solution 2.5-108 mg/5ml</i> | 2 | Schedule II medications are limited to a 34 day maximum.; QL (180 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 5-217 mg/10ml, 7.5-325 mg/15ml</i> | 2 | QL (180 ML per 1 day) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | 2 | QL (12 EA per 1 day) |
| <i>hydrocodone-acetaminophen oral tablet 10-650 mg, 10-660 mg</i> | 2 | QL (6 EA per 1 day) |

| Drug Name | Tier | Notes |
|---|------|--|
| hydrocodone-acetaminophen oral tablet 2.5-500 mg | 2 | QL (8 EA per 1 day) |
| *OPIOID AGONISTS*** | | |
| codeine sulfate oral tablet 15 mg, 30 mg | 2 | PA; Not covered for members under 12 years of age. Prior authorization required for members 12 to 18 years of age.; QL (180 EA per 30 days); AL (Min 12 Years) |
| codeine sulfate oral tablet 60 mg | 3 | PA; Not covered for members under 12 years of age. Prior authorization required for members 12 to 18 years of age.; QL (180 EA per 30 days); AL (Min 12 Years) |
| fentanyl citrate (pf) injection solution 100 mcg/2ml, 1000 mcg/20ml, 250 mcg/5ml, 2500 mcg/50ml, 500 mcg/10ml | MB | |
| fentanyl citrate (pf) injection solution cartridge 100 mcg/2ml | MB | |
| fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr | 2 | QL (10 EA per 30 days) |
| hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent 30 mg, 40 mg, 60 mg | 4 | ST; QL (30 EA per 30 days) |
| hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 12 mg, 16 mg, 8 mg | 4 | ST; QL (30 EA per 30 days) |
| hydromorphone hcl er oral tablet extended release 24 hour 12 mg, 16 mg, 8 mg | 4 | Schedule II medications are limited to a 34 day maximum. |
| hydromorphone hcl injection solution 1 mg/ml | MB | |
| hydromorphone hcl oral tablet 2 mg, 4 mg, 8 mg | 2 | QL (180 EA per 30 days) |
| KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 200 MG | 4 | ST; QL (30 EA per 30 days) |
| levorphanol tartrate oral tablet 2 mg | 4 | QL (180 EA per 30 days) |
| meperidine hcl injection solution 10 mg/ml | MB | |
| meperidine hcl oral solution 50 mg/5ml | 3 | QL (2000 ML per 30 days) |
| methadone hcl oral solution 10 mg/5ml, 5 mg/5ml | 3 | QL (900 ML per 30 days) |
| methadone hcl oral tablet 10 mg, 5 mg | 2 | QL (180 EA per 30 days) |
| morphine sulfate (concentrate) oral solution 20 mg/ml | 2 | QL (180 ML per 30 days) |
| morphine sulfate er beads oral capsule extended release 24 hour 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg | 4 | ST; QL (30 EA per 30 days) |
| morphine sulfate er oral capsule extended release 24 hour 10 mg, 100 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg | 4 | ST; Schedule II medications are limited to a 34 day supply maximum; QL (60 EA per 30 days) |
| morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg | 2 | QL (180 EA per 30 days) |
| morphine sulfate intravenous solution 25 mg/ml | MB | |
| morphine sulfate oral solution 10 mg/5ml, 20 mg/5ml | 2 | QL (1000 ML per 30 days) |

| Drug Name | Tier | Notes |
|--|-------------|--|
| <i>morphine sulfate oral tablet 15 mg, 30 mg</i> | 2 | QL (180 EA per 30 days) |
| NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 150 MG, 200 MG, 250 MG, 50 MG | 4 | PA; QL (60 EA per 30 days) |
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i> | 2 | QL (180 ML per 30 days) |
| <i>oxycodone hcl oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> | 2 | QL (180 EA per 30 days) |
| <i>oxymorphone hcl er oral tablet extended release 12 hour 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg</i> | 4 | ST; QL (60 EA per 30 days) |
| <i>oxymorphone hcl oral tablet 10 mg</i> | 4 | ST; QL (360 EA per 30 days) |
| <i>oxymorphone hcl oral tablet 5 mg</i> | 4 | ST; QL (180 EA per 30 days) |
| <i>tramadol hcl er oral tablet extended release 24 hour 100 mg</i> | 4 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; QL (90 EA per 30 days); AL (Min 12 Years) |
| <i>tramadol hcl er oral tablet extended release 24 hour 200 mg</i> | 4 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; QL (30 EA per 30 days); AL (Min 12 Years) |
| <i>tramadol hcl oral tablet 50 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; QL (240 EA per 30 days); AL (Min 12 Years) |
| *OPIOID COMBINATIONS*** | | |
| ENDOCET ORAL TABLET 2.5-325 MG | 2 | QL (12 EA per 1 day) |
| <i>oxycodone-acetaminophen oral capsule 5-500 mg</i> | 2 | QL (8 EA per 1 day) |
| <i>oxycodone-acetaminophen oral solution 5-325 mg/5ml</i> | 2 | QL (60 ML per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | 2 | QL (12 EA per 1 day) |
| <i>oxycodone-acetaminophen oral tablet 10-650 mg</i> | 2 | QL (6 EA per 1 day) |
| <i>oxycodone-acetaminophen oral tablet 7.5-500 mg</i> | 2 | QL (8 EA per 1 day) |
| <i>oxycodone-aspirin oral tablet 4.8355-325 mg</i> | 2 | QL (180 EA per 30 days) |
| ROXICET ORAL TABLET 5-325 MG | 2 | QL (12 EA per 1 day) |
| XARTEMIS XR ORAL TABLET EXTENDED RELEASE 7.5-325 MG | 4 | PA; QL (120 EA per 30 days) |
| *OPIOID PARTIAL AGONISTS*** | | |

| Drug Name | Tier | Notes |
|--|------|---|
| BRIXADI (WEEKLY) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 16 MG/0.32ML, 8 MG/0.16ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.64 ML per 28 days) |
| BRIXADI (WEEKLY) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 24 MG/0.48ML, 32 MG/0.64ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.92 ML per 28 days) |
| BRIXADI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 128 MG/0.36ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.36 ML per 28 days) |
| BRIXADI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 64 MG/0.18ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.18 ML per 28 days) |
| BRIXADI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 96 MG/0.27ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.27 ML per 28 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3 EA per 1 day); AL (Min 16 Years) |
| <i>buprenorphine hcl sublingual tablet sublingual 8 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (4 EA per 1 day); AL (Min 16 Years) |
| <i>buprenorphine hcl-naloxone hcl sublingual film 12-3 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 16 Years) |
| <i>buprenorphine hcl-naloxone hcl sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 16 Years) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 16 Years) |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 8-2 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 16 Years) |
| <i>butorphanol tartrate nasal solution 10 mg/ml</i> | 4 | QL (10 ML per 30 days) |
| <i>nalbuphine hcl injection solution 10 mg/ml</i> | 2 | |
| SUBLOCADE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.5ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.5 ML per 30 days) |
| SUBLOCADE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/1.5ML | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.5 ML per 30 days) |
| TALWIN INJECTION SOLUTION 30 MG/ML | MB | |
| *PENTAZOCINE COMBINATIONS*** | | |
| <i>pentazocine-acetaminophen oral tablet 25-650 mg</i> | 2 | QL (6 EA per 1 day) |
| *TRAMADOL COMBINATIONS*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; QL (300 EA per 30 days); AL (Min 12 Years) |
| *ANDROGENS-ANABOLIC* | | |
| *ANDROGENS*** | | |
| ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 MG/24HR, 4 MG/24HR | 4 | PA; QL (60 EA per 30 days) |
| ANDROXY ORAL TABLET 10 MG | 4 | PA; QL (120 EA per 30 days) |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml</i> | 2 | |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i> | 3 | |
| <i>testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%)</i> | 4 | QL (150 GM per 30 days) |
| <i>testosterone transdermal gel 10 mg/act (2%)</i> | 4 | QL (120 GM per 30 days) |
| <i>testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%)</i> | 2 | QL (300 GM per 30 days) |
| <i>testosterone transdermal gel 20.25 mg/1.25gm (1.62%)</i> | 4 | QL (75 GM per 30 days) |
| <i>testosterone transdermal gel 25 mg/2.5gm (1%)</i> | 2 | QL (75 GM per 30 days) |
| *ANORECTAL AND RELATED PRODUCTS* | | |
| *INTRARECTAL STEROIDS*** | | |
| CORTIFOAM RECTAL FOAM 10 % | 4 | |
| <i>hydrocortisone rectal enema 100 mg/60ml</i> | 2 | |
| *RECTAL ANESTHETIC/STEROIDS*** | | |
| <i>hydrocortisone ace-pramoxine rectal cream 1-1 %</i> | 2 | |
| <i>lidocaine-hydrocort (perianal) external cream 3-0.5 %</i> | 2 | |
| <i>lidocaine-hydrocortisone ace rectal cream 3-0.5 %</i> | 2 | |
| PROCTOFOAM HC EXTERNAL FOAM 1-1 % | 3 | |
| PROCTOFOAM HC RECTAL FOAM 1-1 % | 3 | |
| *RECTAL LOCAL ANESTHETICS*** | | |
| <i>pramoxine hcl rectal foam 1 %</i> | 2 | |
| PROCTOFOAM EXTERNAL FOAM 1 % | 4 | |
| *RECTAL STEROIDS*** | | |
| <i>hydrocortisone (perianal) external cream 2.5 %</i> | 2 | |
| <i>hydrocortisone rectal cream 2.5 %</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|---|
| PROCTOCARE-HC RECTAL CREAM 2.5 % | 2 | |
| PROCTO-MED HC EXTERNAL CREAM 2.5 % | 2 | |
| PROCTOSOL HC EXTERNAL CREAM 2.5 % | 2 | |
| PROCTOSOL HC RECTAL CREAM 2.5 % | 2 | |
| PROCTOZONE-HC EXTERNAL CREAM 2.5 % | 2 | |
| PROCTOZONE-HC RECTAL CREAM 2.5 % | 2 | |
| *ANTHELMINTICS* | | |
| *ANTHELMINTICS*** | | |
| <i>albendazole oral tablet 200 mg</i> | 5 | |
| BILTRICIDE ORAL TABLET 600 MG | 4 | |
| EMVERM ORAL TABLET CHEWABLE 100 MG | 5 | PA; QL (6 EA per 21 days) |
| <i>ivermectin oral tablet 3 mg</i> | 4 | DX (Diagnosis Code); QL (30 EA per 90 days) |
| *ANTIANGINAL AGENTS* | | |
| *ANTIANGINALS-OTHER*** | | |
| <i>ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg</i> | 4 | ST |
| *NITRATES*** | | |
| DILATRATE-SR ORAL CAPSULE EXTENDED RELEASE 40 MG | 3 | |
| <i>isosorbide dinitrate er oral tablet extended release 40 mg</i> | 3 | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| <i>isosorbide dinitrate oral tablet 30 mg</i> | 3 | |
| <i>isosorbide dinitrate sublingual tablet sublingual 2.5 mg</i> | 2 | |
| <i>isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg</i> | 2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| MINITRAN TRANSDERMAL PATCH 24 HOUR 0.6 MG/HR | 2 | |
| NITRO-BID TRANSDERMAL OINTMENT 2 % | 3 | |
| <i>nitroglycerin er oral capsule extended release 2.5 mg</i> | 3 | |
| <i>nitroglycerin er oral capsule extended release 6.5 mg, 9 mg</i> | 2 | |
| <i>nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg</i> | 2 | |
| <i>nitroglycerin sublingual tablet sublingual 0.6 mg</i> | 3 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 2 | |
| *ANTIANGIETY AGENTS* | | |

| Drug Name | Tier | Notes |
|---|------|---|
| *ANTIANXIETY AGENTS - MISC.*** | | |
| <i>bupirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>droperidol injection solution 2.5 mg/ml</i> | MB | |
| <i>hydroxyzine hcl intramuscular solution 25 mg/ml, 50 mg/ml</i> | MB | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>hydroxyzine hcl oral solution 10 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>hydroxyzine hcl oral syrup 10 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>meprobamate oral tablet 200 mg, 400 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *BENZODIAZEPINES*** | | |
| <i>alprazolam er oral tablet extended release 24 hour 0.5 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>alprazolam er oral tablet extended release 24 hour 1 mg, 2 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>alprazolam er oral tablet extended release 24 hour 3 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)</p> |
| <i>alprazolam oral tablet 2 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (135 EA per 30 days)</p> |
| <i>alprazolam xr oral tablet extended release 24 hour 0.5 mg, 1 mg, 2 mg</i> | 4 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>alprazolam xr oral tablet extended release 24 hour 3 mg</i> | 4 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>clorazepate dipotassium oral tablet 15 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)</p> |
| <i>clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)</p> |
| <i>diazepam injection solution 5 mg/ml</i> | MB | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| <i>lorazepam injection solution 2 mg/ml, 4 mg/ml</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.5 ML per 1 day)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>lorazepam oral concentrate 2 mg/ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (150 ML per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days) |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days) |
| *ANTIARRHYTHMICS* | | |
| *ANTIARRHYTHMICS TYPE I-A*** | | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 2 | |
| <i>quinidine gluconate er oral tablet extended release 324 mg</i> | 2 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 2 | |
| *ANTIARRHYTHMICS TYPE I-B*** | | |
| <i>lidocaine in d5w intravenous solution 3-5 mg/ml-%, 4-5 mg/ml-%</i> | MB | |
| <i>mexiletine hcl oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | |
| *ANTIARRHYTHMICS TYPE I-C*** | | |
| <i>flecainide acetate oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |
| *ANTIARRHYTHMICS TYPE III*** | | |
| <i>amiodarone hcl intravenous solution 150 mg/3ml</i> | 2 | |
| <i>amiodarone hcl oral tablet 200 mg, 400 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|---------------------------------|
| CORVERT INTRAVENOUS SOLUTION 1 MG/10ML | MB | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 4 | |
| MULTAQ ORAL TABLET 400 MG | 4 | PA; QL (60 EA per 30 days) |
| *ANTIASTHMATIC AND BRONCHODILATOR AGENTS* | | |
| *5-LIPOXYGENASE INHIBITORS*** | | |
| <i>zileuton er oral tablet extended release 12 hour 600 mg</i> | 5 | PA; QL (120 EA per 30 days); SP |
| *ADRENERGIC COMBINATIONS*** | | |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/ACT | 3 | QL (60 EA per 30 days) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/INH | 4 | ST; QL (30 EA per 30 days) |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT | 4 | QL (8 GM per 30 days) |
| DULERA INHALATION AEROSOL 100-5 MCG/ACT, 200-5 MCG/ACT, 50-5 MCG/ACT | 4 | ST; QL (13 GM per 30 days) |
| DUONEB INHALATION SOLUTION 0.5-2.5 (3) MG/3ML | MB | |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | 4 | QL (60 EA per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 4 | ST; QL (60 EA per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act</i> | 3 | QL (1 EA per 30 days) |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 2 | |
| STIOLTO RESPIMAT INHALATION AEROSOL SOLUTION 2.5-2.5 MCG/ACT | 3 | QL (4 GM per 30 days) |
| SYMBICORT INHALATION AEROSOL 160-4.5 MCG/ACT, 80-4.5 MCG/ACT | 3 | QL (10.2 GM per 30 days) |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT | 3 | PA; QL (60 EA per 30 days) |
| WIXELA INHUB INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/ACT, 250-50 MCG/ACT, 500-50 MCG/ACT | 4 | QL (60 EA per 30 days) |
| WIXELA INHUB INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE | 4 | ST; QL (60 EA per 30 days) |
| *ANTI-IGE MONOCLONAL ANTIBODIES*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML | MB | PA |
| *ANTI-INFLAMMATORY AGENTS*** | | |
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i> | 2 | |
| *BETA ADRENERGICS*** | | |
| <i>albuterol sulfate er oral tablet extended release 12 hour 4 mg, 8 mg</i> | 2 | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | 2 | Formulary NDCs/Manufactures: Ventolin HFA: 00173-0682-20 (Glaxo Smith Kline) / Generic Proventil HFA: 69097-0142-60 (Cipla US); 00254-1007-52 (PAR Pharmaceutical) / Generic Proair HFA: 00093-3174-31(Teva); 68180-0963-01 (Lupin Pharmaceuticals); 45802-0088-01 (Perrigo Pharmaceuticals) |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml</i> | 2 | |
| <i>albuterol sulfate oral syrup 2 mg/5ml</i> | 2 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 2 | |
| BROVANA INHALATION NEBULIZATION SOLUTION 15 MCG/2ML | MB | |
| <i>isoproterenol hcl injection solution 0.2 mg/ml</i> | MB | |
| <i>levalbuterol tartrate inhalation aerosol 45 mcg/act</i> | 4 | QL (30 GM per 30 days) |
| <i>metaproterenol sulfate oral syrup 10 mg/5ml</i> | 3 | |
| <i>metaproterenol sulfate oral tablet 10 mg, 20 mg</i> | 3 | |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/DOSE | 3 | |
| <i>terbutaline sulfate injection solution 1 mg/ml</i> | 2 | |
| <i>terbutaline sulfate oral tablet 2.5 mg, 5 mg</i> | 2 | |
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT | 3 | Formulary NDCs/Manufactures: Ventolin HFA: 00173-0682-20 (Glaxo Smith Kline) / Generic Proventil HFA: 69097-0142-60 (Cipla US); 00254-1007-52 (PAR Pharmaceutical) / Generic Proair HFA: 00093-3174-31(Teva); 68180-0963-01 (Lupin Pharmaceuticals); 45802-0088-01 (Perrigo Pharmaceuticals) |
| XOPENEX CONCENTRATE INHALATION NEBULIZATION SOLUTION 1.25 MG/0.5ML | MB | |
| *BRONCHODILATORS - ANTICHOLINERGICS*** | | |

| Drug Name | Tier | Notes |
|--|------|------------------------------|
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17 MCG/ACT | 3 | |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | |
| SPIRIVA HANDHALER INHALATION CAPSULE 18 MCG | 3 | |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT | 3 | |
| *LEUKOTRIENE RECEPTOR ANTAGONISTS*** | | |
| <i>montelukast sodium oral tablet 10 mg</i> | 2 | QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i> | 2 | QL (30 EA per 30 days) |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 2 | |
| *SELECTIVE PHOSPHODIESTERASE 4 (PDE4) INHIBITORS*** | | |
| <i>roflumilast oral tablet 500 mcg</i> | 3 | PA; QL (30 EA per 30 days) |
| *STEROID INHALANTS*** | | |
| ALVESCO INHALATION AEROSOL SOLUTION 160 MCG/ACT | 4 | ST; QL (12.2 GM per 30 days) |
| ALVESCO INHALATION AEROSOL SOLUTION 80 MCG/ACT | 4 | ST; QL (6.1 GM per 30 days) |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 3 | QL (30 EA per 30 days) |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml</i> | 2 | QL (120 ML per 30 days) |
| <i>fluticasone propionate diskus inhalation aerosol powder breath activated 100 mcg/act, 250 mcg/act, 50 mcg/act</i> | 3 | |
| <i>fluticasone propionate hfa inhalation aerosol 110 mcg/act, 220 mcg/act, 44 mcg/act</i> | 3 | |
| PULMICORT FLEXHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 180 MCG/ACT, 90 MCG/ACT | 4 | |
| QVAR REDHALER INHALATION AEROSOL BREATH ACTIVATED 40 MCG/ACT | 4 | QL (10.6 GM per 30 days) |
| QVAR REDHALER INHALATION AEROSOL BREATH ACTIVATED 80 MCG/ACT | 4 | QL (21.2 GM per 30 days) |
| *XANTHINES*** | | |
| <i>aminophylline intravenous solution 25 mg/ml</i> | MB | |
| ELIXOPHYLLIN ORAL ELIXIR 80 MG/15ML | 4 | |
| THEOCHRON ORAL TABLET EXTENDED RELEASE 12 HOUR 200 MG | 2 | |
| <i>theophylline er oral tablet extended release 12 hour 100 mg, 200 mg, 450 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|-------------------------|
| <i>theophylline er oral tablet extended release 12 hour 300 mg</i> | 3 | |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | 2 | |
| <i>theophylline in d5w intravenous solution 0.8-5 mg/ml-%</i> | MB | |
| *ANTICOAGULANTS* | | |
| *COUMARIN ANTICOAGULANTS*** | | |
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 2 | |
| *DIRECT FACTOR XA INHIBITORS*** | | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG | 3 | QL (74 EA per 365 days) |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG | 3 | QL (60 EA per 30 days) |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML | 3 | QL (600 ML per 30 days) |
| XARELTO ORAL TABLET 10 MG, 15 MG, 20 MG | 3 | QL (30 EA per 30 days) |
| XARELTO ORAL TABLET 2.5 MG | 3 | QL (60 EA per 30 days) |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG | 3 | QL (51 EA per 90 days) |
| *HEPARINS AND HEPARINOID-LIKE AGENTS*** | | |
| BD HEPARIN POSIFLUSH INTRAVENOUS SOLUTION 10 UNIT/ML, 100 UNIT/ML | 2 | |
| <i>heparin (porcine) in nacl injection solution 100-0.45 unit/ml-%, 50-0.45 unit/ml-%</i> | MB | |
| <i>heparin lock flush intravenous solution 100 unit/ml</i> | 2 | |
| <i>heparin na (pork) lock flsh pf intravenous solution 1 unit/ml, 10 unit/ml, 100 unit/ml</i> | 2 | |
| <i>heparin sod (pork) lock flush intravenous solution 1 unit/ml, 10 unit/ml, 100 unit/ml</i> | 2 | |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 5000 unit/ml</i> | 2 | |
| <i>heparin sodium (porcine) injection solution 20000 unit/ml</i> | 4 | |
| <i>heparin sodium (porcine) intravenous solution prefilled syringe 10000 unit/10ml, 3000 unit/3ml, 5000 unit/5ml</i> | 2 | |
| <i>heparin sodium (porcine) pf injection solution 1000 unit/ml, 5000 unit/0.5ml</i> | 2 | |
| <i>heparin sodium lock flush intravenous solution 10 unit/ml</i> | 2 | |
| *LOW MOLECULAR WEIGHT HEPARINS*** | | |
| <i>enoxaparin sodium injection solution 300 mg/3ml</i> | 2 | PA |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 120 mg/0.8ml, 150 mg/ml, 30 mg/0.3ml, 40 mg/0.4ml, 60 mg/0.6ml, 80 mg/0.8ml</i> | 2 | PA |
| <i>enoxaparin sodium subcutaneous solution 100 mg/ml, 120 mg/0.8ml, 150 mg/ml, 30 mg/0.3ml, 40 mg/0.4ml, 60 mg/0.6ml, 80 mg/0.8ml</i> | 2 | PA |
| FRAGMIN SUBCUTANEOUS SOLUTION 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 2500 UNIT/0.2ML, 25000 UNIT/ML, 5000 UNIT/0.2ML, 7500 UNIT/0.3ML | 5 | PA; QL (30 ML per 30 days) |
| FRAGMIN SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 2500 UNIT/0.2ML, 5000 UNIT/0.2ML, 7500 UNIT/0.3ML | 5 | PA; QL (30 ML per 30 days) |
| *SYNTHETIC HEPARINOID-LIKE AGENTS*** | | |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml, 2.5 mg/0.5ml, 5 mg/0.4ml, 7.5 mg/0.6ml</i> | 5 | PA |
| *THROMBIN INHIBITORS - HIRUDIN TYPE*** | | |
| ANGIOMAX INTRAVENOUS SOLUTION RECONSTITUTED 250 MG | MB | |
| *THROMBIN INHIBITORS - SELECTIVE DIRECT & REVERSIBLE*** | | |
| <i>argatroban intravenous solution 250 mg/2.5ml</i> | MB | |
| <i>dabigatran etexilate mesylate oral capsule 110 mg</i> | 4 | PA; QL (2 EA per 1 Day) |
| <i>dabigatran etexilate mesylate oral capsule 150 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| <i>dabigatran etexilate mesylate oral capsule 75 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| *ANTICONVULSANTS* | | |
| *ANTICONVULSANTS - BENZODIAZEPINES*** | | |
| <i>clonazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 2 | QL (90 EA per 30 days) |
| <i>diazepam rectal gel 10 mg, 2.5 mg, 20 mg</i> | 3 | ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (5 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (10 EA per 30 days) |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML | 5 | PA; QL (10 EA per 30 days) |
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML | 5 | PA; QL (5 packs per 30 Days) |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML | 5 | PA; QL (5 packs per 30 Days) |
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML | 5 | PA; QL (10 EA per 30 days) |
| *ANTICONVULSANTS - MISC.*** | | |
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>carbamazepine oral suspension 100 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>carbamazepine oral tablet 200 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>carbamazepine oral tablet chewable 100 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>gabapentin oral solution 250 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>lacosamide oral solution 10 mg/ml</i> | 5 | ST; QL (1200 ML per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | QL (60 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>lamotrigine er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>lamotrigine er oral tablet extended release 24 hour 200 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>lamotrigine er oral tablet extended release 24 hour 250 mg, 300 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>lamotrigine oral tablet chewable 25 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 4 | QL (120 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|-------------|---|
| <i>levetiracetam intravenous solution 500 mg/5ml</i> | MB | |
| <i>levetiracetam oral solution 100 mg/ml</i> | 2 | |
| <i>levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg</i> | 2 | |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| POTIGA ORAL TABLET 200 MG, 300 MG, 400 MG, 50 MG | 4 | PA; QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>primidone oral tablet 250 mg, 50 mg</i> | 2 | |
| ROWEEPRA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 500 MG, 750 MG | 4 | QL (120 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|-------------|---|
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| *CARBAMATES*** | | |
| <i>felbamate oral suspension 600 mg/5ml</i> | 4 | QL (900 ML per 30 days) |
| <i>felbamate oral tablet 400 mg</i> | 4 | QL (90 EA per 30 days) |
| <i>felbamate oral tablet 600 mg</i> | 5 | QL (180 EA per 30 days) |
| *GABA MODULATORS*** | | |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 4 | |
| *HYDANTOINS*** | | |
| DILANTIN INFATABS ORAL TABLET CHEWABLE 50 MG | 4 | |
| DILANTIN ORAL CAPSULE 30 MG | 4 | |
| <i>fosphenytoin sodium injection solution 100 mg pe/2ml, 500 mg pe/10ml</i> | MB | |
| <i>phenytoin oral suspension 125 mg/5ml</i> | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>phenytoin sodium injection solution 50 mg/ml</i> | MB | |
| *SUCCINIMIDES*** | | |
| <i>ethosuximide oral capsule 250 mg</i> | 2 | |
| <i>ethosuximide oral solution 250 mg/5ml</i> | 2 | |
| *VALPROIC ACID*** | | |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>divalproex sodium oral capsule sprinkle 125 mg</i> | 2 | |
| <i>divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>valproic acid oral capsule 250 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>valproic acid oral syrup 250 mg/5ml</i> | 2 | |
| *ANTIDEPRESSANTS* | | |
| *ALPHA-2 RECEPTOR ANTAGONISTS (TETRACYCLICS)*** | | |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIDEPRESSANTS - MISC.*** | | |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 300 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>maprotiline hcl oral tablet 25 mg, 50 mg, 75 mg</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *MONOAMINE OXIDASE INHIBITORS (MAOIS)*** | | |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>phenelzine sulfate oral tablet 15 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>tranylcypromine sulfate oral tablet 10 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTOR ANTAGONISTS*** | | |

| Drug Name | Tier | Notes |
|--|------|--|
| SPRAVATO (56 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE | MB | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| SPRAVATO (84 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE | MB | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)*** | | |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (600 ML per 30 days) |
| <i>citalopram hydrobromide oral tablet 10 mg, 20 mg</i> | 1 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>citalopram hydrobromide oral tablet 40 mg</i> | 1 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>escitalopram oxalate oral solution 5 mg/5ml</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (600 ML per 30 days)</p> |
| <i>escitalopram oxalate oral tablet 10 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (45 EA per 30 days)</p> |
| <i>escitalopram oxalate oral tablet 20 mg, 5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>paroxetine hcl er oral tablet extended release 24 hour 12.5 mg, 25 mg, 37.5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>paroxetine hcl oral suspension 10 mg/5ml</i> | 4 | <p>PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days)</p> |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg</i> | 1 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>paroxetine hcl oral tablet 40 mg</i> | 1 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (45 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>sertraline hcl oral concentrate 20 mg/ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>sertraline hcl oral tablet 100 mg, 25 mg</i> | 1 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>sertraline hcl oral tablet 50 mg</i> | 1 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (45 EA per 30 days) |
| *SEROTONIN MODULATORS*** | | |
| <i>nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| *SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)*** | | |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 60 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *TRICYCLIC AGENTS*** | | |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>doxepin hcl oral concentrate 10 mg/ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIDIABETICS* | | |
| *ALPHA-GLUCOSIDASE INHIBITORS*** | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| *ANTIDIABETIC - AMYLIN ANALOGS*** | | |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700 MCG/2.7ML | 4 | PA |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500 MCG/1.5ML | 4 | PA |
| *BIGUANIDES*** | | |

| Drug Name | Tier | Notes |
|---|------|----------------------------|
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg</i> | 1 | |
| <i>metformin hcl er oral tablet extended release 24 hour 750 mg</i> | 2 | |
| <i>metformin hcl oral tablet 1000 mg, 500 mg, 850 mg</i> | 1 | |
| *DIABETIC OTHER*** | | |
| BAQSIMI ONE PACK NASAL POWDER 3 MG/DOSE | 3 | |
| BAQSIMI TWO PACK NASAL POWDER 3 MG/DOSE | 3 | |
| GVOKE HYOPEN 1-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.5 MG/0.1ML, 1 MG/0.2ML | 3 | |
| GVOKE HYOPEN 2-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.5 MG/0.1ML, 1 MG/0.2ML | 3 | |
| GVOKE KIT SUBCUTANEOUS SOLUTION 1 MG/0.2ML | 3 | |
| GVOKE PFS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 0.5 MG/0.1ML, 1 MG/0.2ML | 3 | |
| *DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS*** | | |
| <i>alogliptin benzoate oral tablet 12.5 mg, 25 mg, 6.25 mg</i> | 3 | QL (30 EA per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | ST; QL (30 EA per 30 days) |
| <i>saxagliptin hcl oral tablet 2.5 mg, 5 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| *DIPEPTIDYL PEPTIDASE-4 INHIBITOR-BIGUANIDE COMBINATIONS*** | | |
| <i>alogliptin-metformin hcl oral tablet 12.5-1000 mg, 12.5-500 mg</i> | 3 | ST; QL (60 EA per 30 days) |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG | 3 | ST; QL (60 EA per 30 days) |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG | 3 | ST; QL (30 EA per 30 days) |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG, 50-500 MG | 3 | ST; QL (60 EA per 30 days) |
| <i>saxagliptin-metformin er oral tablet extended release 24 hour 2.5-1000 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| <i>saxagliptin-metformin er oral tablet extended release 24 hour 5-1000 mg, 5-500 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| *DPP-4 INHIBITOR-THIAZOLIDINEDIONE COMBINATIONS*** | | |
| <i>alogliptin-pioglitazone oral tablet 12.5-15 mg, 12.5-30 mg, 12.5-45 mg, 25-15 mg, 25-30 mg, 25-45 mg</i> | 3 | ST; QL (30 EA per 30 days) |
| OSENI ORAL TABLET 25-45 MG | 3 | ST; QL (30 EA per 30 days) |
| *HUMAN INSULIN*** | | |

| Drug Name | Tier | Notes |
|--|------|---|
| APIDRA INJECTION SOLUTION 100 UNIT/ML | 4 | ST; QL (50 ML per 30 days) |
| HUMALOG KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 4 | ST; QL (45 ML per 30 days) |
| HUMALOG MIX 50/50 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (50-50) 100 UNIT/ML | 4 | ST; QL (45 ML per 30 days) |
| HUMALOG MIX 50/50 SUBCUTANEOUS SUSPENSION (50-50) 100 UNIT/ML | 4 | ST; QL (50 ML per 30 days) |
| HUMALOG MIX 75/25 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (75-25) 100 UNIT/ML | 4 | ST; QL (45 ML per 30 days) |
| HUMALOG MIX 75/25 SUBCUTANEOUS SUSPENSION (75-25) 100 UNIT/ML | 4 | ST; QL (50 ML per 30 days) |
| HUMALOG SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 4 | ST; QL (50 ML per 30 days) |
| HUMULIN 70/30 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 4 | ST; QL (45 ML per 30 days) |
| HUMULIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 4 | ST; QL (50 ML per 30 days) |
| HUMULIN N KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 4 | ST; QL (45 ML per 30 days) |
| HUMULIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 4 | QL (50 ML per 30 days) |
| HUMULIN R INJECTION SOLUTION 100 UNIT/ML | 4 | ST; QL (50 ML per 30 days) |
| HUMULIN R U-500 (CONCENTRATED) SUBCUTANEOUS SOLUTION 500 UNIT/ML | 4 | PA; QL (20 ML per 30 days) |
| HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 500 UNIT/ML | 4 | PA; QL (18 ML per 30 days) |
| <i>insulin asp prot & asp flexpen subcutaneous suspension pen-injector (70-30) 100 unit/ml</i> | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| <i>insulin aspart flexpen subcutaneous solution pen-injector 100 unit/ml</i> | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>insulin aspart injection solution 100 unit/ml</i> | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| <i>insulin aspart penfill subcutaneous solution cartridge 100 unit/ml</i> | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |
| <i>insulin aspart prot & aspart subcutaneous suspension (70-30) 100 unit/ml</i> | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| <i>insulin aspart subcutaneous solution 100 unit/ml</i> | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>insulin glargine-yfgn subcutaneous solution pen-injector 100 unit/ml</i> | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| <i>insulin lispro injection solution 100 unit/ml</i> | 4 | ST; QL (50 ML per 30 days) |
| <i>insulin lispro subcutaneous solution 100 unit/ml</i> | 4 | ST; QL (50 EA per 30 days) |
| LEVEMIR FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| NOVOLIN 70/30 FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| NOVOLIN 70/30 PENFILL SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| NOVOLIN 70/30 RELION SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| NOVOLIN N FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |

| Drug Name | Tier | Notes |
|--|------|--|
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |
| NOVOLIN N PENFILL SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |
| NOVOLIN N RELION SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| NOVOLIN R FLEXPEN RELION INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| NOVOLIN R PENFILL INJECTION SOLUTION 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |
| NOVOLIN R RELION INJECTION SOLUTION 100 UNIT/ML | 3 | <p>CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)</p> |
| NOVOLOG 70/30 FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3 | <p>Formulary Alternative: Insulin Aspart Protamine Flexpen; CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| NOVOLOG FLEXPEN RELION SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | Formulary Alternative: Insulin Aspart Flexpen; CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |
| NOVOLOG MIX 70/30 RELION SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| NOVOLOG RELION INJECTION SOLUTION 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| NOVOLOG RELION SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days) |
| *INCRETIN MIMETIC AGENTS (GIP & GLP-1 RECEPTOR AGONISTS)*** | | |
| MOUNJARO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML | 3 | PA; QL (2 ML per 28 days) |
| *INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)*** | | |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML | 3 | PA; QL (2 ML per 28 days) |
| *MEGLITINIDE ANALOGUES*** | | |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 1 | |
| <i>repaglinide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 4 | |
| *MEGLITINIDE-BIGUANIDE COMBINATIONS*** | | |
| <i>repaglinide-metformin hcl oral tablet 1-500 mg, 2-500 mg</i> | 4 | |
| *SGLT2 INHIBITOR - DPP-4 INHIBITOR COMBINATIONS*** | | |
| STEGLUJAN ORAL TABLET 15-100 MG, 5-100 MG | 3 | ST; QL (30 EA per 30 days) |
| *SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS*** | | |
| FARXIGA ORAL TABLET 10 MG, 5 MG | 3 | ST; QL (30 EA per 30 days) |
| STEGLATRO ORAL TABLET 15 MG, 5 MG | 3 | ST; QL (30 EA per 30 days) |
| *SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR-BIGUANIDE COMB*** | | |
| SEGLUROMET ORAL TABLET 2.5-1000 MG, 2.5-500 MG, 7.5-1000 MG, 7.5-500 MG | 3 | ST; QL (60 EA per 30 days) |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 10-500 MG, 5-500 MG | 3 | ST; QL (30 EA per 30 days) |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG, 5-1000 MG | 3 | ST; QL (60 EA per 30 days) |
| *SULFONYLUREA-BIGUANIDE COMBINATIONS*** | | |

| Drug Name | Tier | Notes |
|--|------|------------------------|
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg</i> | 2 | |
| <i>glipizide-metformin hcl oral tablet 2.5-500 mg, 5-500 mg</i> | 1 | |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 5-500 mg</i> | 1 | |
| <i>glyburide-metformin oral tablet 2.5-500 mg</i> | 2 | |
| *SULFONYLUREAS*** | | |
| <i>chlorpropamide oral tablet 100 mg, 250 mg</i> | 3 | |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 1 | |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>tolazamide oral tablet 250 mg, 500 mg</i> | 3 | |
| <i>tolbutamide oral tablet 500 mg</i> | 3 | |
| *SULFONYLUREA-THIAZOLIDINEDIONE COMBINATIONS*** | | |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg</i> | 2 | ST |
| *THIAZOLIDINEDIONE-BIGUANIDE COMBINATIONS*** | | |
| AVANDAMET ORAL TABLET 2-1000 MG | 4 | ST |
| AVANDAMET ORAL TABLET 2-500 MG, 4-1000 MG, 4-500 MG | 4 | |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i> | 2 | ST |
| *THIAZOLIDINEDIONES*** | | |
| AVANDIA ORAL TABLET 2 MG, 4 MG, 8 MG | 4 | ST |
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i> | 2 | QL (30 EA per 30 days) |
| *ANTIDIARRHEAL/PROBIOTIC AGENTS* | | |
| *ANTIPERISTALTIC AGENTS*** | | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml</i> | 3 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 2 | |
| *ANTIDOTES AND SPECIFIC ANTAGONISTS* | | |
| *ANTIDOTES AND SPECIFIC ANTAGONISTS*** | | |
| ACETADOTE INTRAVENOUS SOLUTION 200 MG/ML | MB | |

| Drug Name | Tier | Notes |
|---|------|--|
| ANDEXXA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 200 MG | MB | |
| <i>calcium disodium versenate injection solution 1 gm/5ml</i> | MB | |
| DEFERAL INJECTION SOLUTION RECONSTITUTED 500 MG | MB | |
| <i>fomepizole intravenous solution 1.5 gm/1.5ml</i> | MB | |
| PROTOPAM CHLORIDE INTRAVENOUS SOLUTION RECONSTITUTED 1 GM | MB | |
| *OPIOID ANTAGONISTS*** | | |
| <i>naloxone hcl injection solution 0.4 mg/ml</i> | 2 | Naloxone injectable used with nasal atomizer is covered.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2 ML per 30 days) |
| <i>naloxone hcl injection solution 1 mg/ml</i> | 2 | Naloxone injectable used with nasal atomizer is covered.; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (4 ML per 30 days) |
| <i>naloxone hcl injection solution prefilled syringe 2 mg/2ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>naloxone hcl nasal liquid 4 mg/0.1ml</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>naltrexone hcl oral tablet 50 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIEMETICS* | | |
| *5-HT3 RECEPTOR ANTAGONISTS*** | | |
| ANZEMET ORAL TABLET 100 MG, 50 MG | 4 | PA; QL (4 EA per 30 days) |
| <i>granisetron hcl intravenous solution 1 mg/ml, 4 mg/4ml</i> | MB | |
| <i>granisetron hcl oral tablet 1 mg</i> | 2 | ST; QL (20 EA per 30 days) |
| <i>ondansetron hcl injection solution 4 mg/2ml, 40 mg/20ml</i> | MB | |
| <i>ondansetron hcl injection solution prefilled syringe 4 mg/2ml</i> | MB | |
| <i>ondansetron hcl oral solution 4 mg/5ml</i> | 2 | AL (Max 4 Years) |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | QL (90 EA per 30 days) |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | 2 | QL (90 EA per 30 days) |
| <i>palonosetron hcl intravenous solution 0.25 mg/2ml</i> | MB | QL (2 ML per 5 days) |
| <i>palonosetron hcl intravenous solution 0.25 mg/5ml</i> | MB | QL (5 ML per 5 days) |
| *ANTIEMETICS - ANTICHOLINERGIC*** | | |
| <i>meclizine hcl oral tablet 25 mg</i> | 2 | |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i> | 4 | |
| TIGAN INTRAMUSCULAR SOLUTION 100 MG/ML | MB | |
| <i>trimethobenzamide hcl oral capsule 300 mg</i> | 2 | |
| *ANTIEMETICS - MISCELLANEOUS*** | | |
| CESAMET ORAL CAPSULE 1 MG | MB | |
| *SUBSTANCE P/NEUROKININ 1 (NK1) RECEPTOR ANTAGONISTS*** | | |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>aprepitant oral capsule 125 mg, 40 mg</i> | 4 | PA; Quantity is limited to 40mg and 125mg=1 per fill, 80/125 Pack=3(1 package)per fill, 80 mg=3 per fill; QL (1 EA per 30 days) |
| <i>aprepitant oral capsule 80 & 125 mg, 80 mg</i> | 4 | PA; Quantity is limited to 40mg and 125mg=1 per fill, 80/125 Pack=3(1 package)per fill, 80 mg=3 per fill; QL (3 EA per 30 days) |
| CINVANTI INTRAVENOUS EMULSION 130 MG/18ML | MB | PA |
| EMEND ORAL SUSPENSION RECONSTITUTED 125 MG/5ML | 5 | PA; QL (6 EA per 28 days) |
| <i>fosaprepitant dimeglumine intravenous solution reconstituted 150 mg</i> | MB | QL (4 EA per 30 days) |
| *ANTIFUNGALS* | | |
| *ANTIFUNGAL - GLUCAN SYNTHESIS INHIBITORS (ECHINOCANDINS)*** | | |
| <i>caspofungin acetate intravenous solution reconstituted 50 mg, 70 mg</i> | MB | |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG | MB | |
| <i>micafungin sodium intravenous solution reconstituted 50 mg</i> | MB | |
| *ANTIFUNGALS*** | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | MB | |
| AMPHOTEC INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG, 50 MG | MB | |
| <i>amphotericin b injection solution reconstituted 50 mg</i> | MB | |
| <i>bio-statin oral capsule 500000 unit</i> | 3 | |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i> | 2 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg</i> | 4 | |
| GRIS-PEG ORAL TABLET 250 MG | 4 | |
| <i>nystatin oral tablet 500000 unit</i> | 2 | |
| <i>terbinafine hcl oral tablet 250 mg</i> | 2 | QL (90 EA per 365 days) |
| *IMIDAZOLES*** | | |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | |
| *TRIAZOLES*** | | |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%</i> | MB | |
| <i>fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>itraconazole oral capsule 100 mg</i> | 5 | ST; QL (168 EA per 365 days) |
| VFEND IV INTRAVENOUS SOLUTION RECONSTITUTED 200 MG | MB | |
| <i>voriconazole intravenous solution reconstituted 200 mg</i> | MB | |
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i> | 4 | PA; QL (150 ML per 14 days) |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| *ANTIHISTAMINES* | | |
| *ANTIHISTAMINES - ETHANOLAMINES*** | | |
| <i>carbinoxamine maleate oral tablet 4 mg</i> | 4 | |
| <i>diphenhydramine hcl injection solution 50 mg/ml</i> | MB | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>diphenhydramine hcl oral elixir 12.5 mg/5ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIHISTAMINES - NON-SEDATING*** | | |
| <i>cetirizine hcl oral solution 5 mg/5ml</i> | 2 | QL (150 ML per 30 days) |
| <i>cetirizine hcl oral tablet 10 mg, 5 mg</i> | 2 | QL (30 EA per 30 days) |
| <i>desloratadine oral tablet 5 mg</i> | 4 | |
| <i>levocetirizine dihydrochloride oral solution 2.5 mg/5ml</i> | 4 | |

| Drug Name | Tier | Notes |
|---|------|---------------------------------|
| levocetirizine dihydrochloride oral tablet 5 mg | 4 | |
| *ANTIHISTAMINES - PHENOTHIAZINES*** | | |
| promethazine hcl injection solution 25 mg/ml, 50 mg/ml | 2 | |
| promethazine hcl oral solution 6.25 mg/5ml | 2 | |
| promethazine hcl oral syrup 6.25 mg/5ml | 2 | |
| promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg | 2 | |
| promethazine hcl rectal suppository 12.5 mg, 25 mg | 2 | |
| *ANTIHISTAMINES - PIPERIDINES*** | | |
| cyproheptadine hcl oral syrup 2 mg/5ml | 2 | |
| cyproheptadine hcl oral tablet 4 mg | 2 | |
| *ANTHYPERLIPIDEMICS* | | |
| *ANTHYPERLIPIDEMICS - MISC.*** | | |
| omega-3-acid ethyl esters oral capsule 1 gm | 4 | QL (120 EA per 30 days) |
| *BILE ACID SEQUESTRANTS*** | | |
| cholestyramine light oral packet 4 gm | 2 | |
| cholestyramine light oral powder 4 gm/dose | 2 | |
| cholestyramine oral packet 4 gm | 1 | |
| cholestyramine oral powder 4 gm/dose | 2 | |
| colesevelam hcl oral packet 3.75 gm | 5 | QL (30 EA per 30 days) |
| colesevelam hcl oral tablet 625 mg | 2 | |
| colestipol hcl oral tablet 1 gm | 4 | |
| PREVALITE ORAL PACKET 4 GM | 2 | |
| PREVALITE ORAL POWDER 4 GM/DOSE | 2 | |
| *FIBRIC ACID DERIVATIVES*** | | |
| fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg | 2 | |
| fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg | 2 | |
| gemfibrozil oral tablet 600 mg | 2 | |
| *HMG COA REDUCTASE INHIBITORS*** | | |
| atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg | \$0 | QL (30 EA per 30 days) |
| fluvastatin sodium oral capsule 20 mg, 40 mg | 4 | |
| lovastatin oral tablet 10 mg, 20 mg, 40 mg | \$0 | \$0 Copay per PPACA guidelines. |
| pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg | 4 | ST |
| pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg, 80 mg | \$0 | |

| Drug Name | Tier | Notes |
|---|------|---------------------------------|
| <i>rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 2 | |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | \$0 | \$0 Copay per PPACA guidelines. |
| *INTEST CHOLEST ABSORP INHIB-HMG COA REDUCTASE INHIB COMB*** | | |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 4 | |
| *INTESTINAL CHOLESTEROL ABSORPTION INHIBITORS*** | | |
| <i>ezetimibe oral tablet 10 mg</i> | 2 | |
| *NICOTINIC ACID DERIVATIVES*** | | |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg</i> | 2 | |
| *PCSK9 INHIBITORS*** | | |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML | 5 | PA; QL (3.5 ML per 28 days); SP |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML | 5 | PA; QL (2 ML per 28 days); SP |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML | 5 | PA; QL (2 ML per 28 days); SP |
| *ANTIHYPERTENSIVES* | | |
| *ACE INHIBITOR & CALCIUM CHANNEL BLOCKER COMBINATIONS*** | | |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 2 | |
| *ACE INHIBITORS & THIAZIDE/THIAZIDE-LIKE*** | | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 2 | |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | 3 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 2 | |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i> | 2 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 2 | |
| <i>moexipril-hydrochlorothiazide oral tablet 15-12.5 mg, 15-25 mg, 7.5-12.5 mg</i> | 2 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 2 | |
| *ACE INHIBITORS*** | | |

| Drug Name | Tier | Notes |
|---|------|----------------------------|
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>enalapril maleate oral solution 1 mg/ml</i> | 5 | PA; AL (Max 12 Years) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i> | 2 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1 | |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i> | 2 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 4 | |
| QBRELIS ORAL SOLUTION 1 MG/ML | 5 | PA |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 2 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 2 | |
| *AGENTS FOR PHEOCHROMOCYTOMA*** | | |
| <i>phenoxybenzamine hcl oral capsule 10 mg</i> | 4 | |
| <i>phentolamine mesylate injection solution reconstituted 5 mg</i> | MB | |
| *ANGIOTENSIN II RECEPTOR ANTAG & THIAZIDE/THIAZIDE-LIKE*** | | |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 4 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 2 | |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 2 | |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 4 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 2 | |
| *ANGIOTENSIN II RECEPTOR ANTAGONISTS*** | | |
| <i>candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 4 | |
| <i>eprosartan mesylate oral tablet 600 mg</i> | 4 | ST |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 2 | |
| <i>losartan potassium oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 4 | ST; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 4 | QL (60 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| *ANTIADRENERGICS - CENTRALLY ACTING*** | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | |
| <i>clonidine hcl transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 2 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 2 | |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i> | 1 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | 1 | |
| *ANTIADRENERGICS - PERIPHERALLY ACTING*** | | |
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 2 | |
| <i>prazosin hcl oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| *BETA BLOCKER & DIURETIC COMBINATIONS*** | | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 2 | |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 2 | |
| <i>propranolol-hctz oral tablet 40-25 mg, 80-25 mg</i> | 3 | |
| TENORETIC 100 ORAL TABLET 100-25 MG | 2 | |
| TENORETIC 50 ORAL TABLET 50-25 MG | 2 | |
| *DIRECT RENIN INHIBITORS & THIAZIDE/THIAZIDE-LIKE COMB*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG | 4 | PA; QL (30 EA per 30 days) |
| *DIRECT RENIN INHIBITORS*** | | |
| <i>aliskiren fumarate oral tablet 150 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| TEKTURNA ORAL TABLET 150 MG, 300 MG | 4 | PA; QL (30 EA per 30 days) |
| *SELECTIVE ALDOSTERONE RECEPTOR ANTAGONISTS (SARAS)*** | | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 4 | |
| *VASODILATORS*** | | |
| <i>hydralazine hcl injection solution 20 mg/ml</i> | MB | |
| <i>hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | |
| *ANTI-INFECTIVE AGENTS - MISC.* | | |
| *ANTI-INFECTIVE AGENTS - MISC.*** | | |
| <i>baciim intramuscular solution reconstituted 50000 unit</i> | 4 | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| PENTAM INJECTION SOLUTION RECONSTITUTED 300 MG | 5 | |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i> | 4 | QL (1 EA per 28 days) |
| <i>trimethoprim oral tablet 100 mg</i> | 2 | |
| <i>vancomycin hcl intravenous solution reconstituted 5000 mg</i> | 2 | |
| XIFAXAN ORAL TABLET 200 MG | 5 | PA; QL (9 EA per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; QL (60 EA per 30 days) |
| *ANTI-INFECTIVE MISC. - COMBINATIONS*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>erythromycin-sulfisoxazole oral suspension reconstituted 200-600 mg/5ml</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 2 | |
| *ANTIPROTOZOAL AGENTS*** | | |
| <i>atovaquone oral suspension 750 mg/5ml</i> | 2 | |
| *CARBAPENEM COMBINATIONS*** | | |
| PRIMAXIN IV INTRAVENOUS SOLUTION RECONSTITUTED 250-250 MG | MB | |
| *CARBAPENEMS*** | | |
| INVANZ INJECTION SOLUTION RECONSTITUTED 1 GM | MB | |
| MERREM INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | |
| *CHLORAMPHENICALS*** | | |
| <i>chloramphenicol sod succinate intravenous solution reconstituted 1 gm</i> | MB | |
| *GLYCOPEPTIDES*** | | |
| <i>vancomycin hcl in dextrose intravenous solution 1-5 gm/200ml-%, 500-5 mg/100ml-%</i> | MB | |
| <i>vancomycin hcl in nacl intravenous solution 1-0.9 gm/200ml-%, 500-0.9 mg/100ml-%, 750-0.9 mg/150ml-%</i> | MB | |
| <i>vancomycin hcl intravenous solution reconstituted 1000 mg, 500 mg</i> | 2 | |
| <i>vancomycin hcl oral capsule 125 mg</i> | 4 | QL (56 EA per 14 days) |
| <i>vancomycin hcl oral capsule 250 mg</i> | 4 | PA; QL (80 EA per 30 days) |
| <i>vancomycin hcl oral solution reconstituted 25 mg/ml, 50 mg/ml</i> | 3 | QL (300 ML per 14 days) |
| VIBATIV INTRAVENOUS SOLUTION RECONSTITUTED 750 MG | MB | |
| *LEPROSTATICS*** | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 3 | |

| Drug Name | Tier | Notes |
|--|------|--|
| *LINCOSAMIDES*** | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml</i> | 2 | |
| <i>lincomycin hcl injection solution 300 mg/ml</i> | MB | |
| *MONOBACTAMS*** | | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG | 5 | PA; QL (84 ML per 56 days); SP |
| *OXAZOLIDINONES*** | | |
| <i>linezolid intravenous solution 2 mg/ml</i> | MB | PA |
| <i>linezolid oral suspension reconstituted 100 mg/5ml</i> | 5 | PA |
| <i>linezolid oral tablet 600 mg</i> | 5 | PA |
| *POLYMYXINS*** | | |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i> | MB | |
| *STREPTOGRAMIN COMBINATIONS*** | | |
| SYNERCID INTRAVENOUS SOLUTION RECONSTITUTED 150-350 MG | MB | |
| *URINARY ANTI-INFECTIVES*** | | |
| <i>fosfomycin tromethamine oral packet 3 gm</i> | 4 | |
| <i>methenamine hippurate oral tablet 1 gm</i> | 2 | |
| <i>methenamine mandelate oral tablet 0.5 gm</i> | 3 | |
| <i>methenamine mandelate oral tablet 1 gm</i> | 2 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i> | 2 | |
| <i>nitrofurantoin oral suspension 25 mg/5ml</i> | 4 | QL (560 ML per 7 days); AL (Max 12 Years) |
| *ANTIMALARIALS* | | |
| *ANTIMALARIAL COMBINATIONS*** | | |
| <i>atovaquone-proguanil hcl oral tablet 62.5-25 mg</i> | 4 | |

| Drug Name | Tier | Notes |
|--|------|-------------------------------------|
| *ANTIMALARIALS*** | | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>hydroxychloroquine sulfate oral tablet 200 mg</i> | 2 | |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg, 26.3 mg</i> | 3 | |
| *ANTIMYASTHENIC/CHOLINERGIC AGENTS* | | |
| *ANTIMYASTHENIC/CHOLINERGIC AGENTS*** | | |
| FIRDAPSE ORAL TABLET 10 MG | 5 | PA; LA; QL (240 EA per 30 days); SP |
| MESTINON ORAL SYRUP 60 MG/5ML | 4 | |
| <i>neostigmine methylsulfate intravenous solution 5 mg/10ml</i> | MB | |
| <i>pyridostigmine bromide oral solution 60 mg/5ml</i> | 4 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | 2 | |
| *ANTIMYCOBACTERIAL AGENTS* | | |
| *ANTI TB COMBINATIONS*** | | |
| RIFAMATE ORAL CAPSULE 150-300 MG | 5 | |
| *ANTIMYCOBACTERIAL AGENTS*** | | |
| <i>ethambutol hcl oral tablet 100 mg, 400 mg</i> | 2 | |
| <i>isoniazid oral syrup 50 mg/5ml</i> | 3 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 3 | |
| PASER ORAL PACKET 4 GM | 2 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 3 | |
| <i>rifabutin oral capsule 150 mg</i> | 5 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| *ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES* | | |
| *ALKYLATING AGENTS*** | | |
| <i>busulfan intravenous solution 6 mg/ml</i> | MB | |
| <i>carboplatin intravenous solution 50 mg/5ml</i> | MB | |
| <i>cisplatin intravenous solution 100 mg/100ml, 50 mg/50ml</i> | MB | |
| HEXALEN ORAL CAPSULE 50 MG | 5 | PA; SP |
| MYLERAN ORAL TABLET 2 MG | 5 | PA; SP |
| <i>oxaliplatin intravenous solution 50 mg/10ml</i> | MB | |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>thiotepa injection solution reconstituted 15 mg</i> | MB | |
| ZEPZELCA INTRAVENOUS SOLUTION RECONSTITUTED 4 MG | MB | PA |
| *ANDROGEN BIOSYNTHESIS INHIBITORS*** | | |
| <i>abiraterone acetate oral tablet 250 mg</i> | 4 | QL (120 EA per 30 days) |
| *ANTIADRENALS*** | | |
| LYSODREN ORAL TABLET 500 MG | 5 | |
| *ANTIANDROGENS*** | | |
| <i>bicalutamide oral tablet 50 mg</i> | 2 | |
| ERLEADA ORAL TABLET 240 MG | 5 | PA; QL (1 EA per 1 day); SP |
| ERLEADA ORAL TABLET 60 MG | 5 | PA; QL (120 EA per 30 days) |
| <i>flutamide oral capsule 125 mg</i> | 2 | |
| NUBEQA ORAL TABLET 300 MG | 5 | PA; QL (120 EA per 30 days); SP |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA; QL (120 EA per 30 days); SP |
| XTANDI ORAL TABLET 40 MG | 5 | PA; QL (120 EA per 30 days); SP |
| XTANDI ORAL TABLET 80 MG | 5 | PA; QL (60 EA per 30 days); SP |
| *ANTIESTROGENS*** | | |
| FARESTON ORAL TABLET 60 MG | 5 | PA; QL (30 EA per 30 days); SP |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i> | 2 | DX (Diagnosis Code at Point of Sale is accepted.) |
| *ANTIMETABOLITES*** | | |
| ADRUCIL INTRAVENOUS SOLUTION 500 MG/10ML | MB | |
| <i>capecitabine oral tablet 150 mg, 500 mg</i> | 4 | |
| <i>cytarabine (pf) injection solution 100 mg/ml</i> | MB | |
| DEPOCYT INTRATHECAL SUSPENSION 50 MG/5ML | MB | |
| <i>fludarabine phosphate intravenous solution 50 mg/2ml</i> | MB | |
| FUDR INJECTION SOLUTION RECONSTITUTED 0.5 GM | MB | |
| GEMZAR INTRAVENOUS SOLUTION RECONSTITUTED 200 MG | MB | |
| LEUSTATIN INTRAVENOUS SOLUTION 1 MG/ML | MB | |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | |
| <i>methotrexate oral tablet 2.5 mg</i> | 2 | |
| <i>methotrexate sodium (pf) injection solution 1 gm/40ml, 100 mg/4ml, 25 mg/ml, 250 mg/10ml, 50 mg/2ml</i> | 2 | |
| <i>methotrexate sodium injection solution 25 mg/ml, 250 mg/10ml, 50 mg/2ml</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|---------------------------------|
| <i>methotrexate sodium injection solution reconstituted 1 gm</i> | 2 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | |
| <i>nelarabine intravenous solution 5 mg/ml</i> | MB | |
| TABLOID ORAL TABLET 40 MG | 5 | PA; SP |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG | 3 | |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 5 | PA |
| *ANTINEOPLASTIC - ALK INHIBITORS*** | | |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA; LA; QL (240 EA per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA; QL (30 EA per 30 days); SP |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA; QL (60 EA per 30 days); SP |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG | 5 | PA; LA; QL (30 EA per 30 days) |
| LORBRENA ORAL TABLET 100 MG | 5 | PA; QL (30 EA per 30 days); SP |
| LORBRENA ORAL TABLET 25 MG | 5 | PA; QL (90 EA per 30 days); SP |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA; QL (60 EA per 30 days); SP |
| ZYKADIA ORAL CAPSULE 150 MG | 5 | PA; QL (150 EA per 30 days); SP |
| *ANTINEOPLASTIC - ANTI-BCMA ANTIBODY-DRUG COMPLEX*** | | |
| BLENREP INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | PA |
| *ANTINEOPLASTIC - ANTI-CD19 ANTIBODIES*** | | |
| MONJUVI INTRAVENOUS SOLUTION RECONSTITUTED 200 MG | MB | PA |
| *ANTINEOPLASTIC - ANTI-CD20 ANTIBODIES*** | | |
| RUXIENCE INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | MB | PA |
| *ANTINEOPLASTIC - ANTI-CD22 ANTIBODY-DRUG COMPLEX*** | | |
| BESPONSA INTRAVENOUS SOLUTION RECONSTITUTED 0.9 MG | MB | PA |
| *ANTINEOPLASTIC - ANTI-CD30 ANTIBODY-DRUG COMPLEX*** | | |
| ADCETRIS INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | MB | PA |
| *ANTINEOPLASTIC - ANTI-CD33 ANTIBODY-DRUG COMPLEX*** | | |
| MYLOTARG INTRAVENOUS SOLUTION RECONSTITUTED 4.5 MG | MB | PA |

| Drug Name | Tier | Notes |
|---|------|---------------------------------|
| *ANTINEOPLASTIC - ANTI-CD38 ANTIBODIES*** | | |
| DARZALEX INTRAVENOUS SOLUTION 100 MG/5ML, 400 MG/20ML | MB | PA |
| SARCLISA INTRAVENOUS SOLUTION 100 MG/5ML, 500 MG/25ML | MB | PA |
| *ANTINEOPLASTIC - ANTI-CD79B ANTIBODY-DRUG COMPLEX*** | | |
| POLIVY INTRAVENOUS SOLUTION RECONSTITUTED 140 MG, 30 MG | MB | PA |
| *ANTINEOPLASTIC - ANTI-HER2 AGENTS*** | | |
| OGIVRI INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | MB | |
| TUKYSA ORAL TABLET 150 MG, 50 MG | 5 | PA; LA; QL (120 EA per 30 days) |
| *ANTINEOPLASTIC - ANTI-NECTIN-4 ANTIBODY-DRUG COMPLEX*** | | |
| PADCEV INTRAVENOUS SOLUTION RECONSTITUTED 20 MG, 30 MG | MB | PA |
| *ANTINEOPLASTIC - ANTI-PD-1 ANTIBODIES*** | | |
| LIBTAYO INTRAVENOUS SOLUTION 350 MG/7ML | MB | PA |
| *ANTINEOPLASTIC - ANTI-PD-L1 ANTIBODIES*** | | |
| TECENTRIQ INTRAVENOUS SOLUTION 1200 MG/20ML, 840 MG/14ML | MB | PA |
| *ANTINEOPLASTIC - ANTI-SLAMF7 ANTIBODIES*** | | |
| EMPLICITI INTRAVENOUS SOLUTION RECONSTITUTED 300 MG, 400 MG | MB | PA |
| *ANTINEOPLASTIC - BCL-2 INHIBITORS*** | | |
| VENCLEXTA ORAL TABLET 10 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA; LA; QL (120 EA per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 5 | PA; LA; QL (30 EA per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG | 5 | PA; LA; QL (1 EA per 28 days) |
| *ANTINEOPLASTIC - BCR-ABL KINASE INHIBITORS*** | | |
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA; QL (3 EA per 1 day); SP |
| BOSULIF ORAL TABLET 100 MG | 5 | PA; QL (90 EA per 30 days); SP |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA; QL (30 EA per 30 days); SP |

| Drug Name | Tier | Notes |
|---|------|------------------------------------|
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 | PA; LA; QL (30 EA per 30 days); SP |
| <i>imatinib mesylate oral tablet 100 mg, 400 mg</i> | 5 | PA; QL (60 EA per 30 days); SP |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG | 5 | PA; QL (30 EA per 30 days); SP |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG | 5 | PA; QL (120 EA per 30 days); SP |
| *ANTINEOPLASTIC - BRAF KINASE INHIBITORS*** | | |
| BRAFTOVI ORAL CAPSULE 50 MG | 5 | PA; LA; QL (120 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA; QL (180 EA per 30 days); SP |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA; QL (120 EA per 30 days); SP |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA; QL (240 EA per 30 days); SP |
| *ANTINEOPLASTIC - BTK INHIBITORS*** | | |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA; QL (120 EA per 30 days); SP |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA; QL (60 EA per 30 days); SP |
| CALQUENCE ORAL TABLET 100 MG | 5 | PA; QL (60 EA per 30 days); SP |
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG | 5 | PA; LA; QL (1 EA per 1 day) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5 | PA; LA; QL (6 ML per 1 day) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG | 5 | PA; LA; QL (28 EA per 28 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA; QL (60 EA per 30 days); SP |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA; QL (30 EA per 30 days); SP |
| *ANTINEOPLASTIC - EGFR INHIBITORS*** | | |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50ML, 200 MG/100ML | MB | PA |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg</i> | 5 | PA; QL (60 EA per 30 days); SP |
| <i>gefitinib oral tablet 250 mg</i> | 5 | PA; LA; QL (30 EA per 30 days) |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA; LA; QL (30 EA per 30 days) |
| TAGRISSE ORAL TABLET 40 MG, 80 MG | 5 | PA; QL (30 EA per 30 days); SP |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA; QL (30 EA per 30 days); SP |
| *ANTINEOPLASTIC - FGFR KINASE INHIBITORS*** | | |
| BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG | 5 | PA; SP |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA; LA; QL (14 EA per 21 days) |
| *ANTINEOPLASTIC - HEDGEHOG PATHWAY INHIBITORS*** | | |
| DAURISMO ORAL TABLET 100 MG | 5 | PA; QL (30 EA per 30 days); SP |
| DAURISMO ORAL TABLET 25 MG | 5 | PA; QL (60 EA per 30 days); SP |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA; QL (30 EA per 30 days); SP |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA; QL (30 EA per 30 days); SP |

| Drug Name | Tier | Notes |
|--|------|-------------------------------------|
| *ANTINEOPLASTIC - HISTONE DEACETYLASE INHIBITORS*** | | |
| FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG | 5 | PA; LA; QL (6 EA per 21 days) |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | PA; QL (120 EA per 30 days); SP |
| *ANTINEOPLASTIC - IMMUNOMODULATORS*** | | |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA; QL (21 EA per 28 days); SP |
| *ANTINEOPLASTIC - KRAS INHIBITORS*** | | |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA; QL (8 EA per 1 day); SP |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA; QL (3 EA per 1 day); SP |
| *ANTINEOPLASTIC - MEK INHIBITORS*** | | |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA; QL (90 EA per 30 days); SP |
| MEKINIST ORAL TABLET 2 MG | 5 | PA; QL (30 EA per 30 days); SP |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA; LA; QL (180 EA per 30 days) |
| *ANTINEOPLASTIC - MET INHIBITORS*** | | |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA; QL (120 EA per 30 days); SP |
| *ANTINEOPLASTIC - METHYLTRANSFERASE INHIBITORS*** | | |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA; LA; QL (240 EA per 30 days) |
| *ANTINEOPLASTIC - MTOR KINASE INHIBITORS*** | | |
| <i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 5 | PA; SP |
| <i>everolimus oral tablet soluble 2 mg, 3 mg, 5 mg</i> | 5 | PA; SP |
| TORISEL INTRAVENOUS SOLUTION 25 MG/ML | MB | |
| *ANTINEOPLASTIC - MULTIKINASE INHIBITORS*** | | |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG | 5 | PA; QL (30 EA per 30 days); SP |
| CAPRELSA ORAL TABLET 100 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 5 | PA; LA; QL (30 EA per 30 days) |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG | 5 | PA; LA |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG | 5 | PA; LA |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG | 5 | PA; LA |
| <i>lapatinib ditosylate oral tablet 250 mg</i> | 5 | PA; QL (180 EA per 30 days); SP |
| NERLYNX ORAL TABLET 40 MG | 5 | PA; LA; QL (180 EA per 30 days); SP |
| <i>pazopanib hcl oral tablet 200 mg</i> | 5 | PA; QL (120 EA per 30 days); SP |
| QINLOCK ORAL TABLET 50 MG | 5 | PA; LA; QL (90 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA; QL for AML = 120/30QL for ASM, SM-AHN,and MCL= 240/30.; QL (120 EA per 30 days) |
| <i>sorafenib tosylate oral tablet 200 mg</i> | 5 | PA; QL (120 EA per 30 days); SP |
| STIVARGA ORAL TABLET 40 MG | 5 | PA; QL (120 EA per 30 days); SP |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 5 | PA; SP |
| UKONIQ ORAL TABLET 200 MG | 5 | PA; LA; QL (120 EA per 30 days) |
| XOSPATA ORAL TABLET 40 MG | 5 | PA; LA; QL (90 EA per 30 days) |
| *ANTINEOPLASTIC - MULTIPLE RECEPTOR ANTIBODIES*** | | |
| RYBREVAANT INTRAVENOUS SOLUTION 350 MG/7ML | MB | PA |
| *ANTINEOPLASTIC - PDGFR-ALPHA INHIBITORS*** | | |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA; QL (30 EA per 30 days); SP |
| *ANTINEOPLASTIC - PROTEASOME INHIBITORS*** | | |
| <i>bortezomib intravenous solution reconstituted 3.5 mg</i> | MB | |
| *ANTINEOPLASTIC - RET INHIBITORS*** | | |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA; QL (180 EA per 30 days); SP |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA; QL (120 EA per 30 days); SP |
| *ANTINEOPLASTIC - TROPOMYOSIN RECEPTOR KINASE INHIBITORS*** | | |
| ROZLYTREK ORAL CAPSULE 100 MG, 200 MG | 5 | PA; SP |
| *ANTINEOPLASTIC - TYROSINE KINASE INHIBITORS*** | | |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 1 X 80 & 1 X 20 MG | 5 | PA |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 1 X 80 & 3 X 20 MG | 5 | PA |
| *ANTINEOPLASTIC - XPO1 INHIBITORS*** | | |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG | 5 | PA; LA; QL (8 EA per 28 days) |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 40 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA; LA; QL (8 EA per 28 days) |

| Drug Name | Tier | Notes |
|--|------|--------------------------------|
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 60 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA; LA |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; LA; QL (4 EA per 28 days) |
| *ANTINEOPLASTIC ANTIBIOTICS*** | | |
| <i>bleomycin sulfate injection solution reconstituted 15 unit</i> | MB | |
| CERUBIDINE INTRAVENOUS SOLUTION RECONSTITUTED 20 MG | MB | |
| COSMEGEN INTRAVENOUS SOLUTION RECONSTITUTED 0.5 MG | MB | |
| DAUNOXOME INTRAVENOUS INJECTABLE 2 MG/ML | MB | |
| ELLENCEN INTRAVENOUS SOLUTION 200 MG/100ML | MB | |
| IDAMYCIN PFS INTRAVENOUS SOLUTION 5 MG/5ML | MB | |
| <i>mitomycin intravenous solution reconstituted 5 mg</i> | MB | |
| <i>mitoxantrone hcl intravenous concentrate 25 mg/12.5ml</i> | MB | |
| <i>valrubicin intravesical solution 40 mg/ml</i> | MB | |
| *ANTINEOPLASTIC ANTIBODY-DRUG COMPLEXES*** | | |
| ENHERTU INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | PA |
| KADCYLA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 160 MG | MB | PA |
| *ANTINEOPLASTIC COMBINATIONS*** | | |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA; QL (5 EA per 28 days); SP |
| KISQALI FEMARA (200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA; LA; QL (49 EA per 28 days) |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA; LA; QL (70 EA per 28 days) |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA; LA; QL (91 EA per 28 days) |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG | 5 | PA; LA; QL (40 EA per 28 days) |
| VYXEOS INTRAVENOUS SUSPENSION RECONSTITUTED 44-100 MG | MB | PA |

| Drug Name | Tier | Notes |
|---|------|---|
| *ANTINEOPLASTIC ENZYMES*** | | |
| ONCASPAR INJECTION SOLUTION 750 UNIT/ML | MB | PA |
| *ANTINEOPLASTICS - PHOTOACTIVATED AGENTS*** | | |
| PHOTOFRIN INTRAVENOUS SOLUTION RECONSTITUTED 75 MG | MB | |
| *ANTINEOPLASTICS MISC.*** | | |
| ALFERON N INJECTION SOLUTION 5000000 UNIT/ML | MB | |
| <i>dacarbazine intravenous solution reconstituted 100 mg</i> | MB | |
| <i>hydroxyurea oral capsule 500 mg</i> | 2 | |
| INTRON A INJECTION SOLUTION 10000000 UNIT/ML, 6000000 UNIT/ML | 5 | SP |
| INTRON-A SUBCUTANEOUS KIT 10000000 UNIT/0.2ML | 5 | |
| MATULANE ORAL CAPSULE 50 MG | 5 | PA; SP |
| NIPENT INTRAVENOUS SOLUTION RECONSTITUTED 10 MG | MB | |
| ONTAK INTRAVENOUS SOLUTION 150 MCG/ML | MB | |
| SYLATRON SUBCUTANEOUS KIT 4 X 200 MCG, 4 X 300 MCG | 5 | PA |
| SYLATRON SUBCUTANEOUS KIT 600 MCG | 5 | PA; SP |
| TRISENOX INTRAVENOUS SOLUTION 12 MG/6ML | MB | |
| *AROMATASE INHIBITORS*** | | |
| <i>anastrozole oral tablet 1 mg</i> | 2 | DX (Diagnosis Code at Point of Sale is accepted.) |
| <i>exemestane oral tablet 25 mg</i> | 4 | DX (Diagnosis Code at Point of Sale is accepted.) |
| <i>letrozole oral tablet 2.5 mg</i> | 2 | DX (Diagnosis Code at Point of Sale is accepted.) |
| *CARDIAC PROTECTIVE AGENTS*** | | |
| <i>dexrazoxane intravenous solution reconstituted 250 mg</i> | MB | |
| *CYCLIN-DEPENDENT KINASES (CDK) INHIBITORS*** | | |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA; QL (21 EA per 28 days); SP |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; LA; QL (21 EA per 28 days) |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; LA; QL (42 EA per 28 days) |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; LA; QL (63 EA per 28 days) |

| Drug Name | Tier | Notes |
|--|------|--|
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| *ESTROGEN RECEPTOR ANTAGONIST*** | | |
| <i>fulvestrant intramuscular solution 250 mg/5ml</i> | MB | |
| *ESTROGENS-ANTINEOPLASTIC*** | | |
| EMCYT ORAL CAPSULE 140 MG | 5 | PA; SP |
| *FOLIC ACID ANTAGONISTS RESCUE AGENTS*** | | |
| <i>leucovorin calcium injection solution reconstituted 350 mg</i> | MB | PA |
| <i>leucovorin calcium injection solution reconstituted 50 mg</i> | MB | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg</i> | 3 | |
| <i>leucovorin calcium oral tablet 25 mg, 5 mg</i> | 2 | |
| *GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONISTS*** | | |
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 120 MG | MB | |
| *IMIDAZOTETRAZINES*** | | |
| <i>temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg, 5 mg</i> | 5 | PA; SP |
| *ISOCITRATE DEHYDROGENASE-1 (IDH1) INHIBITORS*** | | |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| *JANUS ASSOCIATED KINASE (JAK) INHIBITORS*** | | |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA; QL (60 EA per 30 days); SP |
| *LHRH ANALOGS*** | | |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i> | MB | PA not required if billed with Dx codes F64.1 - F64.9. |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 7.5 MG | MB | PA required if billed with Dx codes F64.1 - F64.9. |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 22.5 MG | MB | PA required if billed with Dx codes F64.1 - F64.9. |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG | MB | PA required if billed with Dx codes F64.1 - F64.9. |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG | MB | PA |
| VANTAS SUBCUTANEOUS KIT 50 MG | MB | |
| *MITOTIC INHIBITORS*** | | |

| Drug Name | Tier | Notes |
|---|------|--------------------------------|
| <i>docetaxel intravenous concentrate 160 mg/8ml, 20 mg/ml, 200 mg/10ml, 80 mg/4ml</i> | MB | |
| ETOPOPHOS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | |
| <i>etoposide oral capsule 50 mg</i> | 4 | |
| IXEMPRA KIT INTRAVENOUS SOLUTION RECONSTITUTED 15 MG, 45 MG | MB | |
| NAVELBINE INTRAVENOUS SOLUTION 10 MG/ML | MB | |
| ONXOL INTRAVENOUS CONCENTRATE 150 MG/25ML | MB | |
| TOPOSAR INTRAVENOUS SOLUTION 100 MG/5ML | MB | |
| <i>vinblastine sulfate intravenous solution 1 mg/ml</i> | MB | |
| VINCASAR PFS INTRAVENOUS SOLUTION 1 MG/ML | MB | |
| *NITROGEN MUSTARDS AND RELATED ANALOGUES*** | | |
| ALKERAN INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | MB | |
| ALKERAN ORAL TABLET 2 MG | MB | |
| <i>cyclophosphamide injection solution reconstituted 1 gm</i> | MB | |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 4 | |
| IFEX INTRAVENOUS SOLUTION RECONSTITUTED 1 GM | MB | |
| LEUKERAN ORAL TABLET 2 MG | 5 | PA; SP |
| <i>melfalan oral tablet 2 mg</i> | 2 | |
| MUSTARGEN INJECTION SOLUTION RECONSTITUTED 10 MG | MB | |
| *NITROSOUREAS*** | | |
| <i>carmustine intravenous solution reconstituted 300 mg, 50 mg</i> | MB | |
| <i>lomustine oral capsule 10 mg, 100 mg, 40 mg</i> | 4 | PA |
| ZANOSAR INTRAVENOUS SOLUTION RECONSTITUTED 1 GM | MB | |
| *PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS*** | | |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; QL (60 EA per 30 days); SP |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG | 5 | PA; QL (60 EA per 30 days) |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG | 5 | PA; QL (60 EA per 30 days); SP |

| Drug Name | Tier | Notes |
|---|------|---|
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| *POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS*** | | |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA; QL (120 EA per 30 days); SP |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA; QL (120 EA per 30 days); SP |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA; QL (30 EA per 30 days); SP |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA; QL (90 EA per 30 days); SP |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA; QL (30 EA per 30 days); SP |
| *PROGESTINS-ANTINEOPLASTIC*** | | |
| DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| <i>megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml</i> | 2 | |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i> | 2 | |
| *SELECTIVE ESTROGEN RECEPTOR DEGRADERS*** | | |
| ORSERDU ORAL TABLET 345 MG | 5 | PA; QL (30 EA per 30 days); SP |
| ORSERDU ORAL TABLET 86 MG | 5 | PA; QL (90 EA per 30 days); SP |
| *SELECTIVE RETINOID X RECEPTOR AGONISTS*** | | |
| <i>bexarotene oral capsule 75 mg</i> | 5 | PA; SP |
| *TOPOISOMERASE I INHIBITORS*** | | |
| CAMPTOSAR INTRAVENOUS SOLUTION 40 MG/2ML | MB | |
| HYCAMTIN ORAL CAPSULE 0.25 MG, 1 MG | 5 | PA; SP |
| *URINARY TRACT PROTECTIVE AGENTS*** | | |
| MESNEX INTRAVENOUS SOLUTION 100 MG/ML | MB | |
| MESNEX ORAL TABLET 400 MG | 5 | |
| *VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS*** | | |
| INLYTA ORAL TABLET 1 MG, 5 MG | 5 | PA; QL (120 EA per 30 days); SP |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG | 5 | PA; LA; QL (30 EA per 30 days) |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG | 5 | PA; LA; QL (90 EA per 30 days) |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG | 5 | PA; LA; QL (90 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG | 5 | PA; LA; QL (90 EA per 30 days) |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG | 5 | PA; LA; QL (30 EA per 30 days) |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG | 5 | PA; LA; QL (60 EA per 30 days) |
| *ANTIPARKINSON AND RELATED THERAPY AGENTS* | | |
| *ANTIPARKINSON ANTICHOLINERGICS*** | | |
| <i>benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| COGENTIN INJECTION SOLUTION 1 MG/ML | MB | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>trihexyphenidyl hcl oral elixir 0.4 mg/ml</i> | 2 | |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIPARKINSON DOPAMINERGICS*** | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral syrup 50 mg/5ml</i> | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | |
| <i>bromocriptine mesylate oral capsule 5 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>bromocriptine mesylate oral tablet 2.5 mg</i> | 2 | |
| *ANTIPARKINSON MONOAMINE OXIDASE INHIBITORS*** | | |
| <i>rasagiline mesylate oral tablet 0.5 mg, 1 mg</i> | 4 | ST |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *CENTRAL/PERIPHERAL COMT INHIBITORS*** | | |
| <i>tolcapone oral tablet 100 mg</i> | 4 | |
| *LEVODOPA COMBINATIONS*** | | |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 4 | |
| *NONERGOLINE DOPAMINE RECEPTOR AGONISTS*** | | |
| APOKYN SUBCUTANEOUS SOLUTION 10 MG/ML | 5 | PA; LA |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; LA; QL (150 EA per 30 days) |
| KYNMOBI TITRATION KIT SUBLINGUAL KIT 10&15&20&25&30 MG | 5 | PA; LA; QL (1 EA per 180 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 2 | |
| *PERIPHERAL COMT INHIBITORS*** | | |
| <i>entacapone oral tablet 200 mg</i> | 2 | |
| ONGENTYS ORAL CAPSULE 50 MG | 5 | PA; QL (30 EA per 30 days); SP |
| *ANTIPSYCHOTICS/ANTIMANIC AGENTS* | | |
| *ANTIMANIC AGENTS*** | | |
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>lithium carbonate oral tablet 300 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>lithium oral solution 8 meq/5ml</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIPSYCHOTICS - MISC.*** | | |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | PA; QL (30 EA per 30 days); AL (Min 18 Years) |
| <i>lurasidone hcl oral tablet 120 mg</i> | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 13 Years) |
| <i>lurasidone hcl oral tablet 20 mg, 40 mg, 60 mg</i> | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 10 Years) |
| <i>lurasidone hcl oral tablet 80 mg</i> | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 10 Years) |

| Drug Name | Tier | Notes |
|---|------|--|
| ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years) |
| *BENZISOXAZOLES*** | | |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 18 Years) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 EA per 365 days); AL (Min 18 Years) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.75 ML per 28 days); AL (Min 18 Years); SP |

| Drug Name | Tier | Notes |
|--|------|--|
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 156 MG/ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 ML per 28 days); AL (Min 18 Years); SP |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 234 MG/1.5ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.5 ML per 28 days); AL (Min 18 Years); SP |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.25 ML per 28 days); AL (Min 18 Years); SP |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 78 MG/0.5ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.5 ML per 28 days); AL (Min 18 Years); SP |

| Drug Name | Tier | Notes |
|---|------|--|
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.875ML, 273 MG/0.88ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.88 ML per 84 days); AL (Min 18 Years); SP |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 410 MG/1.315ML, 410 MG/1.32ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.32 ML per 84 days); AL (Min 18 Years); SP |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 546 MG/1.75ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.75 ML per 84 days); AL (Min 18 Years); SP |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 819 MG/2.625ML, 819 MG/2.63ML | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.63 ML per 84 days); AL (Min 18 Years); SP |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 9 mg</i> | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 18 Years) |
| <i>paliperidone er oral tablet extended release 24 hour 6 mg</i> | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 18 Years) |
| <i>risperidone microspheres er intramuscular suspension reconstituted er 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2 vials per 28 days); AL (Min 18 Years); SP |
| <i>risperidone oral solution 1 mg/ml</i> | 2 | PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (480 ML per 30 days); AL (Min 5 Years) |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>risperidone oral tablet 0.25 mg</i> | 2 | <p>PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 5 Years)</p> |
| <i>risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg</i> | 2 | <p>PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 5 Years)</p> |
| <i>risperidone oral tablet 4 mg</i> | 2 | <p>PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 5 Years)</p> |
| <i>risperidone oral tablet dispersible 0.25 mg</i> | 4 | <p>PA; PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 5 Years)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>risperidone oral tablet dispersible 0.5 mg, 1 mg, 2 mg, 3 mg</i> | 4 | <p>PA; PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 5 Years)</p> |
| <i>risperidone oral tablet dispersible 4 mg</i> | 4 | <p>PA; PA required for patients younger than 5 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 5 Years)</p> |
| *BUTYROPHENONES*** | | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 50 mg/ml</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 18 Years)</p> |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 18 Years)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 3 Years) |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 3 Years) |
| *DIBENZODIAZEPINES*** | | |
| <i>clozapine oral tablet 100 mg</i> | 2 | Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (270 EA per 30 days); AL (Min 6 Years) |
| <i>clozapine oral tablet 200 mg</i> | 2 | Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (135 EA per 30 days); AL (Min 6 Years) |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>clozapine oral tablet 25 mg, 50 mg</i> | 2 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)</p> |
| *DIBENZO-OXEPINO PYRROLES*** | | |
| <i>asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg</i> | 5 | <p>PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 10 Years)</p> |
| *DIBENZOTHIAZEPINES*** | | |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 50 mg</i> | 4 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 400 mg</i> | 4 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 400 mg, 50 mg</i> | 2 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 6 Years)</p> |
| <i>quetiapine fumarate oral tablet 300 mg</i> | 2 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)</p> |
| *DIBENZOXAZEPINES*** | | |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| *PHENOTHIAZINES*** | | |
| <i>chlorpromazine hcl injection solution 25 mg/ml, 50 mg/2ml</i> | MB | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| COMPRO RECTAL SUPPOSITORY 25 MG | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | MB | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 3 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i> | 3 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>fluphenazine hcl oral tablet 5 mg</i> | 2 | |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>prochlorperazine edisylate injection solution 10 mg/2ml</i> | MB | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>prochlorperazine edisylate injection solution 5 mg/ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>prochlorperazine rectal suppository 25 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| *QUINOLINONE DERIVATIVES*** | | |
| <i>aripiprazole oral solution 1 mg/ml</i> | 5 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (750 ML per 30 days); AL (Min 6 Years)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | 2 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)</p> |
| <i>aripiprazole oral tablet dispersible 10 mg, 15 mg</i> | 5 | <p>PA; Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)</p> |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML | 5 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3.9 ML per 56 days); AL (Min 18 Years); SP</p> |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 441 MG/1.6ML | 5 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.6 ML per 28 days); AL (Min 18 Years); SP</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 662 MG/2.4ML | 5 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.4 ML per 28 days); AL (Min 18 Years); SP</p> |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 882 MG/3.2ML | 5 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3.2 ML per 28 days); AL (Min 18 Years); SP</p> |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5 | <p>PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 13 Years)</p> |
| *THIENBENZODIAZEPINES*** | | |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>olanzapine oral tablet dispersible 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | <p>Prior Authorization required for patients under 6 years of age; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)</p> |
| *THIOXANTHENES*** | | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | <p>BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| *ANTISEPTICS & DISINFECTANTS* | | |
| *CHLORINE ANTISEPTICS*** | | |
| <i>chlorhexidine gluconate solution 20 %</i> | 2 | |
| *ANTIVIRALS* | | |
| *ANTIRETROVIRAL COMBINATIONS*** | | |
| <i>abacavir sulfate-lamivudine oral tablet 600-300 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>abacavir-lamivudine-zidovudine oral tablet 300-150-300 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 400 & 600 MG/2ML, 600 & 900 MG/3ML | MB | PA |
| CIMDUO ORAL TABLET 300-300 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| COMPLERA ORAL TABLET 200-25-300 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|--|------|--|
| DELSTRIGO ORAL TABLET 100-300-300 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| DESCOVY ORAL TABLET 120-15 MG | \$0 | <p>PA for New Starts; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| DESCOVY ORAL TABLET 200-25 MG | \$0 | <p>PA for New Starts; DX (Covered at a zero-dollar copay for the diagnosis of Pre-exposure prophylaxis (PrEP) per ACA); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>emtricitabine-tenofovir df oral tablet 100-150 mg, 133-200 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>emtricitabine-tenofovir df oral tablet 167-250 mg, 200-300 mg</i> | \$0 | <p>DX (Covered at a zero-dollar copay for the diagnosis of Pre-exposure prophylaxis (PrEP) per ACA); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| EVOTAZ ORAL TABLET 300-150 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| GENVOYA ORAL TABLET 150-150-200-10 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| JULUCA ORAL TABLET 50-25 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (300 ML per 30 days)</p> |
| <i>lopinavir-ritonavir oral tablet 100-25 mg, 200-50 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| ODEFSEY ORAL TABLET 200-25-25 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| PREZCOBIX ORAL TABLET 800-150 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| STRIBILD ORAL TABLET 150-150-200-300 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| SYM TUZA ORAL TABLET 800-150-200-10 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| TRIUMEQ ORAL TABLET 600-50-300 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)</p> |
| *ANTIRETROVIRALS - CCR5 ANTAGONISTS (ENTRY INHIBITOR)*** | | |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| SELZENTRY ORAL SOLUTION 20 MG/ML | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|--|
| SELZENTRY ORAL TABLET 25 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| SELZENTRY ORAL TABLET 75 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| *ANTIRETROVIRALS - CD4-DIRECTED POST-ATTACHMENT INHIBITOR*** | | |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33ML | MB | |
| *ANTIRETROVIRALS - FUSION INHIBITORS*** | | |
| FUZEON SUBCUTANEOUS KIT 90 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTIRETROVIRALS - GP120-DIRECTED ATTACHMENT INHIBITOR*** | | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| *ANTIRETROVIRALS - INTEGRASE INHIBITORS*** | | |
| ISENTRESS HD ORAL TABLET 600 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| ISENTRESS ORAL PACKET 100 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|--|
| ISENTRESS ORAL TABLET 400 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| ISENTRESS ORAL TABLET CHEWABLE 25 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| TIVICAY ORAL TABLET 10 MG, 25 MG, 50 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |

| Drug Name | Tier | Notes |
|--|------|---|
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG | \$0 | <p>PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days); AL (Max 12 Years)</p> |
| VITEKTA ORAL TABLET 150 MG, 85 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| *ANTIRETROVIRALS - PROTEASE INHIBITORS*** | | |
| APTIVUS ORAL CAPSULE 250 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| APTIVUS ORAL SOLUTION 100 MG/ML | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg, 300 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| CRIXIVAN ORAL CAPSULE 200 MG, 400 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days) |
| <i>darunavir oral tablet 600 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>darunavir oral tablet 800 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>fosamprenavir calcium oral tablet 700 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| INVIRASE ORAL CAPSULE 200 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| INVIRASE ORAL TABLET 500 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)</p> |
| LEXIVA ORAL SUSPENSION 50 MG/ML | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|------------------------------------|------|--|
| NORVIR ORAL CAPSULE 100 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (360 EA per 30 days)</p> |
| NORVIR ORAL SOLUTION 80 MG/ML | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (450 ML per 30 days)</p> |
| PREZISTA ORAL TABLET 150 MG, 75 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| REYATAZ ORAL PACKET 50 MG | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (150 EA per 30 days); AL (Max 8 Years)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>ritonavir oral tablet 100 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (360 EA per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days) |
| *ANTIRETROVIRALS - RTI-NON-NUCLEOSIDE ANALOGUES*** | | |
| EDURANT ORAL TABLET 25 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>efavirenz oral tablet 600 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>etravirine oral tablet 100 mg, 200 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)</p> |
| <i>nevirapine oral suspension 50 mg/5ml</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1200 ML per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>nevirapine oral tablet 200 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| PIFELTRO ORAL TABLET 100 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| RESCRIPTOR ORAL TABLET 100 MG, 200 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days) |
| *ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-PURINES*** | | |
| <i>abacavir sulfate oral solution 20 mg/ml</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days) |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>abacavir sulfate oral tablet 300 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>didanosine oral capsule delayed release 125 mg, 200 mg, 250 mg, 400 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| VIDEX ORAL SOLUTION RECONSTITUTED 2 GM, 4 GM | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1200 ML per 30 days) |
| *ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-PYRIMIDINES*** | | |
| <i>emtricitabine oral capsule 200 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---|
| EMTRIVA ORAL SOLUTION 10 MG/ML | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>lamivudine oral solution 10 mg/ml</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days) |
| <i>lamivudine oral tablet 150 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>lamivudine oral tablet 300 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| *ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-THYMIDINES*** | | |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | \$0 | |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| <i>stavudine oral solution reconstituted 1 mg/ml</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2400 EA per 30 days)</p> |
| <i>zidovudine oral capsule 100 mg</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)</p> |
| <i>zidovudine oral syrup 50 mg/5ml</i> | \$0 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1800 ML per 30 days)</p> |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>zidovudine oral tablet 300 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| *ANTIRETROVIRALS - RTI-NUCLEOTIDE ANALOGUES*** | | |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| VIREAD ORAL POWDER 40 MG/GM | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (225 GM per 30 days) |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| *ANTIRETROVIRALS ADJUVANTS*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| TYBOST ORAL TABLET 150 MG | \$0 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| *ANTIVIRAL COMBINATIONS*** | | |
| PAXLOVID (150/100) ORAL TABLET THERAPY PACK 10 X 150 MG & 10 X 100MG | 4 | QL (40 EA per 365 days) |
| PAXLOVID (300/100) ORAL TABLET THERAPY PACK 20 X 150 MG & 10 X 100MG | 4 | QL (60 EA per 365 days) |
| PAXLOVID ORAL TABLET THERAPY PACK 10 X 150 MG & 10 X 100MG | 4 | QL (40 EA per 365 days) |
| PAXLOVID ORAL TABLET THERAPY PACK 20 X 150 MG & 10 X 100MG | 4 | QL (60 EA per 365 days) |
| *CMV AGENTS*** | | |
| CYTOVENE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | |
| <i>foscarnet sodium intravenous solution 24 mg/ml</i> | MB | |
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | 5 | PA; QL (900 ML per 30 days) |
| <i>valganciclovir hcl oral tablet 450 mg</i> | 5 | PA; QL (60 EA per 30 days) |
| VISTIDE INTRAVENOUS SOLUTION 75 MG/ML | MB | |
| *HEPATITIS B AGENTS*** | | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 5 | PA; QL (30 EA per 30 days); SP |
| EPIVIR HBV ORAL SOLUTION 5 MG/ML | 3 | QL (900 ML per 30 days) |
| <i>lamivudine oral tablet 100 mg</i> | 2 | QL (30 EA per 30 days) |
| VEMLIDY ORAL TABLET 25 MG | 5 | QL (30 EA per 30 days); SP |
| *HEPATITIS C AGENT - COMBINATIONS*** | | |
| MAVYRET ORAL PACKET 50-20 MG | 4 | PA; QL (150 EA per 30 days); SP |
| MAVYRET ORAL TABLET 100-40 MG | 4 | PA; QL (3 EA per 1 day); SP |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | 4 | PA; QL (30 EA per 30 days); SP |
| TECHNIVIE ORAL TABLET 12.5-75-50 MG | 5 | PA; SP |
| VIEKIRA PAK ORAL TABLET THERAPY PACK 12.5-75-50 & 250 MG | 5 | PA; QL (112 EA per 28 days); AL (Min 18 Years); SP |
| VIEKIRA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 200-8.33-50- 33.33 MG | 5 | PA; QL (90 EA per 30 days); SP |
| *HEPATITIS C AGENTS*** | | |

| Drug Name | Tier | Notes |
|--|------|--|
| PEGASYS PROCLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 180 MCG/0.5ML | 5 | PA; QL (2 ML per 28 days); SP |
| PEGASYS SUBCUTANEOUS KIT 180 MCG/0.5ML | 5 | PA |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA; SP |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180 MCG/0.5ML | 5 | PA; QL (2 ML per 28 days); SP |
| <i>ribavirin oral capsule 200 mg</i> | 4 | PA; SP |
| <i>ribavirin oral tablet 200 mg</i> | 4 | PA; SP |
| *HERPES AGENTS - PURINE ANALOGUES*** | | |
| <i>acyclovir oral capsule 200 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>acyclovir oral suspension 200 mg/5ml</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | MB | |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>valacyclovir hcl oral tablet 1 gm, 500 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *HERPES AGENTS - THYMIDINE ANALOGUES*** | | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 4 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *INFLUENZA AGENTS*** | | |
| <i>rimantadine hcl oral tablet 100 mg</i> | 3 | |
| *MISC. ANTIVIRALS*** | | |
| LAGEVRIO ORAL CAPSULE 200 MG | 4 | QL (80 EA per 365 days) |
| VEKLURY INTRAVENOUS SOLUTION 100 MG/20ML | MB | |
| VEKLURY INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | |
| *NEURAMINIDASE INHIBITORS*** | | |
| <i>oseltamivir phosphate oral capsule 30 mg</i> | 4 | QL (20 EA per 180 days) |
| <i>oseltamivir phosphate oral capsule 45 mg, 75 mg</i> | 4 | QL (10 EA per 180 days) |
| <i>oseltamivir phosphate oral suspension reconstituted 6 mg/ml</i> | 4 | QL (180 ML per 180 days) |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/BLISTER | 4 | QL (20 EA per 126 days) |
| *BETA BLOCKERS* | | |
| *ALPHA-BETA BLOCKERS*** | | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | |
| <i>labetalol hcl intravenous solution 5 mg/ml</i> | 2 | |

| Drug Name | Tier | Notes |
|--|-------------|--------------|
| <i>labetalol hcl oral tablet 100 mg, 200 mg, 300 mg</i> | 1 | |
| *BETA BLOCKERS CARDIO-SELECTIVE*** | | |
| <i>acebutolol hcl oral capsule 200 mg, 400 mg</i> | 2 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>betaxolol hcl oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 4 | |
| *BETA BLOCKERS NON-SELECTIVE*** | | |
| LEVATOL ORAL TABLET 20 MG | 4 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg, 80 mg</i> | 2 | |
| <i>propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml</i> | 3 | |
| <i>propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | |
| <i>sotalol hcl (af) oral tablet 120 mg, 160 mg, 80 mg</i> | 1 | |
| <i>sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 3 | |
| *CALCIUM CHANNEL BLOCKERS* | | |
| *CALCIUM CHANNEL BLOCKERS*** | | |
| <i>amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| CARDENE SR ORAL CAPSULE EXTENDED RELEASE 12 HOUR 30 MG, 60 MG | 4 | |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG | 2 | |
| <i>dilt-cd oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1 | |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg</i> | 1 | |
| <i>diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|---|-------------|----------------------------|
| <i>diltiazem hcl er oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>diltiazem hcl intravenous solution 50 mg/10ml</i> | MB | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 2 | |
| <i>felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 2 | |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 4 | AL (Max 12 Years) |
| <i>nicardipine hcl in nacl intravenous solution 20-0.9 mg/200ml-%, 40-0.9 mg/200ml-%</i> | MB | |
| <i>nicardipine hcl oral capsule 20 mg, 30 mg</i> | 2 | |
| NIFEDIAAC CC ORAL TABLET EXTENDED RELEASE 24 HOUR 90 MG | 2 | |
| NIFEDICAL XL ORAL TABLET EXTENDED RELEASE 24 HOUR 30 MG, 60 MG | 2 | |
| <i>nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg</i> | 1 | |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg</i> | 1 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | 2 | |
| <i>nimodipine oral capsule 30 mg</i> | 4 | PA |
| <i>nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg, 8.5 mg</i> | 4 | ST; QL (30 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 360 MG | 2 | |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG | 1 | |
| <i>verapamil hcl er oral capsule extended release 24 hour 100 mg, 200 mg, 300 mg, 360 mg</i> | 3 | |
| <i>verapamil hcl er oral capsule extended release 24 hour 120 mg, 240 mg</i> | 2 | |
| <i>verapamil hcl er oral capsule extended release 24 hour 180 mg</i> | 2 | QL (60 EA per 30 days) |
| <i>verapamil hcl er oral tablet extended release 180 mg, 240 mg</i> | 2 | |
| <i>verapamil hcl oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| *CARDIOTONICS* | | |
| *CARDIAC GLYCOSIDES*** | | |
| <i>digoxin oral tablet 125 mcg, 250 mcg</i> | 2 | |
| LANOXIN INJECTION SOLUTION 0.25 MG/ML | MB | |
| *INOTROPES*** | | |

| Drug Name | Tier | Notes |
|--|------|--------------------------------|
| <i>dobutamine hcl intravenous solution 250 mg/20ml</i> | MB | |
| <i>dopamine hcl intravenous solution 40 mg/ml</i> | MB | |
| <i>milrinone lactate intravenous solution 20 mg/20ml</i> | MB | |
| *CARDIOVASCULAR AGENTS - MISC.* | | |
| *CALCIUM CHANNEL BLOCKER & HMG COA REDUCTASE INHIBIT COMB*** | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 4 | QL (30 EA per 30 days) |
| *NEPRILYSIN INHIB (ARNI)-ANGIOTENSIN II RECEPT ANTAG COMB*** | | |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 4 | PA; QL (60 EA per 30 days) |
| *PERIPHERAL VASODILATORS*** | | |
| <i>papaverine hcl injection solution 30 mg/ml</i> | 4 | PA |
| *PULMONARY HYPERTENSION - ENDOTHELIN RECEPTOR ANTAGONISTS*** | | |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 5 | PA; QL (30 EA per 30 days); SP |
| *PULMONARY HYPERTENSION - PHOSPHODIESTERASE INHIBITORS*** | | |
| <i>sildenafil citrate oral tablet 20 mg</i> | 4 | PA; QL (90 EA per 30 days) |
| *VASOACTIVE NATRIURETIC PEPTIDES*** | | |
| NATRECOR INTRAVENOUS SOLUTION RECONSTITUTED 1.5 MG | MB | |
| *CEPHALOSPORINS* | | |
| *CEPHALOSPORIN COMBINATIONS*** | | |
| AVYCAZ INTRAVENOUS SOLUTION RECONSTITUTED 2.5 (2-0.5) GM | MB | |
| *CEPHALOSPORINS - 1ST GENERATION*** | | |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i> | 2 | |
| <i>cefadroxil oral tablet 1 gm</i> | 2 | |
| <i>cefazolin sodium-dextrose intravenous solution 1-4 gm/50ml-%</i> | MB | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|--|
| *CEPHALOSPORINS - 2ND GENERATION*** | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefotixin sodium intravenous solution reconstituted 1 gm</i> | MB | |
| <i>cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime axetil oral suspension reconstituted 125 mg/5ml</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |
| ZINACEF INTRAVENOUS SOLUTION RECONSTITUTED 750 MG | MB | |
| *CEPHALOSPORINS - 3RD GENERATION*** | | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 2 | |
| <i>cefepodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml</i> | 2 | |
| <i>cefepodoxime proxetil oral tablet 100 mg, 200 mg</i> | 2 | |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg</i> | 2 | |
| FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG | MB | |
| ROCEPHIN INJECTION SOLUTION RECONSTITUTED 250 MG | MB | |
| SUPRAX ORAL TABLET 400 MG | 3 | |
| *CEPHALOSPORINS - 4TH GENERATION*** | | |

| Drug Name | Tier | Notes |
|---|------|---|
| MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM | MB | |
| *CONTRACEPTIVES* | | |
| *BIPHASIC CONTRACEPTIVES - ORAL*** | | |
| AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| KIMIDESS ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LO LOESTRIN FE ORAL TABLET 1 MG-10 MCG / 10 MCG | 4 | PA; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NECON 10/11 (28) ORAL TABLET 35 MCG | 3 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| PIMTREA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| SIMLIYA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>viorele oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| VOLNEA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| *COMBINATION CONTRACEPTIVES - ORAL*** | | |
| AFIRMELLE ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ALTAVERA ORAL TABLET 0.15-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>alyacen 1/35 oral tablet 1-35 mg-mcg</i> | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| APRI ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| AUBRA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| AUROVELA 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| AUROVELA 1/20 ORAL TABLET 1-20 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| AUROVELA 24 FE ORAL TABLET 1-20 MG- MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|--|-------------|---|
| AUROVELA FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| AUROVELA FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| AVIANE ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| AYUNA ORAL TABLET 0.15-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| BALZIVA ORAL TABLET 0.4-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| BLISOVI 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| BLISOVI FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| CHATEAL ORAL TABLET 0.15-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| CRYSSELLE-28 ORAL TABLET 0.3-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| CYCLAFEM 1/35 ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| CYRED ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| DASETTA 1/35 ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| DELYLA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-30 mg-mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>drospiren-eth estrad-levomefol oral tablet 3-0.02-0.451 mg</i> | 4 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ELINEST ORAL TABLET 0.3-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|--|-------------|--|
| EMOQUETTE ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| ENSKYCE ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| ESTARYLLA ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg</i> | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| FALMINA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| FEMYNOR ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| GIANVI ORAL TABLET 3-0.02 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| GILDAGIA ORAL TABLET 0.4-35 MG-MCG | 2 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| GILDESS 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | \$0 copay for the following NDCs: 00603-7606-15, 00603-7606-48. Preventative services.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| GILDESS 1/20 ORAL TABLET 1-20 MG-MCG | 2 | \$0 copay for the following NDCs: 00603-7607-15, 00603-7607-48. Preventative care.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| GILDESS 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| GILDESS FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| GILDESS FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| HAILEY 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| HAILEY 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| HAILEY FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| HAILEY FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|--|-------------|---|
| ISIBLOOM ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JASMIEL ORAL TABLET 3-0.02 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| JULEBER ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JUNEL 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| JUNEL 1/20 ORAL TABLET 1-20 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JUNEL FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JUNEL FE 24 ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| KAITLIB FE ORAL TABLET CHEWABLE 0.8-25 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| KALLIGA ORAL TABLET 0.15-30 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| KELNOR 1/35 ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| KELNOR 1/50 ORAL TABLET 1-50 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| KURVELO ORAL TABLET 0.15-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LARIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LARIN 1/20 ORAL TABLET 1-20 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LARIN 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LARIN FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LARISSIA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LAYOLIS FE ORAL TABLET CHEWABLE 0.8-25 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|---|-------------|---|
| LESSINA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg</i> | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-30 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LOESTRIN 1.5/30 (21) ORAL TABLET 1.5-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LOESTRIN 1/20 (21) ORAL TABLET 1-20 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LOESTRIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LOMEDIA 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LORYNA ORAL TABLET 3-0.02 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LOW-OGESTREL ORAL TABLET 0.3-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LO-ZUMANDIMINE ORAL TABLET 3-0.02 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LUTERA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| MICROGESTIN 1/20 ORAL TABLET 1-20 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| MICROGESTIN 24 FE ORAL TABLET 1-20 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| MILI ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| MONO-LINYAH ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|--|-------------|---|
| MONONESSA ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NECON 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| NECON 1/35 (28) ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NECON 1/50 (28) ORAL TABLET 1-50 MG-MCG | 3 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| NIKKI ORAL TABLET 3-0.02 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norethin ace-eth estrad-fe oral tablet 1.5-30 mg-mcg</i> | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg(24)</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norethin-eth estradiol-fe oral tablet chewable 0.4-35 mg-mcg, 0.8-25 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORTREL 1/35 (28) ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NYMYO ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| OCELLA ORAL TABLET 3-0.03 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| OGESTREL ORAL TABLET 0.5-50 MG-MCG | 3 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ORSYTHIA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| PHILITH ORAL TABLET 0.4-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|---|-------------|---|
| PIRMELLA 1/35 ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| PORTIA-28 ORAL TABLET 0.15-30 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| PREVIFEM ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| RAJANI ORAL TABLET 3-0.02-0.451 MG | 4 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| RECLIPSEN ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| SOLIA ORAL TABLET 0.15-30 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| SPRINTEC 28 ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| SRONYX ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| SYEDA ORAL TABLET 3-0.03 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TARINA 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TARINA FE 1/20 ORAL TABLET 1-20 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| VESTURA ORAL TABLET 3-0.02 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| VIENVA ORAL TABLET 0.1-20 MG-MCG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| VYFEMLA ORAL TABLET 0.4-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| VYLIBRA ORAL TABLET 0.25-35 MG-MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| WERA ORAL TABLET 0.5-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| WYMZYA FE ORAL TABLET CHEWABLE 0.4-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ZARAH ORAL TABLET 3-0.03 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ZENCHENT FE ORAL TABLET CHEWABLE 0.4-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ZENCHENT ORAL TABLET 0.4-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|---|------|--|
| ZOVIA 1/35E (28) ORAL TABLET 1-35 MG-MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| ZUMANDIMINE ORAL TABLET 3-0.03 MG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| *COMBINATION CONTRACEPTIVES - TRANSDERMAL*** | | |
| XULANE TRANSDERMAL PATCH WEEKLY 150-35 MCG/24HR | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8); QL (3 EA per 28 days); AL (Max 55 Years) |
| ZAFEMY TRANSDERMAL PATCH WEEKLY 150-35 MCG/24HR | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8); AL (Max 55 Years) |
| *COMBINATION CONTRACEPTIVES - VAGINAL*** | | |
| ELURYNG VAGINAL RING 0.12-0.015 MG/24HR | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8); QL (1 EA per 28 days); AL (Max 55 Years) |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24hr</i> | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8); QL (1 EA per 28 days); AL (Max 55 Years) |
| *CONTINUOUS CONTRACEPTIVES - ORAL*** | | |
| AMETHYST ORAL TABLET 90-20 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>levonorgestrel-ethinyl estrad oral tablet 90-20 mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| *COPPER CONTRACEPTIVES - IUD*** | | |
| PARAGARD INTRAUTERINE COPPER INTRAUTERINE INTRAUTERINE DEVICE | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| *EMERGENCY CONTRACEPTIVES*** | | |
| AFTERA ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines |
| ECONTRA EZ ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines |
| ELLA ORAL TABLET 30 MG | \$0 | \$0 Copay per PPACA guidelines |
| FALLBACK SOLO ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines |
| <i>levonorgestrel oral tablet 0.75 mg</i> | \$0 | \$0 Copay per PPACA guidelines. |
| <i>levonorgestrel oral tablet 1.5 mg</i> | \$0 | \$0 Copay per PPACA guidelines |
| MY WAY ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines |
| NEXT CHOICE ONE DOSE ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines; QL (3 EA per 365 days) |
| NEXT CHOICE ORAL TABLET 0.75 MG | \$0 | \$0 Copay per PPACA guidelines |
| OPCICON ONE-STEP ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines |
| TAKE ACTION ORAL TABLET 1.5 MG | \$0 | \$0 Copay per PPACA guidelines |

| Drug Name | Tier | Notes |
|---|------|---|
| *EXTENDED-CYCLE CONTRACEPTIVES - ORAL *** | | |
| AMETHIA LO ORAL TABLET 0.1-0.02 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| AMETHIA ORAL TABLET 0.15-0.03 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| ASHLYNA ORAL TABLET 0.15-0.03 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| CAMRESE LO ORAL TABLET 0.1-0.02 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| CAMRESE ORAL TABLET 0.15-0.03 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| DAYSEE ORAL TABLET 0.15-0.03 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| ICLEVIA ORAL TABLET 0.15-0.03 MG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| INTROVALE ORAL TABLET 0.15-0.03 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JAIMIESS ORAL TABLET 0.15-0.03 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JOLESSA ORAL TABLET 0.15-0.03 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>levonorgest-eth estrad 91-day oral tablet 0.1-0.02 & 0.01 mg, 0.15-0.03 mg</i> | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03 & 0.01 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LOJAIMIESS ORAL TABLET 0.1-0.02 & 0.01 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| QUASENSE ORAL TABLET 0.15-0.03 MG | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| SETLAKIN ORAL TABLET 0.15-0.03 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|---|------|---|
| SIMPESSE ORAL TABLET 0.15-0.03 & 0.01 MG | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| *PROGESTIN CONTRACEPTIVES - IMPLANTS*** | | |
| NEXPLANON SUBCUTANEOUS IMPLANT 68 MG | \$0 | \$0 Copay per PPACA guidelines; QL (1 EA per 3 Years); AL (Max 55 Years) |
| *PROGESTIN CONTRACEPTIVES - INJECTABLE*** | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 104 MG/0.65ML | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i> | \$0 | \$0 Copay per PPACA guidelines; Up to a six-month supply. *NMAC 13.10.32.(8); AL (Max 55 Years) |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | \$0 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| *PROGESTIN CONTRACEPTIVES - IUD*** | | |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 19.5 MG | \$0 | |
| MIRENA (52 MG) INTRAUTERINE INTRAUTERINE DEVICE 20 MCG/24HR, 20 MCG/DAY | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| *PROGESTIN CONTRACEPTIVES - ORAL *** | | |
| CAMILA ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| DEBLITANE ORAL TABLET 0.35 MG | \$0 | \$0 Copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| ERRIN ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| HEATHER ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JENCYCLA ORAL TABLET 0.35 MG | \$0 | \$0 Copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| JOLIVETTE ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LYLEQ ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|---|------|---|
| LYZA ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORA-BE ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norethindrone oral tablet 0.35 mg</i> | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORLYDA ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORLYROC ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| OPILL ORAL TABLET 0.075 MG | \$0 | |
| SHAROBEL ORAL TABLET 0.35 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| *TRIPHASIC CONTRACEPTIVES - ORAL *** | | |
| <i>alyacen 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ARANELLE ORAL TABLET 0.5/1/0.5-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| CAZANT ORAL TABLET 0.1/0.125/0.15 -0.025 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| CESIA ORAL TABLET 0.1/0.125/0.15 -0.025 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| CYCLAFEM 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| DASETTA 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/ 125-30 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| LEENA ORAL TABLET 0.5/1/0.5-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>levonorg-eth estrad triphasic oral tablet</i> | \$0 | \$0 Copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|---|-------------|---|
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/125-30 mcg</i> | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| MYZILRA ORAL TABLET 50-30/75-40/ 125-30 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NECON 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| PIRELLA 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TILIA FE ORAL TABLET 1-20/1-30/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI FEMYNOR ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-LEGEST FE ORAL TABLET 1-20/1-30/1-35 MG-MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-LINYAH ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-LO-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-LO-MARZIA ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-LO-MILI ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-LO-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRINESSA (28) ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRINESSA LO ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |

| Drug Name | Tier | Notes |
|--|------|---|
| TRI-NYMYO ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-PREVIFEM ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRIVORA (28) ORAL TABLET 50-30/75-40/ 125-30 MCG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-VYLIBRA LO ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | Up to a six-month supply. *NMAC 13.10.32.(8) |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | \$0 | \$0 copay Per PPACA Guidelines; Up to a six-month supply. *NMAC 13.10.32.(8) |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG | \$0 | \$0 Copay per PPACA guidelines.; Up to a six-month supply. *NMAC 13.10.32.(8) |
| *CORTICOSTEROIDS* | | |
| *GLUCOCORTICOSTEROIDS*** | | |
| A-HYDROCORT INJECTION SOLUTION RECONSTITUTED 100 MG | 4 | |
| ARISTOSPAN INTRA-ARTICULAR INJECTION SUSPENSION 20 MG/ML | MB | |
| <i>budesonide er oral capsule extended release 24 hour 3 mg</i> | 4 | |
| <i>budesonide oral capsule delayed release particles 3 mg</i> | 4 | QL (448 EA per 365 days) |
| <i>cortisone acetate oral tablet 25 mg</i> | 3 | |
| DEPO-MEDROL INJECTION SUSPENSION 20 MG/ML, 40 MG/ML, 80 MG/ML | MB | |
| DEXAMETHASONE INTENSOL ORAL CONCENTRATE 1 MG/ML | 3 | |
| <i>dexamethasone oral elixir 0.5 mg/5ml</i> | 2 | |
| <i>dexamethasone oral solution 0.5 mg/5ml</i> | 2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 2 | |
| <i>dexamethasone sodium phosphate injection solution 4 mg/ml</i> | MB | |
| <i>dexamethasone sodium phosphate injection solution prefilled syringe 4 mg/ml</i> | MB | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| KENALOG INJECTION SUSPENSION 40 MG/ML | MB | |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>methylprednisolone (pak) oral tablet 4 mg</i> | 2 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i> | 2 | |
| <i>methylprednisolone sodium succ injection solution reconstituted 1000 mg, 125 mg, 40 mg</i> | MB | |
| <i>prednisolone oral solution 15 mg/5ml</i> | 2 | |
| <i>prednisolone sodium phosphate oral solution 15 mg/5ml, 6.7 (5 base) mg/5ml</i> | 2 | |
| <i>prednisone oral solution 5 mg/5ml</i> | 2 | |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 2 | |
| SOLU-CORTEF INJECTION SOLUTION RECONSTITUTED 100 MG | MB | |
| SOLU-MEDROL (PF) INJECTION SOLUTION RECONSTITUTED 1000 MG, 125 MG, 40 MG, 500 MG | MB | |
| SOLU-MEDROL INJECTION SOLUTION RECONSTITUTED 1000 MG, 125 MG, 2 GM, 40 MG, 500 MG | MB | |
| *MINERALOCORTICOIDS*** | | |
| <i>fludrocortisone acetate oral tablet 0.1 mg</i> | 2 | |
| *STEROID COMBINATIONS*** | | |
| <i>betamethasone sod phos & acet injection suspension 6 (3-3) mg/ml</i> | MB | |
| CELESTONE SOLUSPAN INJECTION SUSPENSION 6 (3-3) MG/ML | MB | |
| *COUGH/COLD/ALLERGY* | | |
| *ANTITUSSIVE - NONNARCOTIC*** | | |
| <i>benzonatate oral capsule 100 mg, 200 mg</i> | 2 | |
| *ANTITUSSIVE-EXPECTORANT*** | | |
| <i>cheratussin ac oral syrup 100-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |
| <i>dex-tuss oral liquid 300-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |
| FLOWTUSS ORAL SOLUTION 2.5-200 MG/5ML | 4 | QL (473 ML per 30 days) |
| <i>guaiaatussin ac oral syrup 100-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>guaifenesin ac oral syrup 100-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |
| <i>guaifenesin-codeine oral solution 100-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |
| <i>guaifenesin-codeine oral syrup 100-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |
| *MISC. RESPIRATORY INHALANTS*** | | |
| <i>sodium chloride inhalation nebulization solution 0.9 %, 7 %</i> | 2 | |
| *MUCOLYTICS*** | | |
| <i>acetylcysteine inhalation solution 10 %, 20 %</i> | 2 | |
| *OPIOID ANTITUSSIVE-ANTIHISTAMINE*** | | |
| <i>promethazine-codeine oral syrup 6.25-10 mg/5ml</i> | 2 | PA; Not covered for members less than 12 years of age. Prior authorization required for members 12 to 18 years of age.; AL (Min 12 Years) |
| *DERMATOLOGICALS* | | |
| *ACNE ANTIBIOTICS*** | | |
| AKNE-MYCIN EXTERNAL OINTMENT 2 % | 3 | QL (25 GM per 30 days) |
| <i>clindamycin phosphate external gel 1 %</i> | 2 | QL (60 GM per 30 days) |
| <i>clindamycin phosphate external lotion 1 %</i> | 2 | QL (60 ML per 30 days) |
| <i>clindamycin phosphate external solution 1 %</i> | 2 | |
| <i>clindamycin phosphate external swab 1 %</i> | 2 | |
| <i>dapsone external gel 5 %, 7.5 %</i> | 4 | |
| <i>erythromycin external gel 2 %</i> | 2 | |
| <i>erythromycin external solution 2 %</i> | 2 | |
| <i>sulfacetamide sodium (acne) external lotion 10 %</i> | 4 | |
| *ACNE COMBINATIONS*** | | |
| BENZAMYCINPAK EXTERNAL PACKET 5-3 % | 3 | |
| <i>benzoyl peroxide-erythromycin external gel 5-3 %</i> | 2 | |
| <i>clindamycin phos-benzoyl perox external gel 1-5 %, 1.2-5 %</i> | 4 | |
| ROSULA EXTERNAL PAD 10-5 % | 4 | QL (30 EA per 30 days) |
| <i>sulfacetamide sodium-sulfur external cream 10-5 %</i> | 2 | |
| <i>sulfacetamide sodium-sulfur external emulsion 10-5 %</i> | 2 | |

| Drug Name | Tier | Notes |
|---|-------------|--|
| <i>sulfacetamide sodium-sulfur external lotion 10-5 %</i> | 2 | |
| <i>sulfacetamide sodium-sulfur external suspension 10-5 %</i> | 3 | |
| *ACNE PRODUCTS*** | | |
| <i>adapalene external cream 0.1 %</i> | 2 | The following Prior authorization criteria applies to patients greater than 40 years of age: The patient must have a diagnosis of actinic keratosis OR adult acne. **Approval length if criteria is met: 1 year; AL (Max 40 Years) |
| <i>adapalene external gel 0.1 %</i> | 2 | The following Prior authorization criteria applies to patients greater than 40 years of age: The patient must have a diagnosis of actinic keratosis OR adult acne. **Approval length if criteria is met: 1 year; AL (Max 40 Years) |
| AMNESTEEM ORAL CAPSULE 10 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length. |
| AMNESTEEM ORAL CAPSULE 20 MG, 40 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length.; AL (Max 40 Years) |
| AZELEX EXTERNAL CREAM 20 % | 4 | |
| <i>benzoyl peroxide wash external liquid 10 %</i> | 2 | OTC products are not covered. |
| CLARAVIS ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length.; QL (60 EA per 30 days) |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 4 | Length of therapy is limited to 24 weeks. Prior authorization is required for treatment beyond this.; QL (60 EA per 30 days); AL (Min 12 Years) |
| <i>isotretinoin oral capsule 25 mg, 35 mg</i> | 4 | QL (60 EA per 30 days); AL (Min 12 Years) |
| MYORISAN ORAL CAPSULE 10 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length.; QL (60 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|--|
| MYORISAN ORAL CAPSULE 20 MG, 30 MG, 40 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length.; QL (60 EA per 30 days); AL (Max 40 Years) |
| <i>tretinoin external cream 0.025 %, 0.05 %, 0.1 %</i> | 2 | The following Prior authorization criteria applies to patients greater than 40 years of age: The patient must have a diagnosis of actinic keratosis OR adult acne. **Approval length if criteria is met: 1 year; AL (Max 40 Years) |
| <i>tretinoin external gel 0.01 %, 0.025 %</i> | 2 | The following Prior authorization criteria applies to patients greater than 40 years of age: The patient must have a diagnosis of actinic keratosis OR adult acne. **Approval length if criteria is met: 1 year; AL (Max 40 Years) |
| ZENATANE ORAL CAPSULE 10 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length.; QL (60 EA per 30 days) |
| ZENATANE ORAL CAPSULE 20 MG, 30 MG, 40 MG | 4 | Length of therapy is limited to 24 weeks per 365 days. Prior authorization is required for amounts exceeding this treatment length.; QL (60 EA per 30 days); AL (Max 40 Years) |
| *AGENTS FOR EXTERNAL GENITAL AND PERIANAL WARTS*** | | |
| VEREGEN EXTERNAL OINTMENT 15 % | 4 | PA; Coverage duration is limited to 16 weeks total.; QL (15 GM per 30 days) |
| *ANTIBIOTIC STEROID COMBINATIONS - TOPICAL*** | | |
| CORTISPORIN EXTERNAL CREAM 3.5-10000-0.5 | 4 | |
| *ANTIBIOTICS - TOPICAL*** | | |
| ALTABAX EXTERNAL OINTMENT 1 % | 4 | ST |
| <i>gentamicin sulfate external cream 0.1 %</i> | 2 | |
| <i>gentamicin sulfate external ointment 0.1 %</i> | 3 | |
| <i>mupirocin external ointment 2 %</i> | 2 | |
| *ANTIFUNGALS - TOPICAL COMBINATIONS*** | | |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|---------------------------------|
| <i>clotrimazole-betamethasone external lotion 1-0.05 %</i> | 2 | |
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i> | 2 | |
| <i>nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%</i> | 2 | |
| *ANTIFUNGALS - TOPICAL*** | | |
| <i>ciclopirox external gel 0.77 %</i> | 2 | |
| <i>ciclopirox external shampoo 1 %</i> | 2 | |
| <i>ciclopirox external solution 8 %</i> | 2 | QL (19.8 ML per 365 days) |
| <i>ciclopirox olamine external cream 0.77 %</i> | 2 | |
| <i>ciclopirox olamine external suspension 0.77 %</i> | 2 | |
| <i>nystatin external cream 100000 unit/gm</i> | 2 | |
| <i>nystatin external ointment 100000 unit/gm</i> | 2 | |
| <i>nystatin external powder 100000 unit/gm</i> | 2 | |
| NYSTOP EXTERNAL POWDER 100000 UNIT/GM | 2 | |
| <i>pedi-dri external powder 100000 unit/gm</i> | 2 | |
| *ANTINEOPLASTIC ANTIMETABOLITES - TOPICAL*** | | |
| <i>fluorouracil external cream 5 %</i> | 2 | |
| <i>fluorouracil external solution 2 %</i> | 3 | |
| *ANTIPSORIATICS - SYSTEMIC*** | | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 5 | PA; QL (60 EA per 30 days); SP |
| SKYRIZI (150 MG DOSE) SUBCUTANEOUS PREFILLED SYRINGE KIT 75 MG/0.83ML | 4 | PA; QL (1 kit per 12 weeks); SP |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 4 | PA; QL (1 kit per 12 weeks); SP |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 4 | PA; QL (1 kit per 12 weeks); SP |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 4 | PA; QL (0.5 ML per 84 days); SP |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML | 4 | PA; QL (0.5 ML per 84 days); SP |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 90 MG/ML | 4 | PA; QL (1 ML per 56 days); SP |
| TALTZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR 80 MG/ML | 4 | PA; QL (1 ML per 28 days); SP |
| TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 80 MG/ML | 4 | PA; QL (1 ML per 28 days); SP |
| *ANTIPSORIATICS*** | | |
| <i>calcipotriene external cream 0.005 %</i> | 4 | |

| Drug Name | Tier | Notes |
|---|------|----------------------------------|
| <i>calcipotriene external ointment 0.005 %</i> | 4 | |
| <i>calcipotriene external solution 0.005 %</i> | 4 | |
| CALCITRENE EXTERNAL OINTMENT 0.005 % | 4 | |
| <i>calcitriol external ointment 3 mcg/gm</i> | 4 | ST |
| <i>tazarotene external cream 0.1 %</i> | 4 | ST; QL (60 GM per 30 days) |
| <i>tazarotene external gel 0.05 %, 0.1 %</i> | 4 | ST; QL (100 GM per 30 days) |
| TAZORAC EXTERNAL CREAM 0.05 % | 4 | ST; QL (60 GM per 30 days) |
| *ANTISEBORRHEIC PRODUCTS*** | | |
| <i>selenium sulfide external lotion 2.5 %</i> | 2 | |
| *ANTIVIRALS - TOPICAL*** | | |
| <i>penciclovir external cream 1 %</i> | 3 | QL (5 GM per 30 days) |
| *ATOPIC DERMATITIS - MONOCLONAL ANTIBODIES*** | | |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML | 5 | PA; QL (2.28 ML per 28 days); SP |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 MG/2ML | 5 | PA; QL (4 ML per 28 days); SP |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML | 5 | PA; QL (1.34 ML per 28 days); SP |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML | 5 | PA; QL (2.28 ML per 28 days); SP |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML | 5 | PA; QL (4 ML per 28 days); SP |
| *BURN PRODUCTS*** | | |
| <i>mafenide acetate external packet 5 %</i> | 4 | PA |
| <i>silver sulfadiazine external cream 1 %</i> | 2 | |
| *CORTICOSTEROIDS - TOPICAL*** | | |
| <i>alclometasone dipropionate external cream 0.05 %</i> | 2 | |
| <i>alclometasone dipropionate external ointment 0.05 %</i> | 2 | |
| <i>amcinonide external ointment 0.1 %</i> | 4 | |
| <i>betamethasone dipropionate aug external cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate aug external gel 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate external cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate external lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate external ointment 0.05 %</i> | 2 | |

| Drug Name | Tier | Notes |
|--|-------------|----------------------------|
| <i>betamethasone valerate external cream 0.1 %</i> | 2 | |
| <i>betamethasone valerate external lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate external ointment 0.1 %</i> | 2 | |
| <i>clobetasol propionate emollient cream 0.05 % external</i> | 2 | |
| <i>clobetasol propionate external cream 0.05 %</i> | 2 | QL (60 GM per 30 days) |
| <i>clobetasol propionate external gel 0.05 %</i> | 2 | |
| <i>clobetasol propionate external ointment 0.05 %</i> | 2 | |
| <i>clobetasol propionate external solution 0.05 %</i> | 2 | |
| <i>clocortolone pivalate external cream 0.1 %</i> | 4 | ST; QL (45 GM per 30 days) |
| CORMAX SCALP APPLICATION EXTERNAL SOLUTION 0.05 % | 4 | |
| <i>desoximetasone external cream 0.25 %</i> | 2 | |
| <i>diflorasone diacetate external ointment 0.05 %</i> | 4 | |
| <i>fluocinolone acetonide body external oil 0.01 %</i> | 2 | |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | 2 | |
| <i>fluocinolone acetonide external ointment 0.025 %</i> | 2 | |
| <i>fluocinolone acetonide external solution 0.01 %</i> | 2 | |
| <i>fluocinolone acetonide scalp external oil 0.01 %</i> | 2 | |
| <i>fluocinonide external cream 0.05 %</i> | 2 | |
| <i>fluocinonide external gel 0.05 %</i> | 2 | |
| <i>fluocinonide external ointment 0.05 %</i> | 2 | |
| <i>fluocinonide external solution 0.05 %</i> | 2 | |
| <i>fluticasone propionate external cream 0.05 %</i> | 2 | |
| <i>fluticasone propionate external ointment 0.005 %</i> | 2 | |
| <i>halcinonide external cream 0.1 %</i> | 4 | ST; QL (60 GM per 30 days) |
| <i>halobetasol propionate external cream 0.05 %</i> | 2 | |
| <i>hydrocortisone butyrate external cream 0.1 %</i> | 2 | |
| <i>hydrocortisone butyrate external ointment 0.1 %</i> | 2 | |
| <i>hydrocortisone butyrate external solution 0.1 %</i> | 2 | |
| <i>hydrocortisone external cream 2.5 %</i> | 2 | |
| <i>hydrocortisone external lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone external ointment 2.5 %</i> | 2 | |
| <i>hydrocortisone valerate external cream 0.2 %</i> | 2 | |
| LANACORT 10 EXTERNAL CREAM 1 % | 2 | |
| <i>mometasone furoate external cream 0.1 %</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>mometasone furoate external ointment 0.1 %</i> | 2 | |
| <i>mometasone furoate external solution 0.1 %</i> | 2 | |
| <i>prednicarbate external ointment 0.1 %</i> | 4 | |
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i> | 2 | |
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i> | 2 | |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %</i> | 2 | |
| *IMIDAZOLE-RELATED ANTIFUNGALS - TOPICAL*** | | |
| <i>clotrimazole external cream 1 %</i> | 2 | |
| <i>econazole nitrate external cream 1 %</i> | 2 | |
| EXELDERM EXTERNAL CREAM 1 % | 4 | PA |
| EXELDERM EXTERNAL SOLUTION 1 % | 4 | PA |
| <i>ketoconazole external cream 2 %</i> | 2 | |
| <i>ketoconazole external shampoo 2 %</i> | 2 | |
| *IMMUNOMODULATORS IMIDAZOQUINOLINAMINES - TOPICAL*** | | |
| <i>imiquimod external cream 5 %</i> | 4 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (12 EA per 30 days) |
| *KERATOLYTIC/ANTIMITOTIC/VESICANT AGENTS*** | | |
| <i>podofilox external solution 0.5 %</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *LOCAL ANESTHETICS - TOPICAL*** | | |

| Drug Name | Tier | Notes |
|---|-------------|--|
| <i>lidocaine external ointment 5 %</i> | 4 | QL (500 GM per 30 days) |
| <i>lidocaine external patch 5 %</i> | 4 | QL (30 EA per 30 days) |
| <i>lidocaine hcl external cream 3 %</i> | 2 | |
| <i>lidocaine hcl external gel 2 %</i> | 2 | |
| <i>lidocaine hcl external solution 4 %</i> | 2 | |
| *MACROLIDE IMMUNOSUPPRESSANTS - TOPICAL *** | | |
| <i>pimecrolimus external cream 1 %</i> | 4 | **Approval length if criteria is met: 2 months; QL (120 GM per 365 days); AL (Min 2 Years) |
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i> | 4 | **Approval length if criteria is met: 2 months; AL (Min 2 Years) |
| *PHOSPHODIESTERASE 4 (PDE4) INHIBITORS - TOPICAL *** | | |
| EUCRISA EXTERNAL OINTMENT 2 % | 5 | PA; QL (60 GM per 30 days) |
| *PHOTODYNAMIC THERAPY AGENTS - TOPICAL *** | | |
| AMELUZ EXTERNAL GEL 10 % | MB | |
| LEVULAN KERASTICK EXTERNAL SOLUTION RECONSTITUTED 20 % | MB | |
| *PIGMENTING AGENTS*** | | |
| OXSORALEN EXTERNAL LOTION 1 % | 4 | PA; QL (29.57 ML per 30 days) |
| *ROSACEA AGENTS*** | | |
| <i>azelaic acid external gel 15 %</i> | 4 | |
| FINACEA EXTERNAL FOAM 15 % | 3 | |
| <i>metronidazole external cream 0.75 %</i> | 2 | |
| <i>metronidazole external gel 0.75 %</i> | 2 | |
| <i>metronidazole external lotion 0.75 %</i> | 2 | |
| ROSADAN EXTERNAL GEL 0.75 % | 2 | |
| *SCABICIDES & PEDICULICIDES*** | | |
| EURAX EXTERNAL CREAM 10 % | 3 | |
| EURAX EXTERNAL LOTION 10 % | 3 | |
| <i>ivermectin external lotion 0.5 %</i> | 4 | ST; **Approval length if criteria is met: 1 month |
| <i>lindane external shampoo 1 %</i> | 3 | |
| <i>malathion external lotion 0.5 %</i> | 4 | ST; QL (60 ML per 90 days) |
| <i>permethrin external cream 5 %</i> | 2 | |
| ULESFIA EXTERNAL LOTION 5 % | 4 | PA; QL (227 GM per 30 days) |

| Drug Name | Tier | Notes |
|--|------|--|
| *TOPICAL ANESTHETIC COMBINATIONS*** | | |
| ANECREAM EXTERNAL KIT 4 % | 4 | |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i> | 4 | |
| <i>lidocaine-transparent dressing external kit 4 %</i> | 4 | |
| LIDOCREAM EXTERNAL KIT 4 % | 4 | |
| *TOPICAL STEROID COMBINATIONS*** | | |
| <i>calcipotriene-betameth diprop external ointment 0.005-0.064 %</i> | 4 | |
| *WOUND CARE - GROWTH FACTOR AGENTS*** | | |
| REGRANEX EXTERNAL GEL 0.01 % | 4 | |
| *DIAGNOSTIC PRODUCTS* | | |
| *DIAGNOSTIC DRUGS*** | | |
| ACTHREL INTRAVENOUS SOLUTION RECONSTITUTED 100 MCG | MB | |
| CORTROSYN INJECTION SOLUTION RECONSTITUTED 0.25 MG | MB | |
| <i>dipyridamole intravenous solution 5 mg/ml</i> | MB | |
| KINEVAC INJECTION SOLUTION RECONSTITUTED 5 MCG | MB | |
| PROVOCHOLINE INHALATION SOLUTION RECONSTITUTED 100 MG | MB | |
| THYROGEN INTRAMUSCULAR SOLUTION RECONSTITUTED 1.1 MG | MB | |
| *DIAGNOSTIC TESTS*** | | |
| ACCU-CHEK AVIVA PLUS IN VITRO STRIP | 2 | 100 test strips per 30 days or 300 test strips for 90 days are covered for members who are not on insulin. 200 test strips per 30 days or 600 test strips per 90 days are covered for members who are receiving insulin. 50 test strips per 30 days or 150 test strips per 90 days are covered for members on a continuous glucose monitoring system.; QL (100 EA per 30 days) |

| Drug Name | Tier | Notes |
|--|------|--|
| ACCU-CHEK GUIDE IN VITRO STRIP | 2 | 100 test strips per 30 days or 300 test strips for 90 days are covered for members who are not on insulin. 200 test strips per 30 days or 600 test strips per 90 days are covered for members who are receiving insulin. 50 test strips per 30 days or 150 test strips per 90 days are covered for members on a continuous glucose monitoring system.; QL (100 EA per 30 days) |
| ACCU-CHEK SMARTVIEW IN VITRO STRIP | 2 | 100 test strips per 30 days or 300 test strips for 90 days are covered for members who are not on insulin. 200 test strips per 30 days or 600 test strips per 90 days are covered for members who are receiving insulin. 50 test strips per 30 days or 150 test strips per 90 days are covered for members on a continuous glucose monitoring system.; QL (100 EA per 30 days) |
| KETOSTIX IN VITRO STRIP | 3 | |
| *DIGESTIVE AIDS* | | |
| *DIGESTIVE ENZYMES*** | | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 6000-19000 UNIT | 3 | |
| PANCREAZE ORAL CAPSULE DELAYED RELEASE PARTICLES 10500-35500 UNIT, 16800-56800 UNIT, 21000-54700 UNIT, 2600-8800 UNIT, 37000-97300 UNIT, 4200-14200 UNIT | 3 | |
| *DIURETICS* | | |
| *CARBONIC ANHYDRASE INHIBITORS*** | | |
| <i>acetazolamide er oral capsule extended release 12 hour 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection solution reconstituted 500 mg</i> | MB | |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 2 | |
| *DIURETIC COMBINATIONS*** | | |
| ALDACTAZIDE ORAL TABLET 50-50 MG | 3 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 1 | |
| <i>spironolactone-hctz oral tablet 25-25 mg</i> | 1 | |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | 1 | |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |

| Drug Name | Tier | Notes |
|--|------|-----------------------------|
| *LOOP DIURETICS*** | | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>ethacrynic acid oral tablet 25 mg</i> | 5 | PA; QL (480 EA per 30 days) |
| <i>furosemide injection solution 10 mg/ml</i> | MB | |
| <i>furosemide oral solution 10 mg/ml</i> | 2 | |
| <i>furosemide oral solution 8 mg/ml</i> | 3 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 2 | |
| *OSMOTIC DIURETICS*** | | |
| <i>mannitol intravenous solution 25 %</i> | MB | |
| *POTASSIUM SPARING DIURETICS*** | | |
| <i>amiloride hcl oral tablet 5 mg</i> | 1 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>triamterene oral capsule 100 mg, 50 mg</i> | 4 | |
| *THIAZIDES AND THIAZIDE-LIKE DIURETICS*** | | |
| <i>chlorothiazide sodium intravenous solution reconstituted 500 mg</i> | MB | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| <i>methyclothiazide oral tablet 5 mg</i> | 3 | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| *ENDOCRINE AND METABOLIC AGENTS - MISC.* | | |
| *ABORTIFACIENT - PROGESTERONE RECEPTOR ANTAGONISTS*** | | |
| <i>mifepristone oral tablet 200 mg</i> | \$0 | |
| *BISPHOSPHONATES*** | | |
| <i>alendronate sodium oral tablet 10 mg, 35 mg, 5 mg, 70 mg</i> | 2 | |
| <i>alendronate sodium oral tablet 40 mg</i> | 3 | |
| <i>etidronate disodium oral tablet 200 mg, 400 mg</i> | 3 | |
| FOSAMAX PLUS D ORAL TABLET 70-2800 MG-UNIT, 70-5600 MG-UNIT | 4 | |
| <i>ibandronate sodium oral tablet 150 mg</i> | 4 | ST; QL (1 EA per 28 days) |
| <i>risedronate sodium oral tablet 150 mg</i> | 4 | QL (1 EA per 28 days) |

| Drug Name | Tier | Notes |
|--|------|--------------------------------|
| <i>risedronate sodium oral tablet 30 mg, 5 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>risedronate sodium oral tablet 35 mg</i> | 4 | QL (4 EA per 28 days) |
| <i>risedronate sodium oral tablet delayed release 35 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>zoledronic acid intravenous solution 4 mg/100ml</i> | MB | |
| *CALCIMIMETIC AGENTS*** | | |
| <i>cinacalcet hcl oral tablet 30 mg</i> | 3 | |
| <i>cinacalcet hcl oral tablet 60 mg, 90 mg</i> | 5 | PA |
| *CALCITONINS*** | | |
| <i>calcitonin (salmon) injection solution 200 unit/ml</i> | 5 | |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i> | 2 | |
| *CALCIUM REGULATORS - MISC.*** | | |
| GANITE INTRAVENOUS SOLUTION 25 MG/ML | MB | |
| *CARNITINE REPLENISHER - AGENTS*** | | |
| <i>levocarnitine intravenous solution 200 mg/ml</i> | MB | |
| *DOPAMINE RECEPTOR AGONISTS*** | | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | QL (56 EA per 28 days) |
| *GNRH/LHRH ANTAGONISTS*** | | |
| ORILISSA ORAL TABLET 150 MG | 5 | PA; QL (30 EA per 30 days); SP |
| ORILISSA ORAL TABLET 200 MG | 5 | PA; QL (60 EA per 30 days); SP |
| *GROWTH HORMONES*** | | |
| OMNITROPE SUBCUTANEOUS SOLUTION 10 MG/1.5ML, 5 MG/1.5ML | 5 | PA; SP |
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10 MG/1.5ML, 5 MG/1.5ML | 5 | PA; SP |
| *HYPERPARATHYROID TREATMENT - VITAMIN D ANALOGS*** | | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 2 | |
| <i>doxercalciferol intravenous solution 4 mcg/2ml</i> | MB | |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 4 | |
| ZEMPLAR INTRAVENOUS SOLUTION 5 MCG/ML | MB | |
| *HYPOPHOSPHATASIA (HPP) AGENTS*** | | |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45ML, 28 MG/0.7ML, 40 MG/ML, 80 MG/0.8ML | 5 | PA; LA |
| *INSULIN-LIKE GROWTH FACTORS (SOMATOMEDINS)*** | | |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML | 5 | PA; SP |
| *LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS*** | | |

| Drug Name | Tier | Notes |
|--|------|---|
| LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 30 MG | MB | PA not required if billed with Dx codes F64.1 - F64.9. |
| SUPPRELIN LA SUBCUTANEOUS KIT 50 MG | MB | |
| *PARATHYROID HORMONE AND DERIVATIVES*** | | |
| <i>teriparatide subcutaneous solution pen-injector 600 mcg/2.4ml</i> | 5 | PA; SP |
| TYMLOS SUBCUTANEOUS SOLUTION PEN- INJECTOR 3120 MCG/1.56ML | 5 | PA; SP |
| *PHENYLKETONURIA TREATMENT - AGENTS*** | | |
| PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML | 5 | PA; LA; QL (7 ML per 28 days) |
| PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 2.5 MG/0.5ML | 5 | PA; LA; QL (3 ML per 35 days) |
| PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML | 5 | PA; LA; QL (28 ML per 28 days) |
| <i>sapropterin dihydrochloride oral packet 100 mg, 500 mg</i> | 5 | PA; LA |
| <i>sapropterin dihydrochloride oral tablet soluble 100 mg</i> | 5 | PA |
| *RANK LIGAND (RANKL) INHIBITORS*** | | |
| PROLIA SUBCUTANEOUS SOLUTION 60 MG/ML | MB | |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML | MB | |
| *SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)*** | | |
| <i>raloxifene hcl oral tablet 60 mg</i> | 2 | DX (Covered at a zero-dollar copay for the prevention of breast cancer per ACA) |
| *SOMATOSTATIC AGENTS*** | | |
| <i>octreotide acetate injection solution 1000 mcg/ml, 200 mcg/ml</i> | MB | PA |
| SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML | MB | |
| SANDOSTATIN INJECTION SOLUTION 1000 MCG/ML | MB | PA |
| *VASOPRESSIN*** | | |
| DDAVP INJECTION SOLUTION 4 MCG/ML | MB | |
| <i>desmopressin ace rhinal tube nasal solution 0.01 %</i> | 2 | |
| <i>desmopressin ace spray refrig nasal solution 0.01 %</i> | 2 | |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i> | 2 | |
| <i>desmopressin acetate spray nasal solution 0.01 %</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|----------------------------|
| *X-LINKED HYPOPHOSPHATEMIA (XLH) TREATMENT - AGENTS*** | | |
| CRYSVITA SUBCUTANEOUS SOLUTION 10 MG/ML, 20 MG/ML, 30 MG/ML | MB | PA |
| *ESTROGENS* | | |
| *ESTROGEN & ANDROGEN*** | | |
| <i>methyltest-est estrogens oral tablet 2.5-1.25 mg</i> | 2 | |
| *ESTROGEN & PROGESTIN*** | | |
| COMBIPATCH TRANSDERMAL PATCH TWICE WEEKLY 0.05-0.14 MG/DAY, 0.05-0.25 MG/DAY | 3 | ST |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 2 | |
| JINTELI ORAL TABLET 1-5 MG-MCG | 2 | |
| <i>norethindrone-eth estradiol oral tablet 1-5 mg-mcg</i> | 2 | |
| PREFEST ORAL TABLET 1/1-0.09 MG (15/15) | 3 | |
| PREMPHASE ORAL TABLET 0.625-5 MG | 3 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | |
| *ESTROGEN-PROGESTIN-GNRH ANTAGONIST*** | | |
| ORIAHNN ORAL CAPSULE THERAPY PACK 300-1-0.5 & 300 MG | 5 | PA; QL (60 EA per 30 days) |
| *ESTROGENS*** | | |
| ALORA TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR | 4 | QL (8 EA per 28 days) |
| CENESTIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 4 | |
| DELESTROGEN INTRAMUSCULAR OIL 10 MG/ML, 20 MG/ML, 40 MG/ML | MB | |
| DEPO-ESTRADIOL INTRAMUSCULAR OIL 5 MG/ML | MB | |
| DOTTI TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.0375 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR | 2 | QL (8 EA per 28 days) |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>estradiol transdermal gel 0.25 mg/0.25gm, 0.5 mg/0.5gm, 0.75 mg/0.75gm, 1 mg/gm, 1.25 mg/1.25gm</i> | 2 | |
| <i>estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | QL (8 EA per 28 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | QL (4 EA per 28 days) |
| ESTRASORB TRANSDERMAL EMULSION 4.35 MG/1.74GM | 4 | |
| ESTROGEL TRANSDERMAL GEL 0.75 MG/1.25 GM (0.06%) | 4 | |
| <i>estropipate oral tablet 0.75 mg, 1.5 mg, 3 mg</i> | 2 | |
| EVAMIST TRANSDERMAL SOLUTION 1.53 MG/SPRAY | 4 | |
| LYLLANA TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.1 MG/24HR | 2 | QL (8 EA per 30 days) |
| LYLLANA TRANSDERMAL PATCH TWICE WEEKLY 0.0375 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR | 2 | |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG | 3 | |
| MENOSTAR TRANSDERMAL PATCH WEEKLY 14 MCG/24HR | 3 | QL (4 EA per 28 days) |
| PREMARIN INJECTION SOLUTION RECONSTITUTED 25 MG | MB | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 3 | |
| *FLUOROQUINOLONES* | | |
| *FLUOROQUINOLONES*** | | |
| AVELOX INTRAVENOUS SOLUTION 400 MG/250ML | MB | |
| AVELOX ORAL TABLET 400 MG | 4 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| CIPRO ORAL SUSPENSION RECONSTITUTED 500 MG/5ML (10%) | 3 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>ciprofloxacin hcl oral tablet 100 mg</i> | 3 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>ciprofloxacin in d5w intravenous solution 400 mg/200ml</i> | MB | |
| <i>ciprofloxacin oral suspension reconstituted 250 mg/5ml (5%)</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| FACTIVE ORAL TABLET 320 MG | 4 | |
| <i>levofloxacin in d5w intravenous solution 250 mg/50ml</i> | MB | |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>levofloxacin oral solution 25 mg/ml</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>moxifloxacin hcl oral tablet 400 mg</i> | 4 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| NOROXIN ORAL TABLET 400 MG | 4 | |
| *GASTROINTESTINAL AGENTS - MISC.* | | |
| *GALLSTONE SOLUBILIZING AGENTS*** | | |
| <i>ursodiol oral capsule 300 mg</i> | 2 | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 2 | |
| *GASTROINTESTINAL CHLORIDE CHANNEL ACTIVATORS*** | | |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | 3 | QL (60 EA per 30 days) |
| *GASTROINTESTINAL STIMULANTS*** | | |
| <i>metoclopramide hcl injection solution 5 mg/ml</i> | MB | |
| <i>metoclopramide hcl oral solution 5 mg/5ml</i> | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|---------------------------------|
| *IBS AGENT - SELECTIVE 5-HT3 RECEPTOR ANTAGONISTS*** | | |
| <i>alosetron hcl oral tablet 0.5 mg, 1 mg</i> | 5 | |
| *INFLAMMATORY BOWEL AGENTS*** | | |
| <i>balsalazide disodium oral capsule 750 mg</i> | 2 | |
| <i>mesalamine er oral capsule extended release 24 hour 0.375 gm</i> | 4 | QL (120 EA per 30 days) |
| <i>mesalamine oral capsule delayed release 400 mg</i> | 4 | ST |
| <i>mesalamine oral tablet delayed release 1.2 gm</i> | 4 | ST; QL (120 EA per 30 days) |
| <i>mesalamine rectal enema 4 gm</i> | 2 | QL (1682 ML per 28 days) |
| <i>mesalamine rectal suppository 1000 mg</i> | 5 | QL (30 EA per 30 days) |
| <i>sulfasalazine oral tablet 500 mg</i> | 2 | |
| <i>sulfasalazine oral tablet delayed release 500 mg</i> | 2 | |
| *INTERLEUKIN ANTAGONISTS*** | | |
| SKYRIZI INTRAVENOUS SOLUTION 600 MG/10ML | MB | PA; QL (30 ML per 365 days) |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML | 4 | PA; QL (1.2 ML per 56 days); SP |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 360 MG/2.4ML | 4 | PA; QL (2.4 ML per 8 weeks); SP |
| *INTESTINAL ACIDIFIERS*** | | |
| <i>generlac oral solution 10 gm/15ml</i> | 2 | |
| <i>lactulose encephalopathy oral solution 10 gm/15ml</i> | 2 | |
| *PHOSPHATE BINDER AGENTS*** | | |
| AURYXIA ORAL TABLET 1 GM 210 MG(Fe) | 5 | PA; QL (12 EA per 1 day) |
| <i>calcium acetate (phos binder) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate (phos binder) oral tablet 667 mg</i> | 2 | |
| <i>calcium acetate oral capsule 667 mg</i> | 2 | |
| <i>lanthanum carbonate oral tablet chewable 1000 mg, 500 mg</i> | 5 | PA; QL (3 EA per 1 day) |
| <i>lanthanum carbonate oral tablet chewable 750 mg</i> | 5 | PA; QL (6 EA per 1 day) |
| PHOSLYRA ORAL SOLUTION 667 MG/5ML | 3 | |
| <i>sevelamer carbonate oral tablet 800 mg</i> | 5 | |
| <i>sevelamer hcl oral tablet 400 mg</i> | 3 | |
| *TRYPTOPHAN HYDROXYLASE INHIBITORS*** | | |
| XERMELO ORAL TABLET 250 MG | 5 | PA; LA; QL (90 EA per 30 days) |
| *TUMOR NECROSIS FACTOR ALPHA BLOCKERS*** | | |

| Drug Name | Tier | Notes |
|---|------|---------------------------------|
| AVSOLA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | PA |
| CIMZIA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 200 MG/ML | 4 | PA; QL (1 EA per 28 days); SP |
| CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT 6 X 200 MG/ML | 4 | PA; QL (3 EA per 28 days); SP |
| CIMZIA SUBCUTANEOUS KIT 2 X 200 MG | 4 | PA; QL (1 EA per 28 days); SP |
| CIMZIA SUBCUTANEOUS PREFILLED SYRINGE KIT 2 X 200 MG/ML | 4 | PA; QL (1 EA per 28 days); SP |
| *GENITOURINARY AGENTS - MISCELLANEOUS* | | |
| *5-ALPHA REDUCTASE INHIBITORS*** | | |
| <i>dutasteride oral capsule 0.5 mg</i> | 4 | |
| <i>finasteride oral tablet 5 mg</i> | 2 | |
| *ALPHA 1-ADRENOCEPTOR ANTAGONISTS*** | | |
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i> | 2 | QL (30 EA per 30 days) |
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 4 | ST; QL (30 EA per 30 days) |
| <i>tamsulosin hcl oral capsule 0.4 mg</i> | 2 | |
| *ANTI-INFECTIVE GENITOURINARY IRRIGANTS*** | | |
| <i>neomycin-polymyxin b gu irrigation solution 40-200000</i> | 2 | |
| *CITRATES*** | | |
| <i>citric acid-sodium citrate oral solution 334-500 mg/5ml</i> | 2 | |
| <i>potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)</i> | 2 | |
| <i>sod citrate-citric acid oral solution 500-334 mg/5ml</i> | 2 | |
| *INTERSTITIAL CYSTITIS AGENTS*** | | |
| ELMIRON ORAL CAPSULE 100 MG | 4 | PA; QL (90 EA per 30 days) |
| *URINARY ANALGESICS*** | | |
| <i>phenazopyridine hcl oral tablet 100 mg, 200 mg</i> | 2 | |
| *URINARY STONE AGENTS*** | | |
| <i>tiopronin oral tablet 100 mg</i> | 4 | PA; LA; QL (300 EA per 30 days) |
| *GOUT AGENTS* | | |
| *GOUT AGENT COMBINATIONS*** | | |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | 2 | |
| *GOUT AGENTS*** | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|------------------------|
| <i>colchicine oral tablet 0.6 mg</i> | 2 | |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 4 | QL (30 EA per 30 days) |
| *URICOSURICS*** | | |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| *HEMATOLOGICAL AGENTS - MISC.* | | |
| *ANTHEMOPHILIC PRODUCTS*** | | |
| ADVATE INTRAVENOUS SOLUTION RECONSTITUTED 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT | MB | |
| AFSTYLA INTRAVENOUS KIT 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 500 UNIT | MB | |
| ALPHANATE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT | MB | |
| ALPHANATE/VWF COMPLEX/HUMAN INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT | MB | |
| ALPHANINE SD INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT | MB | |
| ALPROLIX INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT | MB | |
| BENEFIX INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT | MB | |
| CORIFACT INTRAVENOUS KIT 1000-1600 UNIT | MB | |
| FEIBA INTRAVENOUS SOLUTION RECONSTITUTED | MB | |
| FIBRYGA INTRAVENOUS SOLUTION RECONSTITUTED | MB | |
| HELIXATE FS INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT | MB | |
| HEMOPIL M INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1700 UNIT, 250 UNIT, 500 UNIT | MB | |
| HUMATE-P INTRAVENOUS SOLUTION RECONSTITUTED 1000-2400 UNIT, 250-600 UNIT, 500-1200 UNIT | MB | |
| KCENTRA INTRAVENOUS KIT 1000 UNIT, 500 UNIT | MB | |
| KOATE-DVI INTRAVENOUS SOLUTION RECONSTITUTED 250 UNIT, 500 UNIT | MB | |
| KOGENATE FS INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT | MB | |

| Drug Name | Tier | Notes |
|--|------|--------------------------------|
| KOVALTRY INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT | MB | |
| MONOCLATE-P INTRAVENOUS KIT 1000 UNIT | MB | |
| MONONINE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT | MB | |
| NOVOEIGHT INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT | MB | |
| NOVOSEVEN RT INTRAVENOUS SOLUTION RECONSTITUTED 1 MG, 2 MG, 5 MG, 8 MG | MB | |
| NUWIQ INTRAVENOUS KIT 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT | MB | |
| NUWIQ INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT | MB | |
| <i>obizur intravenous solution reconstituted 500 unit</i> | MB | |
| PROFILNINE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT | MB | |
| PROFILNINE SD INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT | MB | |
| RECOMBINATE INTRAVENOUS SOLUTION RECONSTITUTED 1241-1800 UNIT, 1801-2400 UNIT, 220-400 UNIT, 401-800 UNIT, 801-1240 UNIT | MB | |
| RIASTAP INTRAVENOUS SOLUTION RECONSTITUTED | MB | |
| <i>rixubis intravenous solution reconstituted 1000 unit, 2000 unit, 250 unit, 3000 unit, 500 unit</i> | MB | |
| TRETEN INTRAVENOUS SOLUTION RECONSTITUTED 2000-3125 UNIT | MB | |
| WILATE INTRAVENOUS KIT 1000-1000 UNIT, 500-500 UNIT | MB | |
| XYNTHA INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT | MB | |
| XYNTHA SOLOFUSE INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT | MB | |
| *BRADYKININ B2 RECEPTOR ANTAGONISTS*** | | |
| <i>icatibant acetate subcutaneous solution 30 mg/3ml</i> | 5 | PA; QL (18 ML per 28 days); SP |
| <i>icatibant acetate subcutaneous solution prefilled syringe 30 mg/3ml</i> | 5 | PA; QL (18 ML per 28 days); SP |
| *C1 ESTERASE INHIBITORS*** | | |
| HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT | MB | PA; SP |

| Drug Name | Tier | Notes |
|--|------|---|
| *COMPLEMENT C5 INHIBITORS*** | | |
| SOLIRIS INTRAVENOUS SOLUTION 300 MG/30ML | MB | PA |
| ULTOMIRIS INTRAVENOUS SOLUTION 1100 MG/11ML, 300 MG/3ML | MB | PA |
| ULTOMIRIS INTRAVENOUS SOLUTION 300 MG/30ML | MB | PA; SP |
| *DIRECT-ACTING P2Y12 INHIBITORS*** | | |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | Maximum of 730 tablets per lifetime; QL (60 EA per 30 days) |
| *GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITORS*** | | |
| AGGRASTAT INTRAVENOUS CONCENTRATE 3.75 MG/15ML | MB | |
| AGGRASTAT INTRAVENOUS SOLUTION 5-0.9 MG/100ML-% | MB | |
| REOPRO INTRAVENOUS SOLUTION 2 MG/ML | MB | |
| *HEMATORHEOLOGIC AGENTS*** | | |
| <i>pentoxifylline er oral tablet extended release 400 mg</i> | 4 | |
| *HUMAN PROTEIN C*** | | |
| CEPROTIN INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 500 UNIT | MB | |
| *PHOSPHODIESTERASE III INHIBITORS*** | | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |
| *PLASMA EXPANDERS*** | | |
| LMD IN D5W INTRAVENOUS SOLUTION 10-5 % | MB | |
| LMD IN NACL INTRAVENOUS SOLUTION 10-0.9 % | MB | |
| *PLASMA KALLIKREIN INHIBITORS - MONOCLONAL ANTIBODIES*** | | |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML | 5 | PA; QL (2 ML per 28 days); SP |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA; QL (2 ML per 28 days); SP |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML | 5 | PA; QL (4 ML per 28 days); SP |
| *PLATELET AGGREGATION INHIBITOR COMBINATIONS*** | | |
| <i>aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg</i> | 4 | |
| *PLATELET AGGREGATION INHIBITORS*** | | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|--|
| *PROTAMINE*** | | |
| <i>protamine sulfate intravenous solution 10 mg/ml</i> | MB | |
| *QUINAZOLINE AGENTS*** | | |
| <i>anagrelide hcl oral capsule 0.5 mg, 1 mg</i> | 2 | |
| *THIENOPYRIDINE DERIVATIVES*** | | |
| <i>clopidogrel bisulfate oral tablet 75 mg</i> | 2 | |
| <i>prasugrel hcl oral tablet 10 mg</i> | 4 | |
| <i>prasugrel hcl oral tablet 5 mg</i> | 4 | PA |
| <i>ticlopidine hcl oral tablet 250 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| *TISSUE PLASMINOGEN ACTIVATORS*** | | |
| ACTIVASE INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG | MB | |
| CATHFLO ACTIVASE INJECTION SOLUTION RECONSTITUTED 2 MG | MB | |
| *HEMATOPOIETIC AGENTS* | | |
| *COBALAMINS*** | | |
| <i>cyanocobalamin injection solution 1000 mcg/ml</i> | 2 | |
| *ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)*** | | |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML | MB | PA |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE 10 MCG/0.4ML, 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML | MB | PA |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML | MB | PA; If billed through medical benefit, the medical coinsurance will apply;; QL (12 ML per 28 days); SP |
| RETACRIT INJECTION SOLUTION 2000 UNIT/ML, 3000 UNIT/ML | MB | PA; If billed through medical benefit, the medical coinsurance will apply;; QL (12 ML per 28 days) |
| RETACRIT INJECTION SOLUTION 20000 UNIT/ML | MB | PA; QL (12 ML per 28 days) |
| RETACRIT INJECTION SOLUTION 40000 UNIT/ML | MB | PA; If billed through medical benefit, the medical coinsurance will apply;; QL (4 ML per 28 days) |
| *FOLIC ACID/FOLATES*** | | |
| <i>cvs folic acid oral tablet 800 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>eql folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |

| Drug Name | Tier | Notes |
|---|-------------|--|
| FA-8 ORAL TABLET 800 MCG | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>folic acid oral tablet 1 mg</i> | 2 | |
| <i>folic acid oral tablet 400 mcg, 800 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>gnp folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>hm folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>kp folic acid oral tablet 800 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>px folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>ra folic acid oral tablet 400 mcg, 800 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>sm folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>th folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| <i>yl folic acid oral tablet 400 mcg</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| *GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)*** | | |
| FULPHILA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML | MB | PA; Specialty Pharmacy Required if drug is filled through pharmacy benefit; SP |
| NEULASTA ONPRO SUBCUTANEOUS PREFILLED SYRINGE KIT 6 MG/0.6ML | MB | PA; Specialty Pharmacy Required if drug is filled through pharmacy benefit; SP |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML | MB | PA; Specialty Pharmacy Required if drug is filled through pharmacy benefit; SP |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML | MB | PA; Specialty Pharmacy Required if drug is filled through pharmacy benefit; SP |
| *INTERLEUKINS*** | | |
| NEUMEGA SUBCUTANEOUS SOLUTION RECONSTITUTED 5 MG | MB | PA |
| *IRON*** | | |
| <i>ferretts ips oral solution 40 mg/15ml</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Max 12 Years) |
| FERRIMIN 150 ORAL TABLET 150 MG | \$0 | \$0 Copay Preventative Services; AL (Max 12 Years) |
| <i>ferronate oral tablet 325 mg</i> | \$0 | \$0 Copay per PPACA guidelines |
| FERRO-SEQUELS ORAL TABLET EXTENDED RELEASE 50 MG | 3 | \$0 Copay Per PPACA Guidelines; AL (Max 12 Years) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>ferumoxytol intravenous solution 510 mg/17ml</i> | MB | PA |
| INJECTAFER INTRAVENOUS SOLUTION 100 MG/2ML | MB | PA |
| <i>iron oral tablet 246 (28 fe) mg, 90 (18 fe) mg</i> | 3 | \$0 Copay per PPACA guidelines; AL (Max 12 Years) |
| NOVAFERRUM PEDIATRIC DROPS ORAL LIQUID 15 MG/ML | \$0 | \$0 Copay per PPACA guidelines; AL (Max 12 Years) |
| <i>slow release iron oral tablet extended release 140 (45 fe) mg</i> | 3 | \$0 Copay per PPACA guidelines; AL (Max 12 Years) |
| *THROMBOPOIETIN (TPO) RECEPTOR AGONISTS*** | | |
| MULPLETA ORAL TABLET 3 MG | 5 | PA; QL (7 EA per 7 days); SP |
| *HEMOSTATICS* | | |
| *HEMOSTATICS - SYSTEMIC*** | | |
| <i>aminocaproic acid oral solution 0.25 gm/ml</i> | 5 | PA; AL (Max 12 Years) |
| <i>aminocaproic acid oral tablet 1000 mg, 500 mg</i> | 5 | |
| CYKLOKAPRON INTRAVENOUS SOLUTION 1000 MG/10ML | MB | |
| <i>tranexamic acid intravenous solution 1000 mg/10ml</i> | MB | |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | QL (30 EA per 30 days) |
| *HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENTS* | | |
| *BARBITURATE HYPNOTICS*** | | |
| AMYTAL SODIUM INJECTION SOLUTION RECONSTITUTED 500 MG | MB | |
| LUMINAL INJECTION SOLUTION 130 MG/ML | MB | |
| <i>pentobarbital sodium injection solution 50 mg/ml</i> | MB | |
| <i>phenobarbital oral elixir 20 mg/5ml</i> | 2 | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 30 mg, 60 mg</i> | 3 | |
| <i>phenobarbital oral tablet 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg</i> | 2 | |
| *BENZODIAZEPINE HYPNOTICS*** | | |
| <i>flurazepam hcl oral capsule 15 mg, 30 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>midazolam hcl (pf) injection solution 10 mg/2ml, 2 mg/2ml, 5 mg/ml</i> | 2 | ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>midazolam hcl injection solution 10 mg/10ml, 10 mg/2ml, 2 mg/2ml, 25 mg/5ml, 5 mg/5ml, 5 mg/ml, 50 mg/10ml</i> | 2 | ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>midazolam hcl oral syrup 2 mg/ml</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>temazepam oral capsule 15 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>temazepam oral capsule 30 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>triazolam oral tablet 0.125 mg, 0.25 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| *NON-BENZODIAZEPINE - GABA-RECEPTOR MODULATORS*** | | |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days) |
| <i>zolpidem tartrate er oral tablet extended release 12.5 mg, 6.25 mg</i> | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| <i>zolpidem tartrate oral tablet 10 mg, 5 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| *OREXIN RECEPTOR ANTAGONISTS*** | | |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 4 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days) |
| DAYVIGO ORAL TABLET 10 MG, 5 MG | 5 | PA; QL (30 EA per 30 days) |
| *SELECTIVE MELATONIN RECEPTOR AGONISTS*** | | |
| <i>ramelteon oral tablet 8 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| *LAXATIVES* | | |
| *BOWEL EVACUANT COMBINATIONS*** | | |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM | \$0 | QL (8000 ML per 365 days); AL (Min 50 Years) |
| GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236 GM | \$0 | QL (8000 ML per 365 days); AL (Min 50 Years) |
| HALFLYTELY WITH FLAVOR PACKS ORAL KIT 5-210 MG-GM | 4 | |
| <i>peg 3350/electrolytes oral solution reconstituted 240 gm</i> | 2 | QL (8000 ML per 30 days) |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | \$0 | \$0 Copay per PPACA guidelines |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i> | 2 | QL (8000 ML per 30 days) |
| PEG-PREP ORAL KIT 5-210 MG-GM | 4 | |
| PREPOPIK ORAL PACKET 10-3.5-12 MG-GM-GM | 4 | PA |
| *LAXATIVES - MISCELLANEOUS*** | | |
| <i>lactulose oral solution 10 gm/15ml</i> | 2 | |
| <i>peg 3350 oral powder 17 gm/scoop</i> | 2 | |
| <i>polyethylene glycol 3350 oral powder 17 gm/scoop</i> | 2 | |
| *SALINE LAXATIVES*** | | |
| <i>magnesium citrate oral solution 1.745 gm/30ml</i> | 2 | |
| *LOCAL ANESTHETICS-PARENTERAL* | | |
| *LOCAL ANESTHETICS - AMIDES*** | | |
| EXPAREL INJECTION SUSPENSION 1.3 % | MB | |
| NAROPIN INJECTION SOLUTION 2 MG/ML | MB | |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>ropivacaine hcl injection solution 10 mg/ml, 2 mg/ml, 5 mg/ml, 7.5 mg/ml</i> | MB | |
| *LOCAL ANESTHETICS - ESTERS*** | | |
| <i>chloroprocaine hcl (pf) injection solution 2 %</i> | MB | |
| *MACROLIDES* | | |
| *AZITHROMYCIN*** | | |
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>azithromycin oral tablet 250 mg, 500 mg, 600 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| ZITHROMAX INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | |
| *CLARITHROMYCIN*** | | |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| *ERYTHROMYCINS*** | | |
| E.E.S. GRANULES ORAL SUSPENSION RECONSTITUTED 200 MG/5ML | 5 | PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years) |

| Drug Name | Tier | Notes |
|--|------|---|
| ERYPED 200 ORAL SUSPENSION RECONSTITUTED 200 MG/5ML | 5 | PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years) |
| ERYPED 400 ORAL SUSPENSION RECONSTITUTED 400 MG/5ML | 5 | PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years) |
| ERY-TAB ORAL TABLET DELAYED RELEASE 250 MG, 333 MG, 500 MG | 5 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | |
| <i>erythromycin base oral tablet 250 mg, 500 mg</i> | 5 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>erythromycin base oral tablet delayed release 250 mg</i> | 4 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>erythromycin base oral tablet delayed release 333 mg, 500 mg</i> | 5 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml</i> | 5 | <p>PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years)</p> |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i> | 5 | <p>STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.</p> <p>* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)</p> |

| Drug Name | Tier | Notes |
|--|------|--|
| <i>erythromycin oral tablet delayed release 250 mg</i> | 4 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>erythromycin oral tablet delayed release 333 mg, 500 mg</i> | 5 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>erythromycin stearate oral tablet 250 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *FIDAXOMICIN*** | | |
| DIFICID ORAL SUSPENSION RECONSTITUTED 40 MG/ML | 5 | PA; QL (136 ML per 30 days) |
| *MEDICAL DEVICES AND SUPPLIES* | | |
| *CERVICAL CAPS*** | | |
| FEMCAP VAGINAL DEVICE 22 MM, 26 MM, 30 MM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| PRENTIF CAVITY-RIM CERV CAP VAGINAL DEVICE 22 MM, 25 MM, 28 MM, 31 MM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| PRENTIF FITTING SET VAGINAL | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| *CONDOMS - FEMALE*** | | |
| FC FEMALE CONDOM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |

| Drug Name | Tier | Notes |
|--|------|--|
| FC2 FEMALE CONDOM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| *CONDOMS - MALE*** | | |
| <i>condoms</i> | \$0 | |
| *DIAPHRAGMS*** | | |
| CAYA VAGINAL DIAPHRAGM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| OMNIFLEX DIAPHRAGM VAGINAL DIAPHRAGM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| ORTHO DIAPHRAGM COIL VAGINAL KIT 100 MM, 105 MM, 50 MM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| ORTHO DIAPHRAGM FLAT VAGINAL KIT 55 MM, 60 MM, 65 MM, 70 MM, 75 MM, 80 MM, 85 MM, 90 MM, 95 MM | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 60 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 65 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 70 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 75 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 80 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 85 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 90 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| WIDE-SEAL DIAPHRAGM 95 VAGINAL DIAPHRAGM 2 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| *GLUCOSE MONITORING TEST SUPPLIES*** | | |
| ACCU-CHEK FASTCLIX LANCET KIT | 2 | QL (1 EA per 180 days) |
| ACCU-CHEK FASTCLIX LANCETS | 2 | 102 lancets per 30 days or 306 lancets for 90 days are covered for members who are not on insulin. 204 lancets per 30 days or 612 lancets per 90 days are covered for members who are receiving insulin. 51 lancets per 30 days or 153 lancets per 90 days are covered for members on a continuous glucose monitoring system.; QL (102 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|-------------|--|
| ACCU-CHEK MULTICLIX LANCETS | 2 | 102 lancets per 30 days or 306 lancets for 90 days are covered for members who are not on insulin. 204 lancets per 30 days or 612 lancets per 90 days are covered for members who are receiving insulin. 51 lancets per 30 days or 153 lancets per 90 days are covered for members on a continuous glucose monitoring system.; QL (102 EA per 30 days) |
| ACCU-CHEK SOFTCLIX LANCET DEV KIT | 2 | QL (1 EA per 180 days) |
| ACCU-CHEK SOFTCLIX LANCETS | 2 | 100 lancets per 30 days or 300 lancets for 90 days are covered for members who are not on insulin. 200 lancets per 30 days or lancets per 90 days are covered for members who are receiving insulin. 50 lancets per 30 days or 150 lancets per 90 days are covered for members on a continuous glucose monitoring system.; QL (100 EA per 30 days) |
| DEXCOM G6 RECEIVER DEVICE | 3 | PA; QL (1 EA per 365 days) |
| DEXCOM G6 SENSOR | 3 | PA; QL (3 EA per 30 days) |
| DEXCOM G6 TRANSMITTER | 3 | PA; QL (1 EA per 90 days) |
| DEXCOM G7 RECEIVER DEVICE | 3 | PA; QL (1 EA per 365 Days) |
| DEXCOM G7 SENSOR | 3 | PA; QL (3 EA per 30 Days) |
| FREESTYLE LIBRE 14 DAY READER DEVICE | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (1 EA per 365 days) |
| FREESTYLE LIBRE 14 DAY SENSOR | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (2 EA per 28 days) |
| FREESTYLE LIBRE 2 READER DEVICE | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (1 EA per 365 days) |
| FREESTYLE LIBRE 2 SENSOR | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (2 EA per 28 days) |
| FREESTYLE LIBRE 3 READER DEVICE | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (1 EA per 365 days) |
| FREESTYLE LIBRE 3 SENSOR | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (2 EA per 28 days) |

| Drug Name | Tier | Notes |
|---|------|--|
| FREESTYLE LIBRE READER DEVICE | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (1 EA per 365 days) |
| FREESTYLE LIBRE SENSOR SYSTEM | 3 | Use of 30-day supply of insulin in the past 120 days required for new starts and continuations; QL (3 EA per 30 days) |
| GUARDIAN 4 GLUCOSE SENSOR | 3 | PA; QL (5 EA per 30 days) |
| GUARDIAN 4 TRANSMITTER | 3 | PA; QL (1 EA per 365 days) |
| GUARDIAN LINK 3 TRANSMITTER | 3 | PA; QL (1 EA per 365 days) |
| GUARDIAN SENSOR (3) | 3 | PA; QL (5 EA per 30 days) |
| <i>guardian sensor 3</i> | 3 | PA; QL (5 EA per 30 days) |
| *INSULIN ADMINISTRATION SUPPLIES*** | | |
| MINIMED GUARDIAN LINK 3 | 3 | PA; QL (1 EA per 365 days) |
| OMNIPOD 5 G6 INTRO (GEN 5) KIT | 4 | PA; QL (1 EA per 1 Lifetime) |
| OMNIPOD 5 G6 PODS (GEN 5) | 4 | PA; QL (10 Pods per 30 days) |
| OMNIPOD DASH INTRO (GEN 4) KIT | 4 | PA; QL (1 EA per 1 lifetime) |
| OMNIPOD DASH PODS (GEN 4) | 4 | PA; QL (10 EA per 30 days) |
| *NEEDLES & SYRINGES*** | | |
| BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 1 ML | 2 | |
| BD PEN NEEDLE MINI U/F 31G X 5 MM | 2 | QL (100 EA per 30 days) |
| BD PEN NEEDLE NANO U/F 32G X 4 MM | 2 | QL (100 EA per 30 days) |
| BD PEN NEEDLE ORIGINAL U/F 29G X 12.7MM | 2 | QL (100 EA per 30 days) |
| BD PEN NEEDLE SHORT U/F 31G X 8 MM | 2 | QL (100 EA per 30 days) |
| NOVOFINE PEN NEEDLE 32G X 6 MM | 2 | |
| NOVOTWIST PEN NEEDLE 32G X 5 MM | 2 | |
| <i>pen needles 3/16" 31g x 5 mm</i> | 2 | QL (100 EA per 30 days) |
| <i>pen needles 5/16" 30g x 8 mm</i> | 2 | QL (100 EA per 30 days) |
| *PEAK FLOW METERS*** | | |
| ASSESS PEAK FLOW METER DEVICE | 3 | |
| *SPACER/AEROSOL-HOLDING CHAMBERS & SUPPLIES*** | | |
| AEROCHAMBER PLUS FLO-VU | 4 | AeroChamber Plus Flow VU NDC-04351-0798-10 is available at tier 1.; QL (2 EA per 180 days) |
| AEROCHAMBER PLUS FLOW VU | 4 | AeroChamber Plus Flow VU NDC-04351-0798-10 is available at tier 1.; QL (2 EA per 180 days) |
| AEROCHAMBER Z-STAT PLUS | 2 | QL (2 EA per 180 days) |
| EASIVENT | 4 | QL (2 EA per 180 days) |

| Drug Name | Tier | Notes |
|--|------|-------------------------------|
| E-Z SPACER DEVICE | 4 | QL (2 EA per 180 days) |
| LITEAIRE DEVICE | 2 | QL (2 EA per 180 days) |
| MICROCHAMBER | 2 | QL (2 EA per 180 days) |
| MICROSPACER | 2 | QL (2 EA per 180 days) |
| OPTICHAMBER DIAMOND | 2 | QL (2 EA per 180 days) |
| OPTICHAMBER DIAMOND-LG MASK DEVICE | 2 | QL (2 EA per 180 days) |
| OPTICHAMBER DIAMOND-MD MASK | 2 | QL (2 EA per 180 days) |
| OPTICHAMBER DIAMOND-SM MASK | 2 | QL (2 EA per 180 days) |
| OPTIHALER | 2 | QL (2 EA per 180 days) |
| POCKET CHAMBER DEVICE | 2 | QL (2 EA per 180 days) |
| *MIGRAINE PRODUCTS* | | |
| *CGRP RECEPTOR ANTAGONISTS - MONOCLONAL ANTIBODIES*** | | |
| AIMOVIG SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML, 70 MG/ML | 5 | PA; QL (1 ML per 28 days); SP |
| *ERGOT COMBINATIONS*** | | |
| CAFERGOT ORAL TABLET 1-100 MG | 4 | QL (40 EA per 30 days) |
| *MIGRAINE PRODUCTS*** | | |
| <i>dihydroergotamine mesylate injection solution 1 mg/ml</i> | 4 | QL (8 ML per 30 days) |
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | 5 | ST; QL (8 ML per 30 days) |
| ERGOMAR SUBLINGUAL TABLET SUBLINGUAL 2 MG | 4 | ST; QL (12 EA per 30 days) |
| *SELECTIVE SEROTONIN AGONISTS 5-HT(1)*** | | |
| <i>almotriptan malate oral tablet 12.5 mg, 6.25 mg</i> | 4 | ST; QL (18 EA per 30 days) |
| <i>eletriptan hydrobromide oral tablet 20 mg, 40 mg</i> | 4 | ST; QL (18 EA per 30 days) |
| <i>frovatriptan succinate oral tablet 2.5 mg</i> | 4 | ST; QL (18 EA per 30 days) |
| IMITREX STATDOSE SYSTEM SUBCUTANEOUS SOLUTION AUTO-INJECTOR 4 MG/0.5ML | MB | |
| IMITREX SUBCUTANEOUS SOLUTION 6 MG/0.5ML | MB | |
| <i>naratriptan hcl oral tablet 1 mg</i> | 4 | QL (18 EA per 30 days) |
| <i>naratriptan hcl oral tablet 2.5 mg</i> | 2 | QL (18 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 10 mg, 5 mg</i> | 2 | QL (18 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg</i> | 2 | QL (18 EA per 30 days) |
| <i>sumatriptan nasal solution 20 mg/act, 5 mg/act</i> | 2 | QL (6 EA per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | QL (18 EA per 30 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 6 mg/0.5ml</i> | 2 | QL (2 ML per 30 days) |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml, 6 mg/0.5ml</i> | 2 | QL (2 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution prefilled syringe 6 mg/0.5ml</i> | 2 | QL (2 ML per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | 2 | ST; QL (18 EA per 30 days) |
| <i>zolmitriptan oral tablet dispersible 2.5 mg, 5 mg</i> | 4 | ST; QL (18 EA per 30 days) |
| ZOMIG NASAL SOLUTION 2.5 MG, 5 MG | 4 | QL (6 EA per 30 days) |
| *MINERALS & ELECTROLYTES* | | |
| *BICARBONATES*** | | |
| <i>sodium acetate intravenous solution 2 meq/ml</i> | 2 | |
| *CALCIUM*** | | |
| CALPHOSAN INJECTION SOLUTION 50-50 MG/10ML | MB | |
| *ELECTROLYTES & DEXTROSE*** | | |
| <i>dextrose in lactated ringers intravenous solution 5 %</i> | MB | |
| <i>dextrose-nacl intravenous solution 5-0.9 %</i> | MB | |
| <i>dextrose-sodium chloride intravenous solution 5-0.9 %</i> | MB | |
| *ELECTROLYTES PARENTERAL *** | | |
| <i>lactated ringers intravenous solution</i> | MB | |
| *FLUORIDE*** | | |
| FLURA-DROPS ORAL SOLUTION 0.275 (0.125 F) MG/DROP | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 6 Years) |
| FLURA-DROPS ORAL SOLUTION 0.55 (0.25 F) MG/DROP | \$0 | \$0 Copay per PPACA guidelines.; AL (Min 1 Years and Max 6 Years) |
| <i>sodium fluoride oral solution 1.1 (0.5 f) mg/ml</i> | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 6 Years) |
| <i>sodium fluoride oral tablet chewable 0.55 (0.25 f) mg, 1.1 (0.5 f) mg, 2.2 (1 f) mg</i> | \$0 | \$0 Copay Preventative Services.; AL (Max 6 Years) |
| *MAGNESIUM*** | | |
| <i>magnesium sulfate in d5w intravenous solution 1-5 gm/100ml-%</i> | MB | |
| <i>magnesium sulfate injection solution 50 %</i> | MB | |
| <i>magnesium sulfate intravenous solution 2 gm/50ml, 20 gm/500ml, 4 gm/100ml, 4 gm/50ml, 40 gm/1000ml</i> | MB | |
| *POTASSIUM*** | | |
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ | 2 | |
| KLOR-CON ORAL PACKET 20 MEQ | 2 | |
| KLOR-CON/EF ORAL TABLET EFFERVESCENT 25 MEQ | 2 | |

| Drug Name | Tier | Notes |
|--|------|-------------------------------|
| potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq | 2 | |
| potassium chloride er oral capsule extended release 10 meq, 8 meq | 2 | |
| potassium chloride er oral tablet extended release 10 meq, 8 meq | 2 | |
| potassium chloride intravenous solution 2 meq/ml | MB | |
| potassium chloride oral packet 20 meq | 2 | |
| potassium chloride oral solution 20 meq/15ml (10%) | 2 | |
| *ZINC*** | | |
| zinc sulfate intravenous solution 3 mg/ml | MB | |
| *MISCELLANEOUS THERAPEUTIC CLASSES* | | |
| *ANTILEPROTICS*** | | |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA; SP |
| *B-LYMPHOCYTE STIMULATOR (BLYS)-SPECIFIC INHIBITORS*** | | |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML | 5 | PA; QL (4 ML per 28 days); SP |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML | 5 | PA; QL (4 ML per 28 days); SP |
| *CHELATING AGENTS*** | | |
| penicillamine oral capsule 250 mg | 5 | PA; QL (240 EA per 30 days) |
| penicillamine oral tablet 250 mg | 5 | PA; QL (240 EA per 30 days) |
| *CYCLOSPORINE ANALOGS*** | | |
| cyclosporine intravenous solution 50 mg/ml | MB | |
| cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg | 2 | |
| cyclosporine modified oral solution 100 mg/ml | 2 | |
| cyclosporine oral capsule 100 mg, 25 mg | 2 | |
| GENGRAF ORAL SOLUTION 100 MG/ML | 3 | |
| SANDIMMUNE INTRAVENOUS SOLUTION 50 MG/ML | MB | |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML | 3 | |
| *ENZYMES*** | | |
| HYLENEX INJECTION SOLUTION 150 UNIT/ML | MB | PA |
| *IMMUNE GLOBULIN IMMUNOSUPPRESSANTS*** | | |
| ATGAM INTRAVENOUS INJECTABLE 50 MG/ML | MB | |

| Drug Name | Tier | Notes |
|--|------|-----------------------------|
| THYMOGLOBULIN INTRAVENOUS SOLUTION RECONSTITUTED 25 MG | MB | |
| *IMMUNOMODULATORS FOR MYELODYSPLASTIC SYNDROMES*** | | |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 25 mg, 5 mg</i> | 5 | PA; LA |
| <i>lenalidomide oral capsule 2.5 mg, 20 mg</i> | 5 | PA; SP |
| REVLIMID ORAL CAPSULE 2.5 MG | 5 | PA; SP |
| *INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS*** | | |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 2 | |
| <i>mycophenolate mofetil oral suspension reconstituted 200 mg/ml</i> | 5 | PA; AL (Max 12 Years) |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 2 | |
| *MACROLIDE IMMUNOSUPPRESSANTS*** | | |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG | 4 | PA; QL (30 EA per 30 days) |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 1 MG | 5 | PA; QL (120 EA per 30 days) |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 5 MG | 5 | PA; QL (90 EA per 30 days) |
| <i>everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg</i> | 5 | PA; SP |
| <i>everolimus oral tablet 1 mg</i> | 5 | PA |
| HECORIA ORAL CAPSULE 0.5 MG, 1 MG, 5 MG | 2 | |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML | MB | |
| <i>sirolimus oral solution 1 mg/ml</i> | 5 | QL (60 ML per 30 days) |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 4 | |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | 2 | |
| *MONOCLONAL ANTIBODIES*** | | |
| GAMIFANT INTRAVENOUS SOLUTION 10 MG/2ML, 50 MG/10ML | MB | PA |
| SIMULECT INTRAVENOUS SOLUTION RECONSTITUTED 20 MG | MB | |
| ZENAPAX INTRAVENOUS CONCENTRATE 25 MG/5ML | MB | |
| *POTASSIUM REMOVING AGENTS*** | | |
| KIONEX ORAL POWDER | 2 | |
| KIONEX ORAL SUSPENSION 15 GM/60ML | 2 | |
| LOKELMA ORAL PACKET 10 GM | 5 | PA; QL (30 EA per 30 days) |
| LOKELMA ORAL PACKET 5 GM | 5 | PA; QL (90 EA per 30 days) |
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|---|
| VELTASSA ORAL PACKET 16.8 GM, 25.2 GM, 8.4 GM | 5 | PA; QL (30 EA per 30 days) |
| *PURINE ANALOGS*** | | |
| azathioprine oral tablet 50 mg | 2 | |
| azathioprine sodium injection solution reconstituted 100 mg | MB | |
| *SCLEROSING AGENTS*** | | |
| ETHAMOLIN INTRAVENOUS SOLUTION 5 % | MB | |
| *MOUTH/THROAT/DENTAL AGENTS* | | |
| *ANESTHETICS TOPICAL ORAL*** | | |
| lidocaine viscous mouth/throat solution 2 % | 2 | |
| *ANTI-INFECTIVES - THROAT*** | | |
| clotrimazole mouth/throat troche 10 mg | 2 | |
| nystatin mouth/throat suspension 100000 unit/ml | 2 | |
| *ANTISEPTICS - MOUTH/THROAT*** | | |
| chlorhexidine gluconate mouth/throat solution 0.12 % | 2 | |
| PAROEX MOUTH/THROAT SOLUTION 0.12 % | 2 | |
| PERIOGARD MOUTH/THROAT SOLUTION 0.12 % | 2 | |
| *SALIVA STIMULANTS*** | | |
| cevimeline hcl oral capsule 30 mg | 4 | ST; QL (90 EA per 30 days) |
| pilocarpine hcl oral tablet 5 mg, 7.5 mg | 2 | QL (90 EA per 30 days) |
| *STEROIDS - MOUTH/THROAT/DENTAL*** | | |
| ORALONE MOUTH/THROAT PASTE 0.1 % | 2 | QL (5 GM per 30 days) |
| triamcinolone acetonide mouth/throat paste 0.1 % | 2 | QL (5 GM per 30 days) |
| *MULTIVITAMINS* | | |
| *PED VITAMINS ACD W/ FLUORIDE*** | | |
| triple-vitamin/fluoride oral solution 0.25 mg/ml | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 6 Years) |
| tri-vit/fluoride oral solution 0.25 mg/ml, 0.5 mg/ml | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 6 Years) |
| tri-vitamin/fluoride oral solution 0.25 mg/ml, 0.5 mg/ml | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 6 Years) |
| vitamins acd-fluoride oral solution 0.25 mg/ml | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 6 Years) |
| *PRENATAL MV & MIN W/FE-FA*** | | |
| completenate oral tablet chewable 29-1 mg | 3 | |
| CO-NATAL FA ORAL TABLET | 3 | |
| INATAL ADVANCE ORAL TABLET 90-1 MG | 3 | |

| Drug Name | Tier | Notes |
|---|-------------|---|
| INATAL GT ORAL TABLET | 3 | |
| INATAL ULTRA ORAL TABLET , 90-1 MG | 3 | |
| <i>multi prenatal oral tablet 27-0.8 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| M-VIT ORAL TABLET | 3 | |
| MYNATAL ADVANCE ORAL TABLET | 3 | |
| MYNATAL ORAL TABLET 90-1 MG | 3 | |
| <i>natal-v rx oral tablet 29-1 mg</i> | 3 | |
| NIVA-PLUS ORAL TABLET 27-1 MG | 3 | |
| OBSTETRIX EC (WITH DOCUSATE) ORAL TABLET 29-1 MG | 3 | |
| OBSTETRIX EC ORAL TABLET 29-1 MG | 3 | |
| OBTREX ORAL TABLET | 3 | |
| O-CAL FA ORAL TABLET 27-1 MG | 3 | |
| <i>pnv folic acid + iron oral tablet 27-1 mg</i> | 3 | |
| <i>pnv prenatal plus multivitamin oral tablet 27-1 mg</i> | 3 | |
| <i>pnv tabs 29-1 oral tablet 29-1 mg</i> | 3 | |
| <i>pnv-vp-u oral capsule 106.5-1 mg</i> | 3 | |
| <i>prenaplus oral tablet 27-1 mg</i> | 3 | |
| <i>prenatabs fa oral tablet</i> | 3 | |
| PRENATABS RX ORAL TABLET 29-1 MG | 3 | |
| <i>prenatal 19 oral tablet chewable , 29-1 mg</i> | 3 | |
| PRENATAL AD ORAL TABLET | 3 | |
| <i>prenatal formula oral tablet 27-1 mg</i> | 3 | |
| <i>prenatal low iron oral tablet 27-0.8 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| <i>prenatal low iron oral tablet 27-1 mg</i> | 3 | |
| PRENATAL MULTIVITAMIN-ULTRA ORAL TABLET | 3 | |
| <i>prenatal one daily oral tablet 27-0.8 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| <i>prenatal oral tablet 27-0.8 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| <i>prenatal oral tablet 27-1 mg</i> | 3 | |
| <i>prenatal plus iron oral tablet 29-1 mg</i> | 3 | |
| <i>prenatal plus oral tablet 27-1 mg</i> | 3 | |
| <i>prenatal plus/iron oral tablet 27-1 mg</i> | 3 | |
| <i>prenatal vitamin oral tablet 27-0.8 mg</i> | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>prenatal vitamins plus oral tablet 27-1 mg</i> | 3 | |
| PRENATAL/FOLIC ACID ORAL TABLET | 3 | |
| PRENATAL-U ORAL CAPSULE 106.5-1 MG | 3 | |
| <i>preplus oral tablet 27-1 mg</i> | 3 | |
| <i>pretab oral tablet 29-1 mg</i> | 3 | |
| RIGHT STEP PRENATAL ORAL TABLET 27-0.8 MG | \$0 | \$0 Copay per PPACA guidelines; AL (Max 55 Years) |
| <i>se-natal 19 oral tablet chewable 29-1 mg</i> | 3 | |
| THERANATAL CORE NUTRITION ORAL TABLET 27-1 MG | 3 | |
| <i>triadvance oral tablet 90-1 mg</i> | 3 | |
| TRICARE ORAL TABLET | 3 | |
| <i>trinatal gt oral tablet 90-1 mg</i> | 3 | |
| <i>trinatal ultra oral tablet 90-1 mg</i> | 3 | |
| TRIVEEN-U ORAL CAPSULE 106.5-1 MG | 3 | |
| ULTRA NATALCARE ORAL TABLET 90-1 MG | 3 | |
| <i>ultra tabs oral tablet</i> | 3 | |
| <i>venatal-fa oral tablet 29-1 mg</i> | 3 | |
| VINATE GT ORAL TABLET 90-1 MG | 3 | |
| <i>vinate ultra oral tablet</i> | 3 | |
| <i>virt-advance oral tablet 90-1 mg</i> | 3 | |
| <i>virt-vite gt oral tablet 90-1 mg</i> | 3 | |
| <i>vol-plus oral tablet 27-1 mg</i> | 3 | |
| <i>vol-tab rx oral tablet 29-1 mg</i> | 3 | |
| *MUSCULOSKELETAL THERAPY AGENTS* | | |
| *CENTRAL MUSCLE RELAXANTS*** | | |
| <i>baclofen intrathecal solution 10 mg/20ml</i> | MB | |
| <i>baclofen oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>chlorzoxazone oral tablet 500 mg</i> | 2 | |
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i> | 2 | |
| LIORESAL INTRATHECAL SOLUTION 0.05 MG/ML | MB | |
| <i>metaxalone oral tablet 800 mg</i> | 4 | ST; QL (120 EA per 30 days) |
| <i>methocarbamol injection solution 1000 mg/10ml</i> | MB | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>orphenadrine citrate er oral tablet extended release 12 hour 100 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|---|------|------------------------------|
| <i>orphenadrine citrate injection solution 30 mg/ml</i> | MB | |
| <i>tizanidine hcl oral tablet 2 mg, 4 mg</i> | 2 | |
| *DIRECT MUSCLE RELAXANTS*** | | |
| <i>dantrolene sodium oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| *MUSCLE RELAXANT COMBINATIONS*** | | |
| <i>norgesic forte oral tablet 50-770-60 mg</i> | 4 | PA; QL (4 EA per 1 day) |
| *VISCOSUPPLEMENTS*** | | |
| DUROLANE INTRA-ARTICULAR PREFILLED SYRINGE 60 MG/3ML | MB | PA |
| *NASAL AGENTS - SYSTEMIC AND TOPICAL* | | |
| *NASAL ANTIBIOTICS*** | | |
| BACTROBAN NASAL NASAL OINTMENT 2 % | 3 | |
| *NASAL ANTICHOLINERGICS*** | | |
| <i>ipratropium bromide nasal solution 0.03 %, 0.06 %</i> | 2 | |
| *NASAL ANTIHISTAMINES*** | | |
| <i>azelastine hcl nasal solution 0.1 %</i> | 2 | |
| <i>olopatadine hcl nasal solution 0.6 %</i> | 4 | PA; QL (30.5 GM per 30 days) |
| *NASAL STEROIDS*** | | |
| BECONASE AQ NASAL SUSPENSION 42 MCG/SPRAY | 4 | ST |
| <i>budesonide nasal suspension 32 mcg/act</i> | 4 | ST |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | 3 | |
| <i>flunisolide nasal solution 29 mcg/act (0.025%)</i> | 2 | |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i> | 2 | |
| <i>mometasone furoate nasal suspension 50 mcg/act</i> | 4 | ST |
| NASACORT AQ NASAL AEROSOL 55 MCG/ACT | 2 | |
| NASACORT AQ NASAL AEROSOL, SOLUTION 55 MCG/ACT | 2 | |
| <i>triamcinolone acetonide nasal aerosol 55 mcg/act</i> | 2 | |
| *TOPICAL DECONGESTANTS*** | | |
| ADRENALIN NASAL SOLUTION 0.1 % | MB | |
| *NEUROMUSCULAR AGENTS* | | |
| *BENZATHIAZOLES*** | | |
| <i>riluzole oral tablet 50 mg</i> | 5 | |
| *DEPOLARIZING MUSCLE RELAXANTS*** | | |
| ANECTINE INJECTION SOLUTION 20 MG/ML | MB | |

| Drug Name | Tier | Notes |
|--|------|-------|
| QUELICIN INJECTION SOLUTION 20 MG/ML | MB | |
| *NEUROMUSCULAR BLOCKING AGENT - NEUROTOXINS*** | | |
| BOTOX INJECTION SOLUTION RECONSTITUTED 200 UNIT | MB | PA |
| MYOBLOC INTRAMUSCULAR SOLUTION 10000 UNIT/2ML, 2500 UNIT/0.5ML, 5000 UNIT/ML | MB | PA |
| *NONDEPOLARIZING MUSCLE RELAXANTS*** | | |
| <i>atracurium besylate intravenous solution 100 mg/10ml</i> | 2 | |
| *NUTRIENTS* | | |
| *AMINO ACIDS-SINGLE*** | | |
| <i>n-acetyl-l-cysteine oral capsule 600 mg</i> | 2 | |
| *CARBOHYDRATES*** | | |
| <i>dextrose intravenous solution 5 %</i> | MB | |
| *OPHTHALMIC AGENTS* | | |
| *BETA-BLOCKERS - OPHTHALMIC COMBINATIONS*** | | |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5 %</i> | 4 | |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 2-0.5 %</i> | 2 | |
| *BETA-BLOCKERS - OPHTHALMIC*** | | |
| <i>betaxolol hcl ophthalmic solution 0.5 %</i> | 2 | |
| BETOPTIC-S OPHTHALMIC SUSPENSION 0.25 % | 3 | |
| <i>carteolol hcl ophthalmic solution 1 %</i> | 2 | |
| <i>levobunolol hcl ophthalmic solution 0.25 %, 0.5 %</i> | 2 | |
| <i>metipranolol ophthalmic solution 0.3 %</i> | 3 | |
| <i>timolol maleate (once-daily) ophthalmic solution 0.5 %</i> | 4 | |
| <i>timolol maleate ophthalmic solution 0.25 %, 0.5 %</i> | 2 | |
| *CYCLOPLEGIC MYDRIATICS*** | | |
| <i>atropine sulfate ophthalmic ointment 1 %</i> | 2 | |
| <i>atropine sulfate ophthalmic solution 1 %</i> | 3 | |
| <i>cyclopentolate hcl ophthalmic solution 1 %, 2 %</i> | 2 | |
| HOMATROPAIRE OPHTHALMIC SOLUTION 5 % | 2 | |
| <i>homatropine hbr ophthalmic solution 5 %</i> | 2 | |
| ISOPTO HOMATROPINE OPHTHALMIC SOLUTION 2 % | 3 | |

| Drug Name | Tier | Notes |
|---|------|---|
| ISOPTO HYOSCINE OPHTHALMIC SOLUTION 0.25 % | 3 | |
| <i>phenylephrine hcl ophthalmic solution 10 %, 2.5 %</i> | 2 | |
| <i>tropicamide ophthalmic solution 0.5 %, 1 %</i> | 2 | |
| *MIOTICS - CHOLINESTERASE INHIBITORS*** | | |
| PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % | 3 | |
| *MIOTICS - DIRECT ACTING*** | | |
| ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % | 3 | |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | 2 | |
| *OPHTHALMIC ANTIALLERGIC*** | | |
| ALOCRILOPHTHALMIC SOLUTION 2 % | 4 | |
| ALOMIDE OPHTHALMIC SOLUTION 0.1 % | 3 | |
| <i>azelastine hcl ophthalmic solution 0.05 %</i> | 2 | |
| <i>bepotastine besilate ophthalmic solution 1.5 %</i> | 4 | PA |
| <i>cromolyn sodium ophthalmic solution 4 %</i> | 2 | |
| EMADINE OPHTHALMIC SOLUTION 0.05 % | 3 | |
| <i>epinastine hcl ophthalmic solution 0.05 %</i> | 2 | |
| *OPHTHALMIC ANTIBIOTICS*** | | |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i> | 3 | |
| CILOXAN OPHTHALMIC OINTMENT 0.3 % | 3 | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i> | 2 | |
| <i>erythromycin ophthalmic ointment 5 mg/gm</i> | \$0 | \$0 Copay for members 1 year of age or younger per PPACA guidelines; AL (Max 1 Years) |
| GENTAK OPHTHALMIC OINTMENT 0.3 % | 2 | |
| <i>gentamicin sulfate ophthalmic ointment 0.3 %</i> | 2 | |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i> | 2 | |
| MITOSOL OPHTHALMIC KIT 0.2 MG | MB | |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i> | 4 | |
| <i>ofloxacin ophthalmic solution 0.3 %</i> | 2 | |
| <i>tobramycin ophthalmic solution 0.3 %</i> | 2 | |
| TOBREX OPHTHALMIC OINTMENT 0.3 % | 4 | |
| *OPHTHALMIC ANTIFUNGAL *** | | |
| NATACYN OPHTHALMIC SUSPENSION 5 % | 4 | PA; QL (30 ML per 30 days) |

| Drug Name | Tier | Notes |
|--|------|---------------------------|
| *OPHTHALMIC ANTI-INFECTIVE COMBINATIONS*** | | |
| <i>ak-poly-bac ophthalmic ointment 500-10000 unit/gm</i> | 2 | |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | 2 | |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 2 | |
| NEO-POLYCIN OPHTHALMIC OINTMENT 3.5-400-10000 | 2 | |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i> | 2 | |
| *OPHTHALMIC ANTIVIRALS*** | | |
| <i>trifluridine ophthalmic solution 1 %</i> | 2 | |
| *OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS*** | | |
| <i>brinzolamide ophthalmic suspension 1 %</i> | 4 | |
| <i>dorzolamide hcl ophthalmic solution 2 %</i> | 2 | |
| *OPHTHALMIC IMMUNOMODULATORS*** | | |
| <i>cyclosporine ophthalmic emulsion 0.05 %</i> | 4 | QL (60 EA per 30 days) |
| *OPHTHALMIC LOCAL ANESTHETICS*** | | |
| <i>proparacaine hcl ophthalmic solution 0.5 %</i> | 2 | |
| *OPHTHALMIC NONSTEROIDAL ANTI-INFLAMMATORY AGENTS*** | | |
| <i>bromfenac sodium ophthalmic solution 0.09 %</i> | 4 | ST; QL (5 ML per 90 days) |
| <i>diclofenac sodium ophthalmic solution 0.1 %</i> | 2 | |
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i> | 2 | |
| <i>ketorolac tromethamine ophthalmic solution 0.4 %, 0.5 %</i> | 2 | |
| *OPHTHALMIC RHO KINASE INHIBITORS*** | | |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 % | 3 | ST |
| *OPHTHALMIC SELECTIVE ALPHA ADRENERGIC AGONISTS*** | | |
| <i>apraclonidine hcl ophthalmic solution 0.5 %</i> | 2 | |
| <i>brimonidine tartrate ophthalmic solution 0.1 %</i> | 3 | |
| <i>brimonidine tartrate ophthalmic solution 0.15 %, 0.2 %</i> | 2 | |
| *OPHTHALMIC STEROID COMBINATIONS*** | | |

| Drug Name | Tier | Notes |
|--|------|---------------------------|
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %</i> | 2 | |
| BLEPHAMIDE OPHTHALMIC SUSPENSION 10-0.2 % | 3 | |
| BLEPHAMIDE S.O.P. OPHTHALMIC OINTMENT 10-0.2 % | 3 | |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 2 | |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 2 | |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 4 | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i> | 2 | |
| TOBRADEX OPHTHALMIC OINTMENT 0.3-0.1 % | 3 | |
| TOBRADEX ST OPHTHALMIC SUSPENSION 0.3-0.05 % | 3 | |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i> | 2 | |
| *OPHTHALMIC STEROIDS*** | | |
| ALREX OPHTHALMIC SUSPENSION 0.2 % | 4 | ST |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i> | 2 | |
| <i>difluprednate ophthalmic emulsion 0.05 %</i> | 4 | ST; QL (5 ML per 30 days) |
| DUREZOL OPHTHALMIC EMULSION 0.05 % | 4 | ST; QL (5 ML per 30 days) |
| <i>fluorometholone ophthalmic suspension 0.1 %</i> | 2 | |
| FML FORTE OPHTHALMIC SUSPENSION 0.25 % | 3 | |
| FML OPHTHALMIC OINTMENT 0.1 % | 3 | |
| LOTEMAX SM OPHTHALMIC GEL 0.38 % | 3 | ST |
| <i>loteprednol etabonate ophthalmic gel 0.5 %</i> | 4 | ST |
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i> | 4 | ST |
| MAXIDEX OPHTHALMIC SUSPENSION 0.1 % | 4 | |
| PRED MILD OPHTHALMIC SUSPENSION 0.12 % | 3 | |
| <i>prednisolone acetate ophthalmic suspension 1 %</i> | 2 | |
| <i>prednisolone sodium phosphate ophthalmic solution 1 %</i> | 4 | |
| VEXOL OPHTHALMIC SUSPENSION 1 % | 4 | |
| *OPHTHALMIC SULFONAMIDES*** | | |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i> | 2 | |
| *OPHTHALMIC SURGICAL AIDS - COMBINATIONS*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| OMIDRIA INTRAOCULAR SOLUTION 1-0.3 % | MB | |
| *PROSTAGLANDINS - OPHTHALMIC*** | | |
| <i>latanoprost ophthalmic solution 0.005 %</i> | 2 | |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % | 3 | |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i> | 4 | |
| *VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTAGONISTS*** | | |
| EYLEA HD INTRAVITREAL SOLUTION 8 MG/0.07ML | MB | |
| EYLEA INTRAVITREAL SOLUTION 2 MG/0.05ML | MB | |
| EYLEA INTRAVITREAL SOLUTION PREFILLED SYRINGE 2 MG/0.05ML | MB | |
| LUCENTIS INTRAOCULAR SOLUTION 0.3 MG/0.05ML, 0.5 MG/0.05ML | MB | |
| LUCENTIS INTRAVITREAL SOLUTION 0.3 MG/0.05ML, 0.5 MG/0.05ML | MB | |
| LUCENTIS INTRAVITREAL SOLUTION PREFILLED SYRINGE 0.3 MG/0.05ML, 0.5 MG/0.05ML | MB | |
| *OTIC AGENTS* | | |
| *OTIC AGENTS - MISCELLANEOUS*** | | |
| <i>acetic acid otic solution 2 %</i> | 2 | |
| <i>acetic acid-aluminum acetate otic solution 2 %</i> | 3 | |
| *OTIC ANALGESIC COMBINATIONS*** | | |
| <i>antipyrine-benzocaine otic solution 5.4-1.4 %</i> | 2 | |
| *OTIC ANTI-INFECTIVES*** | | |
| <i>ofloxacin otic solution 0.3 %</i> | 2 | |
| *OTIC STEROID-ANTI-INFECTIVE COMBINATIONS*** | | |
| CIPRO HC OTIC SUSPENSION 0.2-1 % | 4 | PA |
| <i>ciprofloxacin-dexamethasone otic suspension 0.3-0.1 %</i> | 4 | ST; QL (7.5 ML per 30 days); AL (Max 12 Years) |
| <i>neomycin-polymyxin-hc otic solution 3.5-10000-1</i> | 2 | |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 2 | |
| *OTIC STEROIDS*** | | |
| <i>fluocinolone acetonide otic oil 0.01 %</i> | 2 | |
| <i>hydrocortisone-acetic acid otic solution 1-2 %</i> | 2 | |
| *OXYTOCICS* | | |
| *ABORTIFACIENTS/CERVICAL RIPENING - PROSTAGLANDINS*** | | |

| Drug Name | Tier | Notes |
|---|-------------|--------------|
| <i>carboprost tromethamine intramuscular solution 250 mcg/ml</i> | MB | |
| PREPIDIL VAGINAL GEL 0.5 MG/3GM | 4 | |
| *OXYTOCICS*** | | |
| <i>methylergonovine maleate injection solution 0.2 mg/ml</i> | 4 | |
| <i>methylergonovine maleate oral tablet 0.2 mg</i> | 4 | |
| <i>oxytocin injection solution 10 unit/ml</i> | MB | |
| *PASSIVE IMMUNIZING AND TREATMENT AGENTS* | | |
| *ANTITOXINS-ANTIVENINS*** | | |
| ANAVIP INTRAVENOUS SOLUTION RECONSTITUTED | MB | |
| CROFAB INTRAVENOUS SOLUTION RECONSTITUTED | MB | |
| *ANTIVIRAL MONOCLONAL ANTIBODIES*** | | |
| BEYFORTUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 100 MG/ML, 50 MG/0.5ML | MB | |
| SYNAGIS INTRAMUSCULAR SOLUTION 100 MG/ML, 50 MG/0.5ML | MB | PA |
| *IMMUNE SERUMS*** | | |
| HYPERRHO S/D INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 1500 UNIT, 250 UNIT | MB | |
| HYPERTET S/D INTRAMUSCULAR INJECTABLE 250 UNIT/ML | MB | |
| <i>kedrab intramuscular solution 150 unit/ml</i> | MB | |
| MICRHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 250 UNIT | MB | |
| RHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 1500 UNIT | MB | |
| RHOPHYLAC INJECTION SOLUTION PREFILLED SYRINGE 1500 UNIT/2ML | MB | |
| WINRHO SDF INJECTION SOLUTION 1500 UNIT/1.3ML, 15000 UNIT/13ML, 2500 UNIT/2.2ML, 5000 UNIT/4.4ML | MB | |
| *PENICILLINS* | | |
| *AMINOPENICILLINS*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml</i> | 2 | |
| <i>amoxicillin oral tablet 500 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>amoxicillin oral tablet 875 mg</i> | 2 | |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | 3 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>ampicillin oral capsule 250 mg</i> | 2 | |
| <i>ampicillin oral capsule 500 mg</i> | 3 | |
| <i>ampicillin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 3 | |
| *NATURAL PENICILLINS*** | | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION 600000 UNIT/ML | MB | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 600000 UNIT/ML | MB | |
| <i>penicillin g procaine intramuscular suspension 600000 unit/ml</i> | MB | |

| Drug Name | Tier | Notes |
|---|------|-------|
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 2 | |
| PFIZERPEN INJECTION SOLUTION RECONSTITUTED 5000000 UNIT | MB | |
| *PENICILLIN COMBINATIONS*** | | |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i> | 3 | |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm</i> | MB | |
| BICILLIN C-R 900/300 INTRAMUSCULAR SUSPENSION 900000-300000 UNIT/2ML | MB | |
| BICILLIN C-R INTRAMUSCULAR SUSPENSION 1200000 UNIT/2ML | MB | |
| ZOSYN INTRAVENOUS SOLUTION RECONSTITUTED 2.25 (2-0.25) GM | MB | |
| *PENICILLINASE-RESISTANT PENICILLINS*** | | |
| BACTOCILL IN DEXTROSE INTRAVENOUS SOLUTION 1 GM/50ML | MB | |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i> | 2 | |
| *PHARMACEUTICAL ADJUVANTS* | | |
| *PARENTERAL VEHICLES*** | | |
| <i>saline bacteriostatic injection solution 0.9 %</i> | 2 | |
| *PROGESTINS* | | |
| *PROGESTINS*** | | |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>megestrol acetate oral suspension 625 mg/5ml</i> | 2 | PA |
| <i>norethindrone acetate oral tablet 5 mg</i> | 2 | |
| <i>progesterone intramuscular oil 50 mg/ml</i> | MB | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | 2 | |
| *PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.* | | |
| *ALCOHOL DETERRENTS*** | | |

| Drug Name | Tier | Notes |
|---|------|--|
| <i>acamprosate calcium oral tablet delayed release 333 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days) |
| <i>disulfiram oral tablet 250 mg</i> | 2 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *ANTI-CATAPLECTIC AGENTS*** | | |
| <i>sodium oxybate oral solution 500 mg/ml</i> | 5 | PA; LA; QL (540 ML per 30 days); AL (Min 7 Years) |
| *BENZODIAZEPINES & TRICYCLIC AGENTS*** | | |
| <i>chlordiazepoxide-amitriptyline oral tablet 10-25 mg, 5-12.5 mg</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *CHOLINOMIMETICS - ACHE INHIBITORS*** | | |
| <i>donepezil hcl oral tablet 10 mg</i> | 2 | QL (30 EA per 30 days) |
| <i>donepezil hcl oral tablet 5 mg</i> | 2 | QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 10 mg, 5 mg</i> | 2 | PA; QL (30 EA per 30 days) |
| EXELON ORAL SOLUTION 2 MG/ML | 4 | |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | 2 | |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i> | 3 | |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 4 | |

| Drug Name | Tier | Notes |
|--|------|--|
| *FIBROMYALGIA AGENT - SNRIS*** | | |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 4 | PA; QL (60 EA per 30 days) |
| *MOVEMENT DISORDER DRUG THERAPY*** | | |
| AUSTEDO ORAL TABLET 12 MG | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); SP |
| AUSTEDO ORAL TABLET 6 MG, 9 MG | 5 | PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); SP |
| <i>tetrabenazine oral tablet 12.5 mg</i> | 5 | PA; QL (90 EA per 30 days); SP |
| <i>tetrabenazine oral tablet 25 mg</i> | 5 | PA; QL (120 EA per 30 days); SP |
| *MS AGENTS - PYRIMIDINE SYNTHESIS INHIBITORS*** | | |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> | 4 | QL (30 EA per 30 days); SP |
| *MULTIPLE SCLEROSIS AGENTS - ANTIMETABOLITES*** | | |
| MAVENCLAD (10 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (20 EA per 326 days); SP |
| MAVENCLAD (4 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (8 EA per 326 days); SP |
| MAVENCLAD (5 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (10 EA per 326 days); SP |
| MAVENCLAD (6 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (12 EA per 326 days); SP |
| MAVENCLAD (7 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (14 EA per 326 days); SP |
| MAVENCLAD (8 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (16 EA per 326 days); SP |
| MAVENCLAD (9 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; QL (18 EA per 326 days); SP |

| Drug Name | Tier | Notes |
|---|------|----------------------------|
| *MULTIPLE SCLEROSIS AGENTS - INTERFERONS*** | | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML | 5 | QL (1 EA per 28 days); SP |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML | 5 | QL (1 EA per 28 days); SP |
| EXTAVIA SUBCUTANEOUS KIT 0.3 MG | 5 | QL (1 EA per 30 days); SP |
| REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR 22 MCG/0.5ML, 44 MCG/0.5ML | 5 | QL (6 ML per 28 days); SP |
| REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 6X8.8 & 6X22 MCG | 5 | QL (1 ML per 28 days); SP |
| REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 22 MCG/0.5ML, 44 MCG/0.5ML | 5 | QL (6 ML per 28 days); SP |
| REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6X8.8 & 6X22 MCG | 5 | QL (1 ML per 28 days); SP |
| *MULTIPLE SCLEROSIS AGENTS - NRF2 PATHWAY ACTIVATORS*** | | |
| <i>dimethyl fumarate oral capsule delayed release 120 mg, 240 mg</i> | 5 | QL (60 EA per 30 days); SP |
| <i>dimethyl fumarate starter pack oral 120 & 240 mg</i> | 5 | QL (60 EA per 30 days); SP |
| *MULTIPLE SCLEROSIS AGENTS - POTASSIUM CHANNEL BLOCKERS*** | | |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i> | 4 | QL (60 EA per 30 days) |
| *MULTIPLE SCLEROSIS AGENTS*** | | |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML | MB | SP |
| GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML | 4 | QL (30 ML per 30 days); SP |
| GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/ML | 5 | QL (12 ML per 28 days); SP |
| *N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONISTS*** | | |
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i> | 4 | ST; QL (30 EA per 30 days) |
| <i>memantine hcl oral solution 2 mg/ml</i> | 2 | |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i> | 2 | QL (60 EA per 30 days) |
| *PHENOTHIAZINES & TRICYCLIC AGENTS*** | | |

| Drug Name | Tier | Notes |
|---|------|---|
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | 3 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *PSEUDOBULBAR AFFECT AGENT COMBINATIONS*** | | |
| NUEDEXTA ORAL CAPSULE 20-10 MG | 5 | PA; QL (60 EA per 30 days) |
| *PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.*** | | |
| <i>ergoloid mesylates oral tablet 1 mg</i> | 3 | |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 4 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *SMOKING DETERRENTS*** | | |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg</i> | \$0 | \$0 dollar copayment per ACA guidelines. Limited to two 90 day courses per 365 days.; QL (360 EA per 365 days) |
| <i>goodsense nicotine mouth/throat gum 2 mg</i> | \$0 | \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.; QL (4300 EA per 365 days) |
| <i>nicotine polacrilex mouth/throat gum 2 mg, 4 mg</i> | \$0 | \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.; QL (4300 EA per 365 days) |
| <i>nicotine polacrilex mouth/throat lozenge 2 mg, 4 mg</i> | \$0 | \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.; QL (3600 EA per 365 days) |
| <i>nicotine transdermal kit 21-14-7 mg/24hr</i> | \$0 | \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days. |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>nicotine transdermal patch 24 hour 14 mg/24hr, 21 mg/24hr, 7 mg/24hr</i> | \$0 | \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.; QL (182 EA per 365 days) |
| NICOTROL INHALATION INHALER 10 MG | \$0 | ST; \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.; QL (3024 EA per 365 days) |
| NICOTROL NS NASAL SOLUTION 10 MG/ML | \$0 | ST; \$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.; QL (1440 ML per 365 days) |
| <i>varenicline tartrate (starter) oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42</i> | \$0 | QL (360 EA per 365 days) |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg</i> | \$0 | To qualify for \$0 copay the step therapy requirement has to be met. The patient must have a claim history of one over-the-counter (OTC) nicotine product and bupropion ER.; QL (360 EA per 365 days) |
| <i>varenicline tartrate(continue) oral tablet 1 mg</i> | \$0 | QL (360 EA per 365 days) |
| *SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS*** | | |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; QL (120 EA per 30 days); SP |
| MAYZENT ORAL TABLET 2 MG | 5 | PA; QL (30 EA per 30 days); SP |
| *RESPIRATORY AGENTS - MISC.* | | |
| *CFTR POTENTIATORS*** | | |
| KALYDECO ORAL PACKET 13.4 MG | 5 | PA; QL (2 packets per 1 day); AL (Max 6 Years); SP |
| KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG | 5 | PA; QL (60 EA per 30 days); AL (Max 6 Years); SP |
| KALYDECO ORAL TABLET 150 MG | 5 | PA; QL (60 EA per 30 days); AL (Min 6 Years); SP |
| *CYSTIC FIBROSIS AGENT - COMBINATIONS*** | | |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; QL (120 EA per 30 days); SP |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG, 50-75 & 75 MG | 5 | PA; QL (60 EA per 30 days); AL (Min 6 Years and Max 12 Years); SP |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG, 50-25-37.5 & 75 MG | 5 | PA; QL (90 EA per 30 days); SP |
| TRIKAFTA ORAL THERAPY PACK 100-50-75 & 75 MG, 80-40-60 & 59.5 MG | 5 | PA; QL (2 packets per 1 day); SP |
| *HYDROLYTIC ENZYMES*** | | |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML | 5 | LA |

| Drug Name | Tier | Notes |
|---|------|--|
| *PULMONARY FIBROSIS AGENTS - KINASE INHIBITORS*** | | |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; QL (60 EA per 30 days); SP |
| *SULFONAMIDES* | | |
| *SULFONAMIDES*** | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | |
| *TETRACYCLINES* | | |
| *GLYCYLCYCLINES*** | | |
| <i>tigecycline intravenous solution reconstituted 50 mg</i> | MB | |
| TYGACIL INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | MB | |
| *TETRACYCLINES*** | | |
| <i>demeclocycline hcl oral tablet 150 mg, 300 mg</i> | 4 | |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 4 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>doxycycline hyclate oral tablet 100 mg</i> | 4 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>doxycycline hyclate oral tablet 20 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|--|-------------|--|
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| <i>doxycycline monohydrate oral suspension reconstituted 25 mg/5ml</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| MINOCIN INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | |
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| SEYSARA ORAL TABLET 100 MG | 4 | ST |
| <i>tetracycline hcl oral capsule 250 mg, 500 mg</i> | 3 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *THYROID AGENTS* | | |
| *ANTITHYROID AGENTS*** | | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | |
| *THYROID HORMONES*** | | |
| ARMOUR THYROID ORAL TABLET 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG | 3 | |

| Drug Name | Tier | Notes |
|---|------|--------------------------------------|
| EUTHYROX ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| LEVO-T ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 2 | |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 2 | |
| NATURE-THROID ORAL TABLET 113.75 MG, 130 MG, 146.25 MG, 16.25 MG, 162.5 MG, 195 MG, 260 MG, 32.5 MG, 325 MG, 48.75 MG, 65 MG, 81.25 MG, 97.5 MG | 3 | |
| NP THYROID ORAL TABLET 120 MG, 15 MG, 30 MG, 60 MG, 90 MG | 2 | |
| UNITHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG | 2 | |
| WESTHROID ORAL TABLET 130 MG, 16.25 MG, 195 MG, 260 MG, 32.5 MG, 325 MG, 65 MG, 97.5 MG | 3 | |
| *TOXOIDS* | | |
| *TOXOID COMBINATIONS*** | | |
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 LF-MCG/0.5 | \$0 | \$0 Copay Preventative Services. |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 | \$0 | \$0 Copay Preventative Services. |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5 | \$0 | \$0 Copay per PPACA guidelines. |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5 | \$0 | \$0 Copay for Preventative Services. |
| <i>tetanus-diphtheria toxoids td intramuscular suspension 2-2 lf/0.5ml</i> | \$0 | \$0 Copay Preventative Services. |
| *ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS* | | |
| *ANTICHOLINERGIC COMBINATIONS*** | | |
| <i>chlordiazepoxide-clidinium oral capsule 5-2.5 mg</i> | 2 | |
| *ANTISPASMODICS*** | | |
| BENTYL INTRAMUSCULAR SOLUTION 10 MG/ML | MB | |
| <i>dicyclomine hcl oral capsule 10 mg</i> | 2 | |

| Drug Name | Tier | Notes |
|--|------|---|
| <i>dicyclomine hcl oral solution 10 mg/5ml</i> | 2 | |
| <i>dicyclomine hcl oral tablet 20 mg</i> | 2 | |
| *BELLADONNA ALKALOIDS*** | | |
| <i>hyoscyamine sulfate er oral tablet extended release 12 hour 0.375 mg</i> | 2 | |
| <i>hyoscyamine sulfate oral elixir 0.125 mg/5ml</i> | 2 | |
| <i>hyoscyamine sulfate oral solution 0.125 mg/ml</i> | 2 | |
| <i>hyoscyamine sulfate oral tablet 0.125 mg</i> | 2 | |
| <i>hyoscyamine sulfate oral tablet dispersible 0.125 mg</i> | 2 | |
| <i>hyoscyamine sulfate sublingual tablet sublingual 0.125 mg</i> | 2 | |
| LEVSIN INJECTION SOLUTION 0.5 MG/ML | MB | |
| NULEV ORAL TABLET DISPERSIBLE 0.125 MG | 2 | |
| *H-2 ANTAGONISTS*** | | |
| <i>cimetidine hcl oral solution 300 mg/5ml</i> | 2 | |
| <i>cimetidine oral tablet 300 mg, 400 mg, 800 mg</i> | 2 | |
| <i>famotidine oral suspension reconstituted 40 mg/5ml</i> | 2 | |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 2 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 3 | |
| <i>ranitidine hcl injection solution 1000 mg/40ml, 150 mg/6ml, 50 mg/2ml</i> | MB | |
| <i>ranitidine hcl oral syrup 15 mg/ml, 150 mg/10ml, 75 mg/5ml</i> | 2 | |
| <i>ranitidine hcl oral tablet 150 mg, 300 mg</i> | 2 | |
| *MISC. ANTI-ULCER*** | | |
| <i>sucralfate oral suspension 1 gm/10ml</i> | 4 | QL (1200 ML per 30 days); AL (Max 12 Years) |
| <i>sucralfate oral tablet 1 gm</i> | 2 | |
| *PROTON PUMP INHIBITORS*** | | |
| <i>dexlansoprazole oral capsule delayed release 30 mg, 60 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| <i>esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg</i> | 2 | PA; QL (30 EA per 30 days) |
| <i>lansoprazole oral capsule delayed release 15 mg, 30 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>lansoprazole oral tablet dispersible 15 mg, 30 mg</i> | 4 | PA |
| <i>omeprazole magnesium oral capsule delayed release 20.6 (20 base) mg</i> | 2 | QL (60 EA per 30 days) |
| <i>omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg</i> | 2 | QL (60 EA per 30 days) |

| Drug Name | Tier | Notes |
|---|------|--------------------------------------|
| <i>pantoprazole sodium oral tablet delayed release 20 mg, 40 mg</i> | 2 | QL (60 EA per 30 days) |
| PROTONIX INTRAVENOUS SOLUTION RECONSTITUTED 40 MG | MB | |
| <i>rabeprazole sodium oral tablet delayed release 20 mg</i> | 2 | QL (60 EA per 30 days) |
| *QUATERNARY ANTICHOLINERGICS*** | | |
| <i>glycopyrrolate injection solution 0.2 mg/ml, 0.4 mg/2ml, 1 mg/5ml, 4 mg/20ml</i> | 2 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>propantheline bromide oral tablet 15 mg</i> | 3 | |
| *ULCER DRUGS - PROSTAGLANDINS*** | | |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 2 | |
| *URINARY ANTISPASMODICS* | | |
| *URINARY ANTISPASMODIC - ANTIMUSCARINIC (ANTICHOLINERGIC)*** | | |
| <i>fesoterodine fumarate er oral tablet extended release 24 hour 4 mg, 8 mg</i> | 4 | ST; QL (30 EA per 30 days) |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral syrup 5 mg/5ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 2 | |
| OXYTROL FOR WOMEN TRANSDERMAL PATCH TWICE WEEKLY 3.9 MG/24HR | 4 | PA; QL (8 EA per 28 days) |
| <i>solifenacin succinate oral tablet 10 mg, 5 mg</i> | 2 | QL (30 EA per 30 days) |
| <i>tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>tropium chloride er oral capsule extended release 24 hour 60 mg</i> | 4 | ST |
| <i>tropium chloride oral tablet 20 mg</i> | 4 | |
| *URINARY ANTISPASMODICS - CHOLINERGIC AGONISTS*** | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| *URINARY ANTISPASMODICS - DIRECT MUSCLE RELAXANTS*** | | |
| <i>flavoxate hcl oral tablet 100 mg</i> | 2 | |
| *VACCINES* | | |
| *BACTERIAL VACCINES*** | | |
| MENACTRA INTRAMUSCULAR INJECTABLE | \$0 | \$0 Copay Preventative Services. |
| MENACTRA INTRAMUSCULAR SOLUTION | \$0 | \$0 Copay for Preventative Services. |

| Drug Name | Tier | Notes |
|---|------|---|
| MENOMUNE SUBCUTANEOUS INJECTABLE | \$0 | \$0 Copay Preventative Services |
| MENQUADFI INTRAMUSCULAR SOLUTION | \$0 | |
| MENVEO INTRAMUSCULAR SOLUTION | \$0 | \$0 Copay for Preventative Services. |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | \$0 | \$0 Copay Preventative Services. |
| PENBRAYA INTRAMUSCULAR SUSPENSION RECONSTITUTED | \$0 | |
| PNEUMOVAX 23 INJECTION INJECTABLE 25 MCG/0.5ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| PREVNAR 13 INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| PREVNAR 20 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 1 Lifetime) |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | \$0 | |
| VAXNEUVANCE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay Preventative Services |
| *MIXED VACCINE COMBINATIONS*** | | |
| COMVAX INTRAMUSCULAR SUSPENSION 7.5-5 MCG/0.5ML | \$0 | \$0 Copay Preventative Services. |
| *VIRAL VACCINE COMBINATIONS*** | | |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | \$0 | |
| M-M-R II SUBCUTANEOUS INJECTABLE | \$0 | \$0 Copay Preventative Services. |
| PROQUAD SUBCUTANEOUS INJECTABLE | \$0 | \$0 Copay Preventative Services. |
| TWINRIX INTRAMUSCULAR SUSPENSION 720-20 | \$0 | \$0 Copay Preventative Services. |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | \$0 | |
| *VIRAL VACCINES*** | | |
| ABRYSCO INTRAMUSCULAR SOLUTION RECONSTITUTED 120 MCG/0.5ML | \$0 | AL (Min 60 Years) |
| AFLURIA INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| AFLURIA PRESERVATIVE FREE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| AFLURIA QUADRIVALENT INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay Preventative Services.; QL (0.5 ML per 180 days) |
| AFLURIA QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay Preventative Services.; QL (0.5 ML per 180 days) |
| AREXVY INTRAMUSCULAR SUSPENSION RECONSTITUTED 120 MCG/0.5ML | \$0 | AL (Min 60 Years) |
| <i>astrazeneca covid-19 vaccine intramuscular suspension 0.5 ml</i> | \$0 | |

| Drug Name | Tier | Notes |
|---|-------------|--|
| COMIRNATY INTRAMUSCULAR SUSPENSION 30 MCG/0.3ML | \$0 | QL (0.3 ML per 21 days); AL (Min 12 Years) |
| ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML | \$0 | \$0 Copay Preventative Services. |
| ENGERIX-B INTRAMUSCULAR INJECTABLE 10 MCG/0.5ML, 20 MCG/ML | \$0 | \$0 Copay Preventative Services. |
| FLUAD QUADRIVALENT INTRAMUSCULAR PREFILLED SYRINGE 0.5 ML | \$0 | |
| FLUARIX QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| FLUBLOK QUADRIVALENT INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 0.5 ML | \$0 | PA; \$0 Copay for Preventative Services.; QL (0.5 ML per 180 days) |
| FLUCELVAX QUADRIVALENT INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay for Preventative Services.; QL (0.5 ML per 180 days) |
| FLUCELVAX QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay for Preventative Services.; QL (0.5 ML per 180 days) |
| FLULAVAL INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| FLULAVAL QUADRIVALENT INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| FLULAVAL QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| FLUMIST QUADRIVALENT NASAL SUSPENSION | \$0 | \$0 Copay Preventative Services; QL (1 EA per 180 days); AL (Min 2 Years and Max 49 Years) |
| FLUZONE HIGH-DOSE QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.7 ML | \$0 | QL (0.7 ML per 180 days); AL (Min 65 Years) |
| FLUZONE INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| FLUZONE QUADRIVALENT INTRAMUSCULAR SUSPENSION , 0.5 ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| FLUZONE QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.25 ML, 0.5 ML | \$0 | \$0 Copay Preventative Services; QL (0.5 ML per 180 days) |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 720 EL U/0.5ML | \$0 | \$0 Copay Preventative Services. |
| HEPLISAV-B INTRAMUSCULAR SOLUTION 20 MCG/0.5ML | \$0 | QL (1 ML per 1 day) |
| HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML | \$0 | |
| IPOL INJECTION INJECTABLE | \$0 | |
| <i>janssen covid-19 vaccine intramuscular suspension 0.5 ml</i> | \$0 | Max 2 doses in 365 days; QL (0.5 ML per 56 days); AL (Min 18 Years) |
| <i>moderna covid-19 bival 6m-5y intramuscular suspension 10 mcg/0.2ml</i> | \$0 | |

| Drug Name | Tier | Notes |
|--|-------------|---|
| <i>moderna covid-19 bival booster intramuscular suspension 50 mcg/0.5ml</i> | \$0 | \$0 Copay Preventative; QL (0.5 ML per 365 days); AL (Min 18 Years) |
| <i>moderna covid-19 bivalent intramuscular suspension 50 mcg/0.5ml</i> | \$0 | \$0 Copay Preventative; QL (0.5 ML per 365 days); AL (Min 18 Years) |
| <i>moderna covid-19 vac (booster) intramuscular suspension 50 mcg/0.5ml, 50 mg/0.5ml</i> | \$0 | Max 3 doses in 365 days; QL (0.5 ML per 28 days); AL (Min 6 Years) |
| MODERNA COVID-19 VAC 6M-11Y INTRAMUSCULAR SUSPENSION 25 MCG/0.25ML | \$0 | |
| <i>moderna covid-19 vacc 6-11y intramuscular suspension 50 mcg/0.5ml</i> | \$0 | Max 3 doses in 365 days; QL (0.5 ML per 28 days); AL (Min 6 Years) |
| <i>moderna covid-19 vacc 6m-5y intramuscular suspension 25 mcg/0.25ml</i> | \$0 | Max 3 doses in 365 days; QL (0.25 ML per 28 days); AL (Min 6 Years) |
| <i>moderna covid-19 vaccine intramuscular suspension 100 mcg/0.5ml</i> | \$0 | QL (0.5 ML per 28 days); AL (Min 12 Years) |
| <i>novavax covid-19 vaccine intramuscular suspension 5 mcg/0.5ml</i> | \$0 | Max 2 doses in 365 days; QL (0.5 ML per 21 days); AL (Min 12 Years) |
| <i>pfizer covid-19 vac bivalent intramuscular suspension 30 mcg/0.3ml</i> | \$0 | \$0 Copay Preventative; QL (0.3 ML per 365 days); AL (Min 12 Years) |
| <i>pfizer covid-19 vac-tris 5-11y intramuscular suspension 10 mcg/0.2ml</i> | \$0 | Max 3 doses in 365 days; QL (0.2 ML per 21 days); AL (Min 5 Years) |
| PFIZER COVID-19 VAC-TRIS 5-11Y INTRAMUSCULAR SUSPENSION 10 MCG/0.3ML | \$0 | |
| <i>pfizer covid-19 vac-tris 6m-4y intramuscular suspension 3 mcg/0.2ml</i> | \$0 | Max 3 doses in 365 days; QL (0.2 ML per 21 days); AL (Min 6 Years) |
| <i>pfizer covid-19 vac-tris 6m-4y intramuscular suspension 3 mcg/0.3ml</i> | \$0 | |
| <i>pfizer-biont covid-19 vac-tris intramuscular suspension 30 mcg/0.3ml</i> | \$0 | QL (0.3 ML per 21 days); AL (Min 12 Years) |
| <i>pfizer-biontech covid-19 vacc intramuscular suspension 30 mcg/0.3ml</i> | \$0 | QL (0.3 ML per 21 days); AL (Min 12 Years) |
| RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML | \$0 | \$0 Copay Preventative Services. |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML | \$0 | \$0 copay Per PPACA Guidelines; QL (2 vial per 1 Lifetime); AL (Min 50 Years) |
| SPIKEVAX COVID-19 VACCINE INTRAMUSCULAR SUSPENSION 100 MCG/0.5ML | \$0 | QL (0.5 ML per 28 days); AL (Min 12 Years) |
| SPIKEVAX INTRAMUSCULAR SUSPENSION 50 MCG/0.5ML | \$0 | Max 3 doses in 365 days; QL (0.5 ML per 28 days); AL (Min 6 Years) |
| SPIKEVAX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 50 MCG/0.5ML | \$0 | |
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 50 UNIT/ML | \$0 | \$0 Copay Preventative Services. |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | \$0 | \$0 Copay Preventative Services. |
| ZOSTAVAX SUBCUTANEOUS SUSPENSION RECONSTITUTED 19400 UNT/0.65ML | \$0 | PA; QL (1 EA Max Qty Per Fill Retail); AL (Min 60 Years) |

| Drug Name | Tier | Notes |
|---|------|--|
| *VAGINAL AND RELATED PRODUCTS* | | |
| *IMIDAZOLE-RELATED ANTIFUNGALS*** | | |
| GYNAZOLE-1 VAGINAL CREAM 2 % | 4 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | 2 | |
| *SPERMICIDES*** | | |
| ENCARE VAGINAL SUPPOSITORY 100 MG | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| OPTIONS CONCEPTROL VAGINAL GEL 4 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| OPTIONS GYNOL II CONTRACEPTIVE VAGINAL GEL 3 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| SHUR-SEAL CONTRACEPTIVE VAGINAL GEL 2 % | \$0 | |
| TODAY SPONGE VAGINAL 1000 MG | \$0 | |
| VCF VAGINAL CONTRACEPTIVE VAGINAL FILM 28 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| VCF VAGINAL CONTRACEPTIVE VAGINAL FOAM 12.5 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| VCF VAGINAL CONTRACEPTIVE VAGINAL GEL 4 % | \$0 | \$0 Copay per PPACA guidelines.; AL (Max 55 Years) |
| *VAGINAL ANTI-INFECTIVES*** | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 2 | |
| <i>metronidazole vaginal gel 0.75 %</i> | 2 | STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| *VAGINAL ESTROGENS*** | | |
| <i>estradiol vaginal cream 0.1 mg/gm</i> | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> | 2 | |
| ESTRING VAGINAL RING 7.5 MCG/24HR | 4 | QL (1 EA per 90 days) |
| FEMRING VAGINAL RING 0.05 MG/24HR, 0.1 MG/24HR | 4 | QL (1 EA per 90 days) |
| PREMARIN VAGINAL CREAM 0.625 MG/GM | 3 | |
| YUVAFEM VAGINAL TABLET 10 MCG | 2 | |
| *VAGINAL PROGESTINS*** | | |

| Drug Name | Tier | Notes |
|---|------|-----------------------------|
| CRINONE VAGINAL GEL 8 % | 4 | PA |
| *VASOPRESSORS* | | |
| *ANAPHYLAXIS THERAPY AGENTS*** | | |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> | 2 | |
| SYMJEPI INJECTION SOLUTION PREFILLED SYRINGE 0.15 MG/0.3ML, 0.3 MG/0.3ML | 2 | |
| *NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH) - AGENTS*** | | |
| NORTHERA ORAL CAPSULE 100 MG, 200 MG | 5 | PA; QL (90 EA per 30 days) |
| NORTHERA ORAL CAPSULE 300 MG | 5 | PA; QL (180 EA per 30 days) |
| *VASOPRESSORS*** | | |
| <i>midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>phenylephrine hcl injection solution 10 mg/ml</i> | MB | |
| *VITAMINS* | | |
| *VITAMIN B-1*** | | |
| <i>thiamine hcl injection solution 100 mg/ml</i> | MB | |
| *VITAMIN B-6*** | | |
| <i>pyridoxine hcl injection solution 100 mg/ml</i> | MB | |
| *VITAMIN D*** | | |
| <i>ergocalciferol oral capsule 1.25 mg (50000 ut)</i> | 2 | |
| <i>ergocalciferol oral solution 8000 unit/ml</i> | 2 | |
| <i>vitamin d (ergocalciferol) oral capsule 1.25 mg (50000 ut)</i> | 2 | |
| *VITAMIN K*** | | |
| <i>phytonadione oral tablet 5 mg</i> | 5 | |

Medical Benefit

| Drug Name | Tier | Notes |
|--|------|---|
| ABRAXANE INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG | MB | PA |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10ML, 400 MG/20ML, 80 MG/4ML | MB | PA |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000 UNIT/0.5ML | MB | SP |
| ALIMTA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 500 MG | MB | PA |
| ALIQOPA INTRAVENOUS SOLUTION RECONSTITUTED 60 MG | MB | PA |
| <i>amifostine intravenous solution reconstituted 500 mg</i> | MB | PA |
| ANZEMET INTRAVENOUS SOLUTION 20 MG/ML | MB | PA |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 300 MCG/ML | MB | PA |
| <i>azacitidine injection suspension reconstituted 100 mg</i> | MB | |
| AZEDRA DOSIMETRIC INTRAVENOUS SOLUTION 15 MCI/ML | MB | PA; QL (1 EA per 30 days) |
| AZEDRA THERAPEUTIC INTRAVENOUS SOLUTION 15 MCI/ML | MB | PA; QL (2 EA per 30 days) |
| BAVENCIO INTRAVENOUS SOLUTION 200 MG/10ML | MB | PA |
| BD POSIFLUSH INTRAVENOUS SOLUTION 0.9 % | MB | |
| BELEODAQ INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | PA |
| BENLYSTA INTRAVENOUS SOLUTION RECONSTITUTED 120 MG, 400 MG | MB | PA |
| <i>benztropine mesylate injection solution 1 mg/ml</i> | MB | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| BERINERT INTRAVENOUS KIT 500 UNIT | 5 | PA; QL (2 EA per 28 days); SP |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | MB | |
| BICNU INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | MB | |
| BLINCYTO INTRAVENOUS SOLUTION RECONSTITUTED 35 MCG | MB | PA |
| BOTOX INJECTION SOLUTION RECONSTITUTED 100 UNIT | MB | PA |

| Drug Name | Tier | Notes |
|---|------|---|
| CEREBYX INJECTION SOLUTION 100 MG PE/2ML | MB | |
| CERVARIX INTRAMUSCULAR SUSPENSION | MB | \$0 Copay Preventative Services.; AL (Min 19 Years and Max 26 Years) |
| CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT | 5 | PA; SP |
| CUBICIN INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | |
| CUBICIN RF INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | |
| CYRAMZA INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | MB | PA |
| <i>daptomycin intravenous solution reconstituted 500 mg</i> | MB | |
| DEXFERRUM INJECTION SOLUTION 50 MG/ML | MB | PA |
| <i>doripenem intravenous solution reconstituted 250 mg, 500 mg</i> | MB | |
| DYSPORT INTRAMUSCULAR SOLUTION RECONSTITUTED 300 UNIT, 500 UNIT | MB | PA |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG, 7.5 MG | MB | |
| ELIGARD SUBCUTANEOUS KIT 30 MG, 45 MG | MB | PA required if billed with Dx codes F64.1 - F64.9. |
| ENTYVIO INTRAVENOUS SOLUTION RECONSTITUTED 300 MG | MB | PA; SP |
| <i>ertapenem sodium injection solution reconstituted 1 gm</i> | MB | |
| ERWINAZE INJECTION SOLUTION RECONSTITUTED 10000 UNIT | MB | PA |
| ETHYOL INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | MB | PA |
| EUFLEXXA INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 20 MG/2ML | MB | PA; QL (6 ML per 180 days) |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 0.5 GM/10ML, 10 GM/100ML, 10 GM/200ML, 2.5 GM/50ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML | MB | PA |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | MB | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) |
| FOSCAVIR INTRAVENOUS SOLUTION 24 MG/ML | MB | |

| Drug Name | Tier | Notes |
|--|-------------|--|
| GAMUNEX-C INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML | MB | PA |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | \$0 | \$0 Copay PPACA Guidelines.; AL (Min 9 Years and Max 45 Years) |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | \$0 | \$0 Copay PPACA Guidelines.; AL (Min 9 Years and Max 45 Years) |
| GAZYVA INTRAVENOUS SOLUTION 1000 MG/40ML | MB | PA |
| <i>heparin (porcine) in d5w intravenous solution 40-5 unit/ml-%, 50-5 unit/ml-%</i> | MB | |
| <i>heparin (porcine) in nacl injection solution 2-0.9 unit/ml-%</i> | MB | |
| <i>heparin lock flush intravenous solution 2 unit/ml</i> | MB | |
| <i>heparin sod (porcine) in d5w intravenous solution 100 unit/ml</i> | MB | |
| <i>heparin sodium (porcine) injection solution 2500 unit/ml</i> | MB | |
| <i>heparin sodium (porcine) intravenous solution 2000 unit/ml</i> | MB | |
| <i>heparin sodium flush intravenous kit 10-0.9 unit/ml-%, 100-0.9 unit/ml-%</i> | MB | |
| IMFINZI INTRAVENOUS SOLUTION 120 MG/2.4ML, 500 MG/10ML | MB | PA |
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg</i> | MB | |
| INFED INJECTION SOLUTION 50 MG/ML | MB | PA |
| INJECTAFER INTRAVENOUS SOLUTION 750 MG/15ML | MB | PA |
| JELMYTO SOLUTION RECONSTITUTED 80 (2 X 40) MG | MB | PA; QL (17 EA per 1 day) |
| KALBITOR SUBCUTANEOUS SOLUTION 10 MG/ML | MB | PA |
| KENDALL SODIUM CHLORIDE FLUSH INTRAVENOUS SOLUTION 0.9 % | MB | |
| KEYTRUDA INTRAVENOUS SOLUTION 100 MG/4ML | MB | PA |
| KYPROLIS INTRAVENOUS SOLUTION RECONSTITUTED 10 MG, 30 MG, 60 MG | MB | PA |
| LARTRUVO INTRAVENOUS SOLUTION 500 MG/50ML | MB | PA |
| LUMOXITI INTRAVENOUS SOLUTION RECONSTITUTED 1 MG | MB | PA |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG | MB | PA required if billed with Dx codes F64.1 - F64.9. |

| Drug Name | Tier | Notes |
|---|------|--|
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG | MB | PA required if billed with Dx codes F64.1 - F64.9. |
| LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG | MB | PA not required if billed with Dx codes F64.1 - F64.9. |
| LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG | MB | PA not required if billed with Dx codes F64.1 - F64.9. |
| MARQIBO INTRAVENOUS SUSPENSION 5 MG/31ML | MB | PA |
| <i>methyl dopate hcl intravenous solution 250 mg/5ml</i> | MB | |
| <i>micafungin sodium intravenous solution reconstituted 100 mg</i> | MB | |
| MONOJECT FLUSH SYRINGE INTRAVENOUS SOLUTION 0.9 % | MB | |
| MONOJECT SODIUM CHLORIDE FLUSH INTRAVENOUS SOLUTION 0.9 % | MB | |
| <i>na ferric gluc cplx in sucrose intravenous solution 12.5 mg/ml</i> | MB | PA |
| <i>normal saline flush intravenous solution 0.9 %</i> | MB | |
| OCREVUS INTRAVENOUS SOLUTION 300 MG/10ML | MB | PA; SP |
| ONPATTRO INTRAVENOUS SOLUTION 10 MG/5ML | MB | PA |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 240 MG/24ML, 40 MG/4ML | MB | PA |
| ORENCIA INTRAVENOUS SOLUTION RECONSTITUTED 250 MG | MB | PA |
| PERJETA INTRAVENOUS SOLUTION 420 MG/14ML | MB | PA |
| <i>potassium chloride in nacl intravenous solution 20-0.9 meq/l-%</i> | MB | |
| POTELIGEO INTRAVENOUS SOLUTION 20 MG/5ML | MB | PA |
| <i>procainamide hcl injection solution 100 mg/ml, 500 mg/ml</i> | MB | |
| PROVENGE INTRAVENOUS SUSPENSION | MB | PA |
| <i>romidepsin intravenous solution 27.5 mg/5.5ml</i> | MB | PA |
| <i>saline flush intravenous solution 0.9 %</i> | MB | |
| SALINE FLUSH ZR INTRAVENOUS SOLUTION 0.9 % | MB | |
| SANDOSTATIN LAR DEPOT INTRAMUSCULAR KIT 10 MG, 20 MG, 30 MG | MB | |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 13.5 MG | \$0 | \$0 Copay per PPACA guidelines |
| <i>sodium chloride flush intravenous solution 0.9 %</i> | MB | |
| <i>sodium chloride intravenous solution 0.9 %</i> | MB | |

| Drug Name | Tier | Notes |
|---|-------------|--|
| SWABFLUSH SALINE FLUSH INTRAVENOUS SOLUTION 0.9 % | MB | |
| TESTOPEL IMPLANT PELLETT 75 MG | MB | PA; QL (6 EA per 90 days) |
| TRAZIMERA INTRAVENOUS SOLUTION RECONSTITUTED 420 MG | MB | |
| TRODELVY INTRAVENOUS SOLUTION RECONSTITUTED 180 MG | MB | PA |
| TYSABRI INTRAVENOUS CONCENTRATE 300 MG/15ML | MB | PA |
| UDENYCA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML | MB | PA; Specialty Pharmacy Required if drug is filled through pharmacy benefit; SP |
| VARIZIG INTRAMUSCULAR SOLUTION 125 UNIT/1.2ML | MB | PA |
| VARIZIG INTRAMUSCULAR SOLUTION RECONSTITUTED 125 UNIT | MB | PA |
| VENOFER INTRAVENOUS SOLUTION 20 MG/ML | MB | PA |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG | 5 | BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at no zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 EA per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML | MB | PA |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG | MB | PA |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40ML, 50 MG/10ML | MB | PA |
| ZALTRAP INTRAVENOUS SOLUTION 100 MG/4ML, 200 MG/8ML | MB | PA |
| ZIRABEV INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML | MB | PA |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | MB | |
| <i>zoledronic acid intravenous concentrate 4 mg/5ml</i> | MB | |
| <i>zoledronic acid intravenous solution 5 mg/100ml</i> | MB | |